Cape Town Plans Vaccine Outreach Targeting Homeless as Part of ‘Healthy Cities’ grant 07/05/2021 Kerry Cullinan Bloomberg Philanthropies is supporting cities’ COVID-19 prevention effort CAPE TOWN – The city is planning a vaccine outreach campaign aimed at encouraging an estimated 530,000 homeless people and migrants to get vaccinated. Cape Town is one of 18 cities that has been chosen by Bloomberg Philanthropies’ ‘Healthy Cities’ initiative for a grant of up to $50,000 to support vaccine distribution to reach high-risk populations. The city plans to use the grant for advertising on minibus taxis, mobile billboards and sky banners, and to fight misinformation via radio ads. In addition, vaccine registration units “will partner with trusted community leaders and hold socially distanced face-to-face consultations with people in hard-to-reach areas”, according to a news release. “It is important that, while our communities have access to health care, they also have access to reliable health information,” said Cape Town mayor Dan Plato. “We’ve seen the power of working with trusted local voices to share COVID-19 safety messages with vulnerable people earlier in the pandemic, and we plan to build on those efforts to encourage vaccination for all.” South Africa is currently only vaccinating health workers due to vaccine shortages but will start vaccinating those over the age of 60 on 17 May. Buenos Aires in Argentina, will tackle a vaccine hesitancy problem among older homeless or isolated adults, using targeted messaging and by training formerly homeless “peer companions” for local outreach. Ending The Pandemic Everywhere Phnom Penh in Cambodia will improve vaccine logistics and delivery, including acquiring new cold storage equipment to protect the vaccines as the onset of the local rainy season slows road travel. Brazil’s Rio de Janeiro will use the new funds to reach transgender people who are unhoused or in otherwise high-risk or isolated situations. Bloomberg Philanthropies founder Michael Bloomberg said that “local leaders have helped spearhead the world’s response to the pandemic from the beginning, and that now includes pushing to ensure vaccinations happen as quickly as possible, especially in high-risk communities”. Meanwhile, World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus, described the equitable distribution of vaccines as “not only a moral imperative, it is also an epidemiological and economic imperative”. “As long as this virus is transmitting anywhere, the higher the chances that a variant will emerge that evades vaccines, and the longer the global economic recovery will take,” said Dr Tedros. “We simply will not end the pandemic anywhere until we end it everywhere. These grants will support city leaders to reach some of the most vulnerable groups with vaccines.” Founded in 2017, the Partnership for Healthy Cities has grown into a network of 70 cities around the world committed to saving lives by preventing non-communicable diseases, such as heart disease, diabetes, chronic lung disease and cancer, and injuries. In March 2020, Bloomberg Philanthropies expanded support to help member cities by providing tools and information for COVID-19 prevention and mitigation measures as part of a $40 million Bloomberg Philanthropies COVID-19 Global Response Initiative. “Cities are drivers of public health and over the past year have mounted a remarkable COVID-19 response. The path to widespread vaccination is complex and requires detailed planning, coordination, data management, and logistics support by urban leaders and their staff,” said José Luis Castro, CEO of Vital Strategies, which is a partner in the initiative. “We look forward to using our expertise to help cities improve their ability to reach high-risk communities as they develop and implement equitable policies and practices to safeguard health and rebuild stronger health, social, and economic systems.” Image Credits: Bloomberg Philanthropies. WTO’s DG Okonjo-Iweala Welcomes New US Support For Waiver On COVID Vaccine IP: ‘We Need To Respond Urgently’ 06/05/2021 Chandre Prince, Raisa Santos & Elaine Ruth Fletcher WTO Director-General Ngozi Okonjo-Iweala World Trade Organization’s (WTO) director general Ngozi Onkonjo-Iweala on Thursday hailed the United States government’s decision to support the suspension of intellectual property rules on COVID-19 vaccines – while also emphasising the urgency of even more immediate actions to increase vaccine supplies to lower-income countries. In a statement after a two-day closed-door WTO General Council meeting, Onkonjo-Iweala said she “warmly welcomed” the US’s willingness to “engage with proponents of a temporary waiver of the TRIPS agreement to help in combating the Covid-19 pandemic”. “We need to respond urgently to COVID-19 because the world is watching and people are dying,” Onkonjo-Iwela said, in a carefully measured statement. That statement also underlined the fact the lead sponsors of the blanket waiver, South Africa and India, were revising their proposal to reconcile the deep differences among high- and low-income WTO member states. “I am pleased that the proponents are preparing a revision to their proposal and I urge them to put this on the table as soon as possible so that text-based negotiations can commence,” Onkonjo-Iweala said. “It is only by sitting down together, that we will find a pragmatic way forward, acceptable to all members, which enhances developing countries, access to vaccines, while protecting and sustaining the research and innovation, so vital to the production of these life saving vaccines.” The global trade body has for months been facing calls by a group of 60 low-income countries, led by India and South Africa to temporarily remove the intellectual property protections on COVID-19 vaccines, medicines and tests, which are governed by the WTO’s Trade Related Aspects of Intellectual Property (TRIPS). Proponents say this would help boost medicines and vaccine production in developing countries that so far have received far fewer jabs – as well as oiling the wheels of international trade – in which developing countries that produce generic or biosimilar versions of drugs and vaccines, can face IP barriers in producing and exporting those products to other countries in need. Until now, however, most leading developed countries, as well as the pharma industry, have opposed the blanket waiver, saying that it would not really serve to ramp up technologically complex medicines or vaccine production. The US change in position vis a vis vaccines, at least, under the new administration of President Joe Biden, is a significant shift that could pull other countries along too – particularly the European Union. Already on Thursday, New Zealand’s trade minister, Damien O’Connor, said that the country would align with the initiative for an IP waiver on vaccines. “We welcome the US announcement and look forward to taking this forward with urgency.” And European Commission President Ursula von der Leyen signalled that the EU might also reconsider its previously staunch opposition to the TRIPS waiver, saying “we are open to discuss any other effective and pragmatic solution.” Our priority is to ramp up production to achieve global vaccination. At the same time we are open to discuss any other effective and pragmatic solution. In this context we are ready to assess how the US proposal could help achieve that objective. — Ursula von der Leyen (@vonderleyen) May 6, 2021 Speaking at the European University Institute in Florence, Italy, Von der Leyen said that the EU was ready to discuss the US-backed proposal. But she also called upon all vaccine-producing countries to immediately remove export limits on their products and avoid other measures that disrupt supply chains – a thinly-veiled criticism of the United States and the United Kingdom’s moves that have, at times, limited exports of vaccines or their inputs. Mood At WTO General Council More Constructive WTO spokesman Keith Rockwell At a press briefing on Thursday, WTO Spokesperson Keith Rockwell noted that the “‘mood was very different” and “discussions were constructive” at the General Council meeting following the announcement by US Trade Representative, Ambassador Katherine Tai, Wednesday evening, in a statement that declared: “This is a global health crisis, and the extraordinary circumstances of the Covid-19 pandemic call for extraordinary measures.”. Said Rockwell: “Clearly, there is a change in the atmosphere,” adding that while the US support does not guarantee an agreement, it signals a ‘very different dynamic’ from the United States, which is a key WTO player – that will move the negotiations to a concrete text formulation. “Without this kind of change, an agreement could not be possible. And we don’t tend to come up with agreements by magic. These agreements tend to arise when we have when we have a text from which to negotiate,” Rockwell said. Global Health Experts Applaud the United States’ Leadership The US move has been widely applauded by many leading global health experts – although opposed by industry voices as something that won’t really achieve the aim of ramping up needed. “This is a game changer. US is stepping up. Doing the right thing. Doing the smart thing,” said Lawrence Gostin, Director of a WHO Collaborating Center on Global Health Law, on Twitter. “I never thought I would live to see the day the US used its political muscle to waive IP rights against the implacable opposition of the pharma industry,” added Gostin. He described the pandemic as a ‘long game’ that could rage globally for many years until everyone is vaccinated. “The answer isn’t only sharing a scarce supply of vaccine doses, even if that is still important. It’s also vital to build capacity globally so that there’s enough doses for everyone. A win-win.” This is a game changer! US is stepping upDoing the right thingDoing the smart thing Now we must go beyond IP waiver to full tech transfer I am thrilled at US leadership! https://t.co/r6IppNvL8C — Lawrence Gostin (@LawrenceGostin) May 5, 2021 Conversely, a statement by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) warned that: “Waiving patents of COVID-19 vaccines will not increase production nor provide practical solutions needed to battle this global health crisis. “On the contrary, it is likely to lead to disruption, while distracting from addressing the real challenges in scaling up production and distribution of COVID-19 vaccines globally.” A patent waiver for COVID-19 vaccines does not address the real challenges in vaccinating the world. Our industry is steadfast in its commitment to ensure quick scaling up of and equitable vaccine access. We need pragmatic and constructive dialogue: https://t.co/445Rf1N7Ht pic.twitter.com/LPv2Q5gNUi — IFPMA (@IFPMA) May 6, 2021 In a BBC interview, IFPMA Director-General Thomas Cueni said he was “even more concerned” about bolstering pandemic preparedness in the wake of the US change in position. “Here you had 300 plus vaccine developers engaged in trying to be the first to the finishing line on COVID-19, trusting that the legal framework would be honoured. Now, with this precedent, if it is carried through, the message for future pandemic preparedness to investors, to companies is ‘don’t count that this legal framework will be honoured” – if there is a crisis, the patent will be ignored, which is not really the incentive you need.” The so-called “Ottawa Group-plus”, led by Canada and including a mix of high- and lower-income WTO countries, have meanwhile tried to advance a more general declaration on Trade and Health, which would aspire to eliminate export restrictions on vital COVID-19 health products and curb vaccine nationalism. But many other WTO members, including not only the sponsors but other Latin America countries, have said that the initiative falls short of achieving real impacts. “What they said was that these things do not go far enough,” said Rockwell, reporting on the results of Thursday’s WTO General Council session. “And reference was made on a number of occasions to the need to have a waiver of TRIPS that this is really a critical tool for combating this. Many countries have spoken up in favour of the statement made by Katherine Tai yesterday.” Image Credits: Africa Centre for International Trade&Development, WTO. WHO & UNICEF Call For Better Hygiene & More Affordable Water & Sanitation To Stop The Spread Of Deadly Infections 06/05/2021 Editorial team Low-and-middle-income countries have made significantly less progress than high-income countries in implementing hand hygiene and infection prevention programmes that can stop deadly diseases, from diarrhoea to COVID-19, according to a recent A World Health Organization survey of 88 countries. And one in four health care facilities in poorer countries do not have basic water services and one in three lacks hand hygiene supplies, said WHO, marking World Hygiene Day on Wednesday. Meanwhile, universal access to safe drinking waters, sanitation and hygiene, are unlikely to be met unless affordability is addressed and monitored – according to a new report by UNICEF and WHO, released on World Hygiene Day. Improved monitoring of “affordability” indicators will ultimately allow governments and the water, sanitation and hygiene (WASH) sector to more effectively target support and to make WASH services affordable to all. Good Hygiene Critical to Stopping COVID-10 – as well as Other Deadly Diseases Good hygiene practices remain a “serious challenge” at any time, but more so when the world is fighting the deadly COVID-19 pandemic, WHO said in a statement. “COVID-19 has dramatically demonstrated just how important good hand hygiene practices are in reducing the risk of transmission, when used as part of a comprehensive package of preventative measures. “For example, in some low-and-middle-income countries, only one in 10 have workers who practice proper hand hygiene while caring for patients at high-risk of health care susceptibility infection in intensive care units. While, also in high-income countries, hand hygiene compliance rarely exceeds 60% to 70%.” Moreover, few low-income countries have the capacity to monitor Infection, Prevention and Control (IPC) effectively. A new WHO online monitoring portal will help countries identify and address gaps. The first ever IPC monitoring portal is a protected online platform for countries to collect data in a standardised and user-friendly manner and download their situation analysis following data entry along with advice on areas and approaches for improvement. Infections acquired in health care settings like hospitals and clinics affect millions of patients and health workers globally. Europe alone records nearly nine million infections yearly, said the U.N. agency. But highly effective and low-cost hand hygiene strategies are available that could reduce these infections by half. “Half these infections can be avoided by implementing effective IPC practices and programmes, including hand hygiene improvement strategies. Such strategies can also prevent 3 out of 4 the AMR-related deaths that occur in health care facilities.” The organisation has also declared 2021 the “Year of the Health and Care Worker”, and in relation to that, evidence has shown that appropriate hand hygiene practices reduce infections during health care delivery: “So, engaging different health professionals, as well as patients and everyone in the society in World Hand Hygiene Day 2021 is critical also to supporting the “Year of Health and Care Workers”. Image Credits: Pixabay. New Report Calls For More Midwives To Help Prevent Millions Of Childbirth Deaths 05/05/2021 Chandre Prince A new report recommends that governments prioritise funding and support for midwifery amid a global shortfall of 900,000 midwives. Two in every three deaths in childbirth could be prevented by 2035 if the world starts recruiting and training more midwives, a new report on the “State of World’s Midwifery 2021” has found. The report, launched by the UN Population Fund (UNFPA) on Wednesday found a global shortfall of 900,000 midwives – and said that the global midwifery workforce needs to be expanded by some 30% to close that gap. Compiled by the UNFPA, the UN’s sexual and reproductive health agency (UNFPA), WHO (World Health Organization), the International Confederation of Midwives (ICM) and other partners, the report evaluates the midwifery workforce and related health resources in 194 countries. It states that for “midwives to achieve their life-saving and life-changing potential, greater investment is needed in their education and training, midwife-led service delivery, and midwifery leadership”. Governments must prioritise funding and support for midwifery and take concrete steps to include midwives in determining health policies. “Midwives play a vital role in reducing the risks of childbirth for women all over the world,” said WHO director general Dr Tedros Adhanom Ghebreyesus. Increasing their numbers will “deliver a triple dividend in contributing to better health, gender equality and inclusive economic growth,” he said. The last State of the World’s Midwifery report, published in 2014, also raised the alarm over shortages and provided a roadmap on how to remedy this deficit. But progress over the past eight years has been too slow, the report found. The analysis in this year’s report shows that, at current rates of progress, the situation will have improved only slightly by 2030. ICM president Franka Cadee said “midwives are continually overlooked and ignored” and called on “governments to acknowledge the evidence surrounding the life-promoting, life-saving impact of midwife-led care, and take action on the report’s recommendations”. Almost one in five women give birth without a skilled health provider, exposing both mothers and babies to risk, the report further found. It gives the latest stillbirths estimates at about two million a year, along with an estimated 2.4 million new-born deaths and some 295,000 maternal deaths, either during or soon after pregnancy. Describing the report’s findings as “alarming”, UNFPA executive director Dr Natalia Kanem said 1.1million more essential health workers are needed to deliver sexual, reproductive, maternal, newborn and adolescent health care, and 80 per cent of these missing essential health workers are midwives. “A capable, well-trained midwife can have an enormous impact on childbearing women and their families – an impact often passed on from one generation to the next,” Kanem said. The lack of midwives, the report states, is driven by gender inequality, with countries overlooking sexual and reproductive health and under-estimating the value of a female-dominated workforce. Fixing the gaps in provision could save an estimated 4.3 million mothers and babies a year, cutting two in three needless deaths by 2035, said analysis conducted for the report published in The Lancet medical journal last December. The report urged governments to put money into boosting midwife numbers, improving training and offering midwives a greater role in health policy and maternal healthcare. Image Credits: WHO, WHO SEARO. WHO Global Data Hub To Help Fight Future Pandemics 05/05/2021 Chandre Prince German Chancellor Angela Merkel The World Health Organization and the German government on Wednesday announced the launch of a new Global Hub for Pandemic and Epidemic Intelligence that aims to harness the world of big data, media and epidemiological reports to more rapidly identify and respond to emerging disease risks. The hub, to be launched in Berlin later this year, would bring together scientists, data experts and other know-how from governments, international organizations and the private sector, in new, and more flexible forms of collaboration, WHO’s Director of Health Emergencies, Mike Ryan, said at a press briefing on Wednesday. Launch of the hub is being supported by €30 million in seed funds from the German government, said officials at the briefing, addressed by German Chancellor Angela Merkel and Health Minister Jens Spahn. “The WHO Hub for Pandemic and Epidemic Intelligence can make a difference for a safer future…(we should focus on) the development of a global data ecosystem to produce timely insights and tools for policymakers, before and after an epidemic and pandemic events,” Spahn said. The hub would help gather data more efficiently to predict, prevent and respond to future pandemics and epidemic risks worldwide, said WHO Director General Dr Tedros Adhanom Ghebreyesus. “One of the lessons of the Covid-19 pandemic is that the world needs a significant leap forward in data analysis to help leaders make informed public health decisions,” Tedros said. “This requires harnessing the potential of advanced technologies such as artificial intelligence, combining diverse data sources, and collaborating across multiple disciplines. Better data and better analytics will lead to better decisions,” he said. Faster Identification of Threats and Responses Some of the first SARS-COV-2 cases emerged around Wuhan’s “wet markets” selling wild animals for slaughter and meat consumption; such markets can be a flashpoint for pathogen transmission to humans. The initiative responds to a key issue raised by WHO member states and independent reviewers regarding the initial stages of COVID-19 pandemic response – and the belated recognition of the SARS-CoV2 outbreak that was now obviously simmering in Wuhan throughout the fall of 2019 – and possibly even spreading then to other countries, such as Italy, where COVID-positive serum samples from the period were later identified. Even so, the first Chinese government and media reports of the mysterious pneumonia-like outbreak in Wuhan were only picked up on 31 December, 2019 – by WHO’s China country office as well as by the WHO EIOS (Epidemic Intelligence Open Sources) platform – which noted a report from ProMED, the International Society for Infectious Diseases. Following that, criticism has also been leveraged against the quality of data collection by WHO, China and other member states reflecting the early days of the pandemic spread – which may have contributed to WHO’s delays in declaring an international public health emergency over the virus – which so far has killed over 3.2 million people worldwide. Although not “new”, the idea of a hub, according to Tedros, coalesced during discussions with Merkel in October 2020 about the creation of a centre that would serve as a global nerve centre to enhance global capacity for pandemic and epidemic intelligence. Merkel, in a video message, said that the COVID-19 pandemic “has taught us that we can only fight pandemics and epidemics together”. “The new WHO Hub will be a global platform for pandemic prevention, bringing together various governmental, academic and private sector institutions,” Merkel said, further welcoming WHO’s decision to base the hub in Berlin. The hub will bring together governmental, academic and private sector institutions to harness global data, surveillance and analytics and will involve a global collaboration of countries and partners to look for pre-signals that go beyond current systems that monitor publicly available information for signs of emerging outbreaks. Build Upon EIOS – CERN-like Model For Cooperation WHO’s Director of Health Emergencies, Mike Ryan Ryan said that the hub would not be about creating another “big bureaucratic WHO institution” but rather a transformed and engaging centre. He said that WHO envisages the platform as functioning similar to CERN, the European Organization for Nuclear Research – an iconic Geneva-area institution that brings together research fellows, visiting scholars and other experts for brief stints, where they can share and apply their knowledge and skills. “It’s about creating a platform with Germany, where everyone can come and contribute. And this becomes a facilitating environment. We bring the best minds, we bring the best ideas and we facilitate that with the infrastructure and the tools and all of the things that we need…(to) allow others to take the real innovative steps to move us forward in this regard,” Ryan added. He said that the hub would build upon the networks created by EIOS – in a more sophisticated model – to become operational from September. Germany has offered a seed fund of €30 million annually as a startup for the hub, with WHO still working on further details of the budget, he added. . Appeals for further funding are being discussed with various potential donors at the G7 level, said Ryan. Berlin “Ideal Location” for Global Hub German Health Minister Jens Spahn Merkel said Berlin was an ideal location for the hub as it already had leading players in the digital and health fields, such as the Robert Koch Institute, the German federal government’s scientific research institution. “If that expertise is now supplemented by the WHO Hub, we will create a unique environment for pandemic and health research here in Berlin — an environment from which important action-oriented insights will emerge for governments and leaders around the world,” she said. Emphasising that the new hub would still fall under WHO’s governance, Spahn said Germany was offering an “enabling environment for the inter linkages between public health and digital players”. “We are very confident that this local environment will provide numerous opportunities for synergies with a new double edge for the hub,” Spahn said, echoing Tedros’ sentiments that there was a clear need for stronger early local warning alerts and emergency response system to help improve public health intelligence and risk analysis. Transparent Data is Imperative WHO affirmed that data from the new global hub will be held openly and transparently. While affirming that data, in principle, should be held openly and transparently, Ryan acknowledged that it will still be up to the member states and the rules of the International Health Regulations to decide how, and with whom, to share verified information. “The aim is to bring together partners from around the world to develop better access to data and to develop tools we need to generate the insights we need before, during and after pandemics. But, also to build trust between partners in sharing that data in sharing those insights. We aim to bring that whole process together,” Ryan said. He acknowledged, however, that access to data as well as tools for generating insight from such data is not evenly distributed across the member states. And the hub would try to address those inequalities, as well. “I can assure you that that’s the point of the centre… to democratize that process, bring more parameters and create facilities, translate trends and transformative technologies on the capabilities to our member states.” However, issues around transparency and accountability will not be solved by new technologies, but by building trust between partners in sharing data and insights, Ryan added. Three independent panels are due to report at the upcoming World Health Assembly (WHA)on how the WHO and member states reacted to the pandemic, and propose reforms in rules and procedures. Effectively the creation of the hub leapfrogs over what is likely to be highly politicized deliberations on those reforms at the WHA – to create at least one fait accompli that would support earlier warnings. Image Credits: Breaking Asia, UCT. Time to End ‘Delaying Tactics’ on TRIPS Waiver, Say India And South Africa Ahead Of Critical WTO Meeting 04/05/2021 Kerry Cullinan High-level panel on TRIPS waiver CAPE TOWN – The “circular discussion” at the World Trade Organization (WTO) on the TRIPS waiver needs to move to “text-based” negotiations, Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO said on Tuesday. Her Indian counterpart, Brajendra Navnit, added that opponents of the waiver had been using “delaying tactics” since the beginning of the year, “changing goalposts” to raise new problems once their earlier concerns had been addressed. Mlumbi-Peter and Navnit were addressing a high-level panel on Tuesday organised by a range of civil society organisations, on the eve of yet another meeting of the TRIPS Council on the waiver issue, set for Wednesday and Thursday. A waiver in the enforcement of patents, copyright, industrial designs, and trade secrets, under WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), was proposed in October 2020 by India and South Africa, for all COVID-related health products for the duration of the pandemic. This proposal has been supported by over 60 member states, but opposed by mostly high-income nations. During the ensuing six months of negotiations, a further two million people have died from the SARS-CoV2 virus, participants at Tuesday’s panel pointed out. A revised version of the TRIPS waiver proposal is to be presented at Wednesday’s TRIPS General Council “in a bid to reconcile positions”, according to the WTO. ‘Hopeful Signs” on US Position Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO Until recently, Mlumbi-Peters had chaired the WTO TRIPS Council, on behalf of South Africa, and had thus been unable to speak publicly in support of the waiver proposal. Another panelist, United States Congresswoman Jan Schakowsky, who has been championing the waiver in her country, said that it was still unclear if the US administration would support the waiver – but there were some hopeful signs of “dramatic change”. “The United States position is evolving. There are divisions even within the administration – and [within] the Members of Congress, a majority of the Democrats have weighed in, in favour of a TRIPS waiver,” said Schakowsky. “When Big Pharma talks about its priorities and that intellectual property rights rule everything, they are forgetting that the American people, the taxpayers, have spent billions and billions of dollars in research and development and distribution, have a huge stake in this,” she added. No ‘Good Examples’ of Voluntary Licensing Schakowsky supported text-based negotiations on the waiver “to make the changes that are necessary that are going to allow all countries to have access”. “We really don’t have the time to argue with the pharmaceutical industry,” said added. Kathleen Van Brempt, Belgian Member of the European Parliament and the trade coordinator for the Parliament’s Progressive Alliance of Socialists and Democrats Group, proposed “a coalition of the willing” involving European and US politicians in particular. Van Brempt said that opponents of the waiver claimed that it was an “ideological” proposal that would not facilitate the technology transfer needed to speed up vaccine production, and that this could be achieved with voluntary licensing of COVID-19 treatments and medicines. “The facts and figures prove them wrong,” said Van Brempt. “I don’t know any good examples of voluntary licensing, or even of compulsory licensing, that would ramp up production. That is not the case today, and that’s why we have to move on.” Kathleen Van Brempt, Belgian Member of the European Parliament Van Brempt added: “I’m very happy to see my colleague of the US Congress [Schakowsky]. I think we should work much more closely together because I hear that the Biden Administration might move.” She also suggested engaging with the pharmaceutical industry as a first step to inform them about “how unacceptable it is that they decide on the price, and they decide who can produce”, when these decisions “should be steered by governments”. She also suggested opening up the discussion on the TRIPS waiver with the aim of “ramping up [vaccine] production”. More Pragmatic Than Ideological Ruth Dreifuss, former President of Switzerland, said that “unilateral, bilateral tools, like voluntary licenses, compulsory licenses, parallel imports have not adapted to the current situation”. “We urgently need a more global approach as proposed by India and South Africa,” added Dreifuss, who chairs WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) and was co-chair of the UN Secretary General’s High-Level Panel on Access to Medicines. Neither voluntary licenses (issued by pharma companies) nor compulsory licenses (which may be issued by countries in health emergencies) are tools “that would allow us to go as swiftly as we should”, as they have always involved bilateral arrangements or decisions by individual states, which do not address the broader global situation. “With more than $100 billion of public money invested in R&D and supply of vaccines and therapeutics, the risk taken by the pharmaceutical industry has been largely overtaken by the taxpayers,” Dreifuss added. “It is, therefore, an obligation for the states to guarantee fair access, and therefore the means to control the pandemic worldwide.” Dreifuss added that Switzerland “doesn’t share this idea, but I think it is a victim of a vision that is more ideological – not really pragmatic and adapted to the challenge we are facing now.” “Making the rights of intellectual property something very sacred is not a political position I can share,” she added. Van Brempt, meanwhile, said she had been encouraged that the ambassadors of India and South Africa are “not locked into their own truth” but open to negotiations. “I might be wrong but I think I can establish a majority of the European Parliamentarians, but it will involve compromises, and maybe it will not say that we fully support the waiver, as requested by India and South Africa. Maybe it will need another wording, but what I want is a shift in how the Commission looks at it.” Image Credits: Tadeau Andre/MSF . As Indian Pandemic Worsens, Social Networks Save Lives – Government Promotes Alternative Therapies 04/05/2021 Disha Shetty India has received emergency COVID-19 supplies from several countries. PUNE – For two weeks now Sijo Raju, along with a group of 20 young men and women, have been fielding calls from family members looking for oxygen cylinders, ventilator beds and ambulances. Finding a match can take a few hours as India’s overwhelmed health system and front-line healthcare workers try desperately to provide a semblance of care to the massive number of COVID patients. In the absence of a centrally coordinated response, citizens like Raju have stepped up. They verify messages posted online, guide family members to facilities with resources, and do their best to step in place of a government machinery that has effectively abandoned its citizens. “There is just too much information on the internet,” Raju told Health Policy Watch. While the group members, most of them in their 20s and 30s, are based in the Mumbai metropolitan area, they are now trying to help verify requests coming from across India and are among many such citizen groups that have banded together in the past few weeks. On 1 May, India reported over 400,000 cases – a record-high figure in the history of the COVID-19 pandemic so far. It was also the day the country officially lowered the age for those eligible for vaccines from 45 and above to 18 and above. The government had placed orders for the additional vaccines that would be needed just two days before vaccination was to be expanded, and not surprisingly most young people aren’t able to find slots as they try to register for vaccines. But Adar Poonawalla, whose company Serum Institute of India (SII) is responsible for supplying the bulk of the vaccines, said given that the orders were recently received, ramping up production would take still time. Cases continue to rise in India overwhelming the country’s already fragile health infrastructure Promoting Alternative Medicines Meanwhile, India’s government is promoting a poly herbal drug named Ayush-64, calling it a “ray of hope”. The drug is being promoted by the Ministry of Ayurvedic Medicines, Yoga, Unani, Siddha and Homeopathy (AYUSH). Alternative therapies are widely popular albeit not without controversy as mainstream treatments in the pandemic. The government said the drug has been found to be useful in mild to moderate cases. It is also promoting yoga as a way to “strengthen natural immunity”. Most COVID-19 cases are mild to moderate that require little to no treatment under normal circumstances. “The claims made about certain AYUSH interventions in the absence of quality clinical studies and data being presented is unfortunate,” said Anant Bhan, a bioethicist and global health policy expert based in India. “It could lead to reliance on interventions which could not be working, and take the focus away from interventions which do. As is the requirement with allopathic medicines, any claims about AYUSH interventions and utility in COVID-19 needs to be backed by data.” Indian government’s push for alternative medicines comes at a time when Indians are in need of a planned COVID-19 response and urgent ramping up of health facilities. The country’s cases have been on an upward trajectory since March when Prime Minister Narendra Modi held massive election rallies in the state of West Bengal and allowed the Hindu religious event Kumbh Mela to go on that saw gathering of thousands of devotees to perform rituals by the holy river Ganges. Both these events ended up being super spreader ones and worsened the pandemic. Restrictions continue in many high burden states in India and the popular cricket tournament Indian Premier League has also been postponed. The tournament had come under heavy criticism for continuing despite rising COVID-19 deaths. The secretary of the Board of Cricket Administration is Jay Shah, the son of India’s home minister Amit Shah, a key figure in the Modi Administration. Aid Distribution and Vaccine Rollout After India’s pandemic made headlines around the world, the country started receiving aid. Ireland became the most recent country to send aid and US aid has also arrived. Despite this, ordinary citizens continue to struggle for basics based on messages on social media. The government issued a statement saying that the aid will be distributed based on the number of cases and the need in the states – after questions were raised in the Indian media about the plans for distribution. This while the public waits for the Serum Institute to ramp up its production further. Amongst multiple reports it is important that correct information be shared with the public. pic.twitter.com/nzyOZwVBxH — Adar Poonawalla (@adarpoonawalla) May 3, 2021 India’s Supreme Court has also pulled up the Modi administration for failing to regulate the prices of the vaccines. Currently vaccine manufacturers are offering different prices to the centre and state governments, as well as private players, as Health Policy Watch reported in an earlier story. Health experts have said this would set a dangerous precedent while policy experts have criticized the government for its handling of the vaccine distribution. Disha Shetty is an independent journalist based in Pune, India Image Credits: @MEAIndia -Ministry of External Affairs, Spokesman's office , Our World In Data . East Africa Restricts Travellers From India And Tightens Tests for Truckers 04/05/2021 Esther Nakkazi East African truck drivers will get access to one common COVID-19 testing system by mid-May. KAMPALA – Uganda, Kenya and Rwanda have suspended passenger flights from India amid that country’s surge in COVID-19 cases and fears that a number of African countries are on the brink of their own surges. “All flights from India and all passengers originating from India are suspended from 1 May,” the Uganda Ministry of Health said in a statement. “All passenger flights are suspended until further notice. No travellers from India shall be allowed into Uganda regardless of the route of travel.” Meanwhile, Kenya has suspended flights from India for 14 days, according to the Kenya Ministry of Health. Kenya Airways and Rwandair have also suspended flights from and to India. However, East African residents will be allowed to return home. India is a top medical tourism destination for residents in East Africa. The three countries are demanding that travellers who have been to India or travelled through India in the last 14 days, be in possession of a negative PCR COVID-19 test certificate that is digitally verifiable and has been conducted within 120 hours of travel. They will also undergo a PCR test upon arrival. Uganda will allow cargo flights from India where the crew do not disembark and technical stops where travelers do not disembark. It is also allowing aircraft in a state of emergency, operations related to humanitarian aid, medical evacuation, diplomatic flights approved by the appropriate Authority. Uganda has also advised travellers from the USA, United Kingdom, United Arab Emirates, Turkey, South Africa, and Tanzania to consider postponing non-essential travel to Uganda. Travellers from these countries, including Ugandans, will be subjected to a PCR test upon arrival at the points of entry into the country said Dr Jane Ruth Aceng, Uganda’s Minister of Health, during a weekly briefing. “We should make a difference between people and the virus. The virus is the enemy, not the people. If someone has an authentic negative PCR test, they do not cause a problem,” said Dr John Nkengasong, director for Africa Centres for Disease Control and Prevention (CDC). Truck Drivers’ Testing is Tightened The East African Community (EAC) is tightening up on the COVID-19 testing requirements of interstate truck drivers, identified as vectors of the virus, amid numerous problems including forged tests At a recent EAC meeting, Uganda, Kenya, Tanzania, Burundi and South Sudan agreed to submit the names of accredited national laboratories for COVID-19 testing so that these could be linked to the upgraded Regional Electronic Cargo and Driver Tracking System (RECDTS), which recognises digital COVID-19 certificates for truck drivers. The deadline for uploading all accredited COVID-19 testing laboratories in the RECDTS is 15 May. This will ensure that interstate truck drivers and other travellers test for COVID-19 in only through accredited laboratories and that all partner states take up and implement the RECDTS system. Digital certificates are uploaded on the drivers’ smartphones through an app and are valid for 14 days. The App, which was launched in September 2020, was developed with donor funding. It provides a surveillance system to monitor long-distance truckers’ health and enables contact tracing. It also allows partner states to electronically share truck drivers’ COVID-19 test results. The new system is aimed at resolving some of the challenges that were being experienced in the execution of health protocols including multiple testing of truck drivers at the border crossing as there lacked a framework of mutual recognition, document fraud and conflicting test results. The interstate truck drivers also are the single largest group of people who have been identified to be carrying the variants of concern – the B.1.351 variant from South Africa and the B.1.1.7 from the UK. From 399 samples sequenced by the Uganda Virus Research Institute (UVRI) these two variants were detected in 30 truck drivers.The Indian variant has been identified in one patient who was admitted to Mulago Hospital. By Wednesday, the EAC Secretariat expects to have shared a detailed concept note on the development of a common regional health pass to be linked to the upgraded surveillance. Uganda and Kenya Cases Increase By Monday, the Ministry of Health in Kenya had reported that 369 people had tested positive for the disease, from a sample of 4,469 tested in the last 24 hours – a positivity rate of 8.3% compared to the world average of 2.2%. A total of 1,298 patients are in various health facilities countrywide, while 6,652 patients are in isolation at their homes and 19 had died in the 24 hours before Monday. Total confirmed positive cases are now 160,422 and cumulative tests so far conducted are 1,679,779. Some 190 patients are in the ICU, 29 of whom are on ventilatory support and 118 on supplemental oxygen – 43 patients are on observation. Aceng said that Uganda was “experiencing a gradual increase in the COVID-19 cases and it is the beginning of a resurgence”. “This surge is already showing in districts that have remained on high alert and have been carrying out active surveillance,” said Aceng, adding that “this second wave will be worse than the first one”. Uganda has already organised a resurgence plan which is projected to cost over $290 million and is organised around three thresholds: control, alert, and action. The alert threshold is reached when there is a 10% increase in cases while the action threshold begins when there is a 20% increase in the cases observed from the baseline in any geographical location. “The main objective of the resurgence plan is to mitigate transmission and minimise the public health and social economic impact,” said Aceng. The resurgence plan will include enhanced surveillance, active case search, contact tracing, procurement of test kits, Personal Protective Equipment, critical care support, strengthening community engagement and risk communications, and supporting the vaccination teams but it does not include procurement of vaccines. By 30 April, Uganda’s cumulative COVID-19 cases stood at 41,866 with 342 deaths. There are currently 444 active cases. WHO Warns of African Resurgence Dr Matshidiso Moeti, WHO Regional Director for Africa. The World Health Organisation (WHO) predicts a high risk of COVID-19 resurgence in several African countries due to poor adherence to public health measures, mass gatherings, low testing and vaccination rates. “We cannot be lulled into a false sense of security. The devastating surge of cases and deaths in India, and increases in other regions of the world, are clear signs that the pandemic is not yet over in African countries,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “ A new upsurge of COVID-19 infections is a real risk in many countries even if the region’s case count in recent weeks appears to be stable,” she added. “Combatting COVID-19 fatigue appears to be the key battle in our collective response to the pandemic.” According to the WHO analysis of 46 African countries, Kenya, Egypt, Ethiopia face a very high risk of resurgence, while a further 20 countries face a high risk and 22, moderate risk, and only one country faces low risk. The risk was calculated using seven indicators with data from the past four weeks, including COVID-19 cases per million people; the percentage of change in new cases; the percentage of change in new deaths; the reproductive number (the rate at which an infection spreads); the pandemic trend; the average weekly number of tests per 10 000 people; and the percentage of the population that has received at least one vaccine dose. With more than 4.5 million confirmed cases and over 120 000 deaths to date, the continent has not experienced a surge in cases since January and the epidemic curve has plateaued for six weeks. But the relatively low number of cases has encouraged complacency and reduced adherence to behavioural measures to prevent the spread of the virus. In addition, recent political rallies in Benin, Cote d’Ivoire, Guinea and Kenya caused a spike in new cases. Upcoming elections in Cape Verde, Ethiopia, Gambia, Sao Tome and Principe and Zambia could also trigger cases due to mass gatherings, said Moeti. Of the 46 countries analysed, 31 performed fewer than 10 tests per 10,000 people per week in the past four weeks. “Most new cases are still not being detected among known contacts. Investigation of clusters of cases and contact tracing are worryingly low in most countries in the region,” Moeti said. “We must scale up testing including through rapid diagnostic tests to enhance response to the pandemic.” Image Credits: EAC. WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines 03/05/2021 Svĕt Lustig Vijay A shipment of the Chinese Sinopharm vaccine reaches Peru The World Health Organization (WHO) appears to be inching towards the approval of the Chinese Sinopharm and Sinovac vaccines as it struggles to fill a looming vaccine vacuum left by India’s Serum Institute – which has halted exports as the country continues to reel from a tragic coronavirus outbreak. Meanwhile, the WHO declared the latest Ebola outbreak in the Democratic Republic of Congo to be over, just three months after the first case was reported in North Kivu. Chinese Sinopharm & Sinovac May be Approved By End of Week Mariângela Simão, WHO Assistant-Director General for Access to Medicines The Chinese vaccines from Sinopharm and Sinovac could be approved by the end of this week, noted the WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals Mariangela Simao, speaking at a WHO press conference on Monday. “We are finalizing the assessment of Sinopharm [but] there’s still some documentation that needs to be added,” she said. “We will start the final assessment for the listing of Sinovac on the fifth [of May], so we expect both the Chinese vaccines [to] be finalized by the end of this week.” If both vaccines receive the WHO’s green light, China could could become the world’s largest vaccine supplier, assuming that Sinovac and Sinopharm will honor their commitment to produce two billion vaccine doses this year. Despite the lack of published data for the two vaccines, as well as their hefty price, both seem to have met the WHO’s minimum efficacy requirement of 50%, the WHO’s chairperson of Strategic Advisory Group of Experts (SAGE) said late last month. With regards to the WHO’s approval of another vaccine frontrunner that seems to be significantly more potent and cheaper than its Chinese counterparts, Russia’s Sputnik V, the WHO expects a final decision by June or even July, said Simao. “WHO still does not have the entire dossier [for Sputnik], it’s not complete yet,” she said, noting that the WHO is in the process of assessing good clinical practices for Sputnik V and is set to begin evaluating manufacturing practices next Monday until early June. “We expect that as soon as we have the entire dossier, plus the compliance to both good manufacturing practices and the good clinical practice, the vaccine can be assessed then by the technical expert group [SAGE] and we expect that this is likely to happen [by the] end of June or probably in July.” Ebola Outbreak in DRC Declared Over by WHO Meanwhile, the WHO’s Director General, Dr Tedros Adhanom Ghebreyesus, hailed the DRC’s milestone in bringing an end to the twelfth Ebola outbreak in the country – a deadly disease that kills about half of the people it infects. The latest #Ebola outbreak in #DRC🇨🇩 has been declared over after just 3 months. Twelve cases, six deaths & six recoveries were recorded in four health zones in North Kivu during this outbreak.@WHO congratulates DRC’s swift response to this outbreak! 👉🏿https://t.co/2gNHJR22B6 pic.twitter.com/hNZ1moYLaT — WHO African Region (@WHOAFRO) May 3, 2021 “Earlier today, the government of the Democratic Republic of the Congo, announced the end of the most recent Ebola outbreak three months after the first case was reported in North Kivu,” said Dr. Tedros on Monday, emphasizing that a comprehensive public health approach was crucial in ending the latest outbreak of Ebola. “Huge credit must be given to the local health workers and the national authorities for their prompt response, tenacity, experience and hard work that brought this outbreak under control,” added Dr Matshidiso Moeti, WHO Regional Director for Africa. She was referring to the country’s swift move to vaccinate almost 2,000 people at high-risk of contracting the virus and providing treatment as soon as the outbreak was declared in February. However, she stressed that going forward, strong surveillance systems will be crucial to swiftly detect potential flare-ups and to fight parallel epidemics of measles, cholera and COVID-19. “Although the outbreak has ended, we must stay alert for possible resurgence and at the same time use the growing expertise on emergency response to address other health threats the country faces.” Image Credits: Sinopharm, Peruvian Ministry of External Affairs. After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WTO’s DG Okonjo-Iweala Welcomes New US Support For Waiver On COVID Vaccine IP: ‘We Need To Respond Urgently’ 06/05/2021 Chandre Prince, Raisa Santos & Elaine Ruth Fletcher WTO Director-General Ngozi Okonjo-Iweala World Trade Organization’s (WTO) director general Ngozi Onkonjo-Iweala on Thursday hailed the United States government’s decision to support the suspension of intellectual property rules on COVID-19 vaccines – while also emphasising the urgency of even more immediate actions to increase vaccine supplies to lower-income countries. In a statement after a two-day closed-door WTO General Council meeting, Onkonjo-Iweala said she “warmly welcomed” the US’s willingness to “engage with proponents of a temporary waiver of the TRIPS agreement to help in combating the Covid-19 pandemic”. “We need to respond urgently to COVID-19 because the world is watching and people are dying,” Onkonjo-Iwela said, in a carefully measured statement. That statement also underlined the fact the lead sponsors of the blanket waiver, South Africa and India, were revising their proposal to reconcile the deep differences among high- and low-income WTO member states. “I am pleased that the proponents are preparing a revision to their proposal and I urge them to put this on the table as soon as possible so that text-based negotiations can commence,” Onkonjo-Iweala said. “It is only by sitting down together, that we will find a pragmatic way forward, acceptable to all members, which enhances developing countries, access to vaccines, while protecting and sustaining the research and innovation, so vital to the production of these life saving vaccines.” The global trade body has for months been facing calls by a group of 60 low-income countries, led by India and South Africa to temporarily remove the intellectual property protections on COVID-19 vaccines, medicines and tests, which are governed by the WTO’s Trade Related Aspects of Intellectual Property (TRIPS). Proponents say this would help boost medicines and vaccine production in developing countries that so far have received far fewer jabs – as well as oiling the wheels of international trade – in which developing countries that produce generic or biosimilar versions of drugs and vaccines, can face IP barriers in producing and exporting those products to other countries in need. Until now, however, most leading developed countries, as well as the pharma industry, have opposed the blanket waiver, saying that it would not really serve to ramp up technologically complex medicines or vaccine production. The US change in position vis a vis vaccines, at least, under the new administration of President Joe Biden, is a significant shift that could pull other countries along too – particularly the European Union. Already on Thursday, New Zealand’s trade minister, Damien O’Connor, said that the country would align with the initiative for an IP waiver on vaccines. “We welcome the US announcement and look forward to taking this forward with urgency.” And European Commission President Ursula von der Leyen signalled that the EU might also reconsider its previously staunch opposition to the TRIPS waiver, saying “we are open to discuss any other effective and pragmatic solution.” Our priority is to ramp up production to achieve global vaccination. At the same time we are open to discuss any other effective and pragmatic solution. In this context we are ready to assess how the US proposal could help achieve that objective. — Ursula von der Leyen (@vonderleyen) May 6, 2021 Speaking at the European University Institute in Florence, Italy, Von der Leyen said that the EU was ready to discuss the US-backed proposal. But she also called upon all vaccine-producing countries to immediately remove export limits on their products and avoid other measures that disrupt supply chains – a thinly-veiled criticism of the United States and the United Kingdom’s moves that have, at times, limited exports of vaccines or their inputs. Mood At WTO General Council More Constructive WTO spokesman Keith Rockwell At a press briefing on Thursday, WTO Spokesperson Keith Rockwell noted that the “‘mood was very different” and “discussions were constructive” at the General Council meeting following the announcement by US Trade Representative, Ambassador Katherine Tai, Wednesday evening, in a statement that declared: “This is a global health crisis, and the extraordinary circumstances of the Covid-19 pandemic call for extraordinary measures.”. Said Rockwell: “Clearly, there is a change in the atmosphere,” adding that while the US support does not guarantee an agreement, it signals a ‘very different dynamic’ from the United States, which is a key WTO player – that will move the negotiations to a concrete text formulation. “Without this kind of change, an agreement could not be possible. And we don’t tend to come up with agreements by magic. These agreements tend to arise when we have when we have a text from which to negotiate,” Rockwell said. Global Health Experts Applaud the United States’ Leadership The US move has been widely applauded by many leading global health experts – although opposed by industry voices as something that won’t really achieve the aim of ramping up needed. “This is a game changer. US is stepping up. Doing the right thing. Doing the smart thing,” said Lawrence Gostin, Director of a WHO Collaborating Center on Global Health Law, on Twitter. “I never thought I would live to see the day the US used its political muscle to waive IP rights against the implacable opposition of the pharma industry,” added Gostin. He described the pandemic as a ‘long game’ that could rage globally for many years until everyone is vaccinated. “The answer isn’t only sharing a scarce supply of vaccine doses, even if that is still important. It’s also vital to build capacity globally so that there’s enough doses for everyone. A win-win.” This is a game changer! US is stepping upDoing the right thingDoing the smart thing Now we must go beyond IP waiver to full tech transfer I am thrilled at US leadership! https://t.co/r6IppNvL8C — Lawrence Gostin (@LawrenceGostin) May 5, 2021 Conversely, a statement by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) warned that: “Waiving patents of COVID-19 vaccines will not increase production nor provide practical solutions needed to battle this global health crisis. “On the contrary, it is likely to lead to disruption, while distracting from addressing the real challenges in scaling up production and distribution of COVID-19 vaccines globally.” A patent waiver for COVID-19 vaccines does not address the real challenges in vaccinating the world. Our industry is steadfast in its commitment to ensure quick scaling up of and equitable vaccine access. We need pragmatic and constructive dialogue: https://t.co/445Rf1N7Ht pic.twitter.com/LPv2Q5gNUi — IFPMA (@IFPMA) May 6, 2021 In a BBC interview, IFPMA Director-General Thomas Cueni said he was “even more concerned” about bolstering pandemic preparedness in the wake of the US change in position. “Here you had 300 plus vaccine developers engaged in trying to be the first to the finishing line on COVID-19, trusting that the legal framework would be honoured. Now, with this precedent, if it is carried through, the message for future pandemic preparedness to investors, to companies is ‘don’t count that this legal framework will be honoured” – if there is a crisis, the patent will be ignored, which is not really the incentive you need.” The so-called “Ottawa Group-plus”, led by Canada and including a mix of high- and lower-income WTO countries, have meanwhile tried to advance a more general declaration on Trade and Health, which would aspire to eliminate export restrictions on vital COVID-19 health products and curb vaccine nationalism. But many other WTO members, including not only the sponsors but other Latin America countries, have said that the initiative falls short of achieving real impacts. “What they said was that these things do not go far enough,” said Rockwell, reporting on the results of Thursday’s WTO General Council session. “And reference was made on a number of occasions to the need to have a waiver of TRIPS that this is really a critical tool for combating this. Many countries have spoken up in favour of the statement made by Katherine Tai yesterday.” Image Credits: Africa Centre for International Trade&Development, WTO. WHO & UNICEF Call For Better Hygiene & More Affordable Water & Sanitation To Stop The Spread Of Deadly Infections 06/05/2021 Editorial team Low-and-middle-income countries have made significantly less progress than high-income countries in implementing hand hygiene and infection prevention programmes that can stop deadly diseases, from diarrhoea to COVID-19, according to a recent A World Health Organization survey of 88 countries. And one in four health care facilities in poorer countries do not have basic water services and one in three lacks hand hygiene supplies, said WHO, marking World Hygiene Day on Wednesday. Meanwhile, universal access to safe drinking waters, sanitation and hygiene, are unlikely to be met unless affordability is addressed and monitored – according to a new report by UNICEF and WHO, released on World Hygiene Day. Improved monitoring of “affordability” indicators will ultimately allow governments and the water, sanitation and hygiene (WASH) sector to more effectively target support and to make WASH services affordable to all. Good Hygiene Critical to Stopping COVID-10 – as well as Other Deadly Diseases Good hygiene practices remain a “serious challenge” at any time, but more so when the world is fighting the deadly COVID-19 pandemic, WHO said in a statement. “COVID-19 has dramatically demonstrated just how important good hand hygiene practices are in reducing the risk of transmission, when used as part of a comprehensive package of preventative measures. “For example, in some low-and-middle-income countries, only one in 10 have workers who practice proper hand hygiene while caring for patients at high-risk of health care susceptibility infection in intensive care units. While, also in high-income countries, hand hygiene compliance rarely exceeds 60% to 70%.” Moreover, few low-income countries have the capacity to monitor Infection, Prevention and Control (IPC) effectively. A new WHO online monitoring portal will help countries identify and address gaps. The first ever IPC monitoring portal is a protected online platform for countries to collect data in a standardised and user-friendly manner and download their situation analysis following data entry along with advice on areas and approaches for improvement. Infections acquired in health care settings like hospitals and clinics affect millions of patients and health workers globally. Europe alone records nearly nine million infections yearly, said the U.N. agency. But highly effective and low-cost hand hygiene strategies are available that could reduce these infections by half. “Half these infections can be avoided by implementing effective IPC practices and programmes, including hand hygiene improvement strategies. Such strategies can also prevent 3 out of 4 the AMR-related deaths that occur in health care facilities.” The organisation has also declared 2021 the “Year of the Health and Care Worker”, and in relation to that, evidence has shown that appropriate hand hygiene practices reduce infections during health care delivery: “So, engaging different health professionals, as well as patients and everyone in the society in World Hand Hygiene Day 2021 is critical also to supporting the “Year of Health and Care Workers”. Image Credits: Pixabay. New Report Calls For More Midwives To Help Prevent Millions Of Childbirth Deaths 05/05/2021 Chandre Prince A new report recommends that governments prioritise funding and support for midwifery amid a global shortfall of 900,000 midwives. Two in every three deaths in childbirth could be prevented by 2035 if the world starts recruiting and training more midwives, a new report on the “State of World’s Midwifery 2021” has found. The report, launched by the UN Population Fund (UNFPA) on Wednesday found a global shortfall of 900,000 midwives – and said that the global midwifery workforce needs to be expanded by some 30% to close that gap. Compiled by the UNFPA, the UN’s sexual and reproductive health agency (UNFPA), WHO (World Health Organization), the International Confederation of Midwives (ICM) and other partners, the report evaluates the midwifery workforce and related health resources in 194 countries. It states that for “midwives to achieve their life-saving and life-changing potential, greater investment is needed in their education and training, midwife-led service delivery, and midwifery leadership”. Governments must prioritise funding and support for midwifery and take concrete steps to include midwives in determining health policies. “Midwives play a vital role in reducing the risks of childbirth for women all over the world,” said WHO director general Dr Tedros Adhanom Ghebreyesus. Increasing their numbers will “deliver a triple dividend in contributing to better health, gender equality and inclusive economic growth,” he said. The last State of the World’s Midwifery report, published in 2014, also raised the alarm over shortages and provided a roadmap on how to remedy this deficit. But progress over the past eight years has been too slow, the report found. The analysis in this year’s report shows that, at current rates of progress, the situation will have improved only slightly by 2030. ICM president Franka Cadee said “midwives are continually overlooked and ignored” and called on “governments to acknowledge the evidence surrounding the life-promoting, life-saving impact of midwife-led care, and take action on the report’s recommendations”. Almost one in five women give birth without a skilled health provider, exposing both mothers and babies to risk, the report further found. It gives the latest stillbirths estimates at about two million a year, along with an estimated 2.4 million new-born deaths and some 295,000 maternal deaths, either during or soon after pregnancy. Describing the report’s findings as “alarming”, UNFPA executive director Dr Natalia Kanem said 1.1million more essential health workers are needed to deliver sexual, reproductive, maternal, newborn and adolescent health care, and 80 per cent of these missing essential health workers are midwives. “A capable, well-trained midwife can have an enormous impact on childbearing women and their families – an impact often passed on from one generation to the next,” Kanem said. The lack of midwives, the report states, is driven by gender inequality, with countries overlooking sexual and reproductive health and under-estimating the value of a female-dominated workforce. Fixing the gaps in provision could save an estimated 4.3 million mothers and babies a year, cutting two in three needless deaths by 2035, said analysis conducted for the report published in The Lancet medical journal last December. The report urged governments to put money into boosting midwife numbers, improving training and offering midwives a greater role in health policy and maternal healthcare. Image Credits: WHO, WHO SEARO. WHO Global Data Hub To Help Fight Future Pandemics 05/05/2021 Chandre Prince German Chancellor Angela Merkel The World Health Organization and the German government on Wednesday announced the launch of a new Global Hub for Pandemic and Epidemic Intelligence that aims to harness the world of big data, media and epidemiological reports to more rapidly identify and respond to emerging disease risks. The hub, to be launched in Berlin later this year, would bring together scientists, data experts and other know-how from governments, international organizations and the private sector, in new, and more flexible forms of collaboration, WHO’s Director of Health Emergencies, Mike Ryan, said at a press briefing on Wednesday. Launch of the hub is being supported by €30 million in seed funds from the German government, said officials at the briefing, addressed by German Chancellor Angela Merkel and Health Minister Jens Spahn. “The WHO Hub for Pandemic and Epidemic Intelligence can make a difference for a safer future…(we should focus on) the development of a global data ecosystem to produce timely insights and tools for policymakers, before and after an epidemic and pandemic events,” Spahn said. The hub would help gather data more efficiently to predict, prevent and respond to future pandemics and epidemic risks worldwide, said WHO Director General Dr Tedros Adhanom Ghebreyesus. “One of the lessons of the Covid-19 pandemic is that the world needs a significant leap forward in data analysis to help leaders make informed public health decisions,” Tedros said. “This requires harnessing the potential of advanced technologies such as artificial intelligence, combining diverse data sources, and collaborating across multiple disciplines. Better data and better analytics will lead to better decisions,” he said. Faster Identification of Threats and Responses Some of the first SARS-COV-2 cases emerged around Wuhan’s “wet markets” selling wild animals for slaughter and meat consumption; such markets can be a flashpoint for pathogen transmission to humans. The initiative responds to a key issue raised by WHO member states and independent reviewers regarding the initial stages of COVID-19 pandemic response – and the belated recognition of the SARS-CoV2 outbreak that was now obviously simmering in Wuhan throughout the fall of 2019 – and possibly even spreading then to other countries, such as Italy, where COVID-positive serum samples from the period were later identified. Even so, the first Chinese government and media reports of the mysterious pneumonia-like outbreak in Wuhan were only picked up on 31 December, 2019 – by WHO’s China country office as well as by the WHO EIOS (Epidemic Intelligence Open Sources) platform – which noted a report from ProMED, the International Society for Infectious Diseases. Following that, criticism has also been leveraged against the quality of data collection by WHO, China and other member states reflecting the early days of the pandemic spread – which may have contributed to WHO’s delays in declaring an international public health emergency over the virus – which so far has killed over 3.2 million people worldwide. Although not “new”, the idea of a hub, according to Tedros, coalesced during discussions with Merkel in October 2020 about the creation of a centre that would serve as a global nerve centre to enhance global capacity for pandemic and epidemic intelligence. Merkel, in a video message, said that the COVID-19 pandemic “has taught us that we can only fight pandemics and epidemics together”. “The new WHO Hub will be a global platform for pandemic prevention, bringing together various governmental, academic and private sector institutions,” Merkel said, further welcoming WHO’s decision to base the hub in Berlin. The hub will bring together governmental, academic and private sector institutions to harness global data, surveillance and analytics and will involve a global collaboration of countries and partners to look for pre-signals that go beyond current systems that monitor publicly available information for signs of emerging outbreaks. Build Upon EIOS – CERN-like Model For Cooperation WHO’s Director of Health Emergencies, Mike Ryan Ryan said that the hub would not be about creating another “big bureaucratic WHO institution” but rather a transformed and engaging centre. He said that WHO envisages the platform as functioning similar to CERN, the European Organization for Nuclear Research – an iconic Geneva-area institution that brings together research fellows, visiting scholars and other experts for brief stints, where they can share and apply their knowledge and skills. “It’s about creating a platform with Germany, where everyone can come and contribute. And this becomes a facilitating environment. We bring the best minds, we bring the best ideas and we facilitate that with the infrastructure and the tools and all of the things that we need…(to) allow others to take the real innovative steps to move us forward in this regard,” Ryan added. He said that the hub would build upon the networks created by EIOS – in a more sophisticated model – to become operational from September. Germany has offered a seed fund of €30 million annually as a startup for the hub, with WHO still working on further details of the budget, he added. . Appeals for further funding are being discussed with various potential donors at the G7 level, said Ryan. Berlin “Ideal Location” for Global Hub German Health Minister Jens Spahn Merkel said Berlin was an ideal location for the hub as it already had leading players in the digital and health fields, such as the Robert Koch Institute, the German federal government’s scientific research institution. “If that expertise is now supplemented by the WHO Hub, we will create a unique environment for pandemic and health research here in Berlin — an environment from which important action-oriented insights will emerge for governments and leaders around the world,” she said. Emphasising that the new hub would still fall under WHO’s governance, Spahn said Germany was offering an “enabling environment for the inter linkages between public health and digital players”. “We are very confident that this local environment will provide numerous opportunities for synergies with a new double edge for the hub,” Spahn said, echoing Tedros’ sentiments that there was a clear need for stronger early local warning alerts and emergency response system to help improve public health intelligence and risk analysis. Transparent Data is Imperative WHO affirmed that data from the new global hub will be held openly and transparently. While affirming that data, in principle, should be held openly and transparently, Ryan acknowledged that it will still be up to the member states and the rules of the International Health Regulations to decide how, and with whom, to share verified information. “The aim is to bring together partners from around the world to develop better access to data and to develop tools we need to generate the insights we need before, during and after pandemics. But, also to build trust between partners in sharing that data in sharing those insights. We aim to bring that whole process together,” Ryan said. He acknowledged, however, that access to data as well as tools for generating insight from such data is not evenly distributed across the member states. And the hub would try to address those inequalities, as well. “I can assure you that that’s the point of the centre… to democratize that process, bring more parameters and create facilities, translate trends and transformative technologies on the capabilities to our member states.” However, issues around transparency and accountability will not be solved by new technologies, but by building trust between partners in sharing data and insights, Ryan added. Three independent panels are due to report at the upcoming World Health Assembly (WHA)on how the WHO and member states reacted to the pandemic, and propose reforms in rules and procedures. Effectively the creation of the hub leapfrogs over what is likely to be highly politicized deliberations on those reforms at the WHA – to create at least one fait accompli that would support earlier warnings. Image Credits: Breaking Asia, UCT. Time to End ‘Delaying Tactics’ on TRIPS Waiver, Say India And South Africa Ahead Of Critical WTO Meeting 04/05/2021 Kerry Cullinan High-level panel on TRIPS waiver CAPE TOWN – The “circular discussion” at the World Trade Organization (WTO) on the TRIPS waiver needs to move to “text-based” negotiations, Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO said on Tuesday. Her Indian counterpart, Brajendra Navnit, added that opponents of the waiver had been using “delaying tactics” since the beginning of the year, “changing goalposts” to raise new problems once their earlier concerns had been addressed. Mlumbi-Peter and Navnit were addressing a high-level panel on Tuesday organised by a range of civil society organisations, on the eve of yet another meeting of the TRIPS Council on the waiver issue, set for Wednesday and Thursday. A waiver in the enforcement of patents, copyright, industrial designs, and trade secrets, under WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), was proposed in October 2020 by India and South Africa, for all COVID-related health products for the duration of the pandemic. This proposal has been supported by over 60 member states, but opposed by mostly high-income nations. During the ensuing six months of negotiations, a further two million people have died from the SARS-CoV2 virus, participants at Tuesday’s panel pointed out. A revised version of the TRIPS waiver proposal is to be presented at Wednesday’s TRIPS General Council “in a bid to reconcile positions”, according to the WTO. ‘Hopeful Signs” on US Position Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO Until recently, Mlumbi-Peters had chaired the WTO TRIPS Council, on behalf of South Africa, and had thus been unable to speak publicly in support of the waiver proposal. Another panelist, United States Congresswoman Jan Schakowsky, who has been championing the waiver in her country, said that it was still unclear if the US administration would support the waiver – but there were some hopeful signs of “dramatic change”. “The United States position is evolving. There are divisions even within the administration – and [within] the Members of Congress, a majority of the Democrats have weighed in, in favour of a TRIPS waiver,” said Schakowsky. “When Big Pharma talks about its priorities and that intellectual property rights rule everything, they are forgetting that the American people, the taxpayers, have spent billions and billions of dollars in research and development and distribution, have a huge stake in this,” she added. No ‘Good Examples’ of Voluntary Licensing Schakowsky supported text-based negotiations on the waiver “to make the changes that are necessary that are going to allow all countries to have access”. “We really don’t have the time to argue with the pharmaceutical industry,” said added. Kathleen Van Brempt, Belgian Member of the European Parliament and the trade coordinator for the Parliament’s Progressive Alliance of Socialists and Democrats Group, proposed “a coalition of the willing” involving European and US politicians in particular. Van Brempt said that opponents of the waiver claimed that it was an “ideological” proposal that would not facilitate the technology transfer needed to speed up vaccine production, and that this could be achieved with voluntary licensing of COVID-19 treatments and medicines. “The facts and figures prove them wrong,” said Van Brempt. “I don’t know any good examples of voluntary licensing, or even of compulsory licensing, that would ramp up production. That is not the case today, and that’s why we have to move on.” Kathleen Van Brempt, Belgian Member of the European Parliament Van Brempt added: “I’m very happy to see my colleague of the US Congress [Schakowsky]. I think we should work much more closely together because I hear that the Biden Administration might move.” She also suggested engaging with the pharmaceutical industry as a first step to inform them about “how unacceptable it is that they decide on the price, and they decide who can produce”, when these decisions “should be steered by governments”. She also suggested opening up the discussion on the TRIPS waiver with the aim of “ramping up [vaccine] production”. More Pragmatic Than Ideological Ruth Dreifuss, former President of Switzerland, said that “unilateral, bilateral tools, like voluntary licenses, compulsory licenses, parallel imports have not adapted to the current situation”. “We urgently need a more global approach as proposed by India and South Africa,” added Dreifuss, who chairs WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) and was co-chair of the UN Secretary General’s High-Level Panel on Access to Medicines. Neither voluntary licenses (issued by pharma companies) nor compulsory licenses (which may be issued by countries in health emergencies) are tools “that would allow us to go as swiftly as we should”, as they have always involved bilateral arrangements or decisions by individual states, which do not address the broader global situation. “With more than $100 billion of public money invested in R&D and supply of vaccines and therapeutics, the risk taken by the pharmaceutical industry has been largely overtaken by the taxpayers,” Dreifuss added. “It is, therefore, an obligation for the states to guarantee fair access, and therefore the means to control the pandemic worldwide.” Dreifuss added that Switzerland “doesn’t share this idea, but I think it is a victim of a vision that is more ideological – not really pragmatic and adapted to the challenge we are facing now.” “Making the rights of intellectual property something very sacred is not a political position I can share,” she added. Van Brempt, meanwhile, said she had been encouraged that the ambassadors of India and South Africa are “not locked into their own truth” but open to negotiations. “I might be wrong but I think I can establish a majority of the European Parliamentarians, but it will involve compromises, and maybe it will not say that we fully support the waiver, as requested by India and South Africa. Maybe it will need another wording, but what I want is a shift in how the Commission looks at it.” Image Credits: Tadeau Andre/MSF . As Indian Pandemic Worsens, Social Networks Save Lives – Government Promotes Alternative Therapies 04/05/2021 Disha Shetty India has received emergency COVID-19 supplies from several countries. PUNE – For two weeks now Sijo Raju, along with a group of 20 young men and women, have been fielding calls from family members looking for oxygen cylinders, ventilator beds and ambulances. Finding a match can take a few hours as India’s overwhelmed health system and front-line healthcare workers try desperately to provide a semblance of care to the massive number of COVID patients. In the absence of a centrally coordinated response, citizens like Raju have stepped up. They verify messages posted online, guide family members to facilities with resources, and do their best to step in place of a government machinery that has effectively abandoned its citizens. “There is just too much information on the internet,” Raju told Health Policy Watch. While the group members, most of them in their 20s and 30s, are based in the Mumbai metropolitan area, they are now trying to help verify requests coming from across India and are among many such citizen groups that have banded together in the past few weeks. On 1 May, India reported over 400,000 cases – a record-high figure in the history of the COVID-19 pandemic so far. It was also the day the country officially lowered the age for those eligible for vaccines from 45 and above to 18 and above. The government had placed orders for the additional vaccines that would be needed just two days before vaccination was to be expanded, and not surprisingly most young people aren’t able to find slots as they try to register for vaccines. But Adar Poonawalla, whose company Serum Institute of India (SII) is responsible for supplying the bulk of the vaccines, said given that the orders were recently received, ramping up production would take still time. Cases continue to rise in India overwhelming the country’s already fragile health infrastructure Promoting Alternative Medicines Meanwhile, India’s government is promoting a poly herbal drug named Ayush-64, calling it a “ray of hope”. The drug is being promoted by the Ministry of Ayurvedic Medicines, Yoga, Unani, Siddha and Homeopathy (AYUSH). Alternative therapies are widely popular albeit not without controversy as mainstream treatments in the pandemic. The government said the drug has been found to be useful in mild to moderate cases. It is also promoting yoga as a way to “strengthen natural immunity”. Most COVID-19 cases are mild to moderate that require little to no treatment under normal circumstances. “The claims made about certain AYUSH interventions in the absence of quality clinical studies and data being presented is unfortunate,” said Anant Bhan, a bioethicist and global health policy expert based in India. “It could lead to reliance on interventions which could not be working, and take the focus away from interventions which do. As is the requirement with allopathic medicines, any claims about AYUSH interventions and utility in COVID-19 needs to be backed by data.” Indian government’s push for alternative medicines comes at a time when Indians are in need of a planned COVID-19 response and urgent ramping up of health facilities. The country’s cases have been on an upward trajectory since March when Prime Minister Narendra Modi held massive election rallies in the state of West Bengal and allowed the Hindu religious event Kumbh Mela to go on that saw gathering of thousands of devotees to perform rituals by the holy river Ganges. Both these events ended up being super spreader ones and worsened the pandemic. Restrictions continue in many high burden states in India and the popular cricket tournament Indian Premier League has also been postponed. The tournament had come under heavy criticism for continuing despite rising COVID-19 deaths. The secretary of the Board of Cricket Administration is Jay Shah, the son of India’s home minister Amit Shah, a key figure in the Modi Administration. Aid Distribution and Vaccine Rollout After India’s pandemic made headlines around the world, the country started receiving aid. Ireland became the most recent country to send aid and US aid has also arrived. Despite this, ordinary citizens continue to struggle for basics based on messages on social media. The government issued a statement saying that the aid will be distributed based on the number of cases and the need in the states – after questions were raised in the Indian media about the plans for distribution. This while the public waits for the Serum Institute to ramp up its production further. Amongst multiple reports it is important that correct information be shared with the public. pic.twitter.com/nzyOZwVBxH — Adar Poonawalla (@adarpoonawalla) May 3, 2021 India’s Supreme Court has also pulled up the Modi administration for failing to regulate the prices of the vaccines. Currently vaccine manufacturers are offering different prices to the centre and state governments, as well as private players, as Health Policy Watch reported in an earlier story. Health experts have said this would set a dangerous precedent while policy experts have criticized the government for its handling of the vaccine distribution. Disha Shetty is an independent journalist based in Pune, India Image Credits: @MEAIndia -Ministry of External Affairs, Spokesman's office , Our World In Data . East Africa Restricts Travellers From India And Tightens Tests for Truckers 04/05/2021 Esther Nakkazi East African truck drivers will get access to one common COVID-19 testing system by mid-May. KAMPALA – Uganda, Kenya and Rwanda have suspended passenger flights from India amid that country’s surge in COVID-19 cases and fears that a number of African countries are on the brink of their own surges. “All flights from India and all passengers originating from India are suspended from 1 May,” the Uganda Ministry of Health said in a statement. “All passenger flights are suspended until further notice. No travellers from India shall be allowed into Uganda regardless of the route of travel.” Meanwhile, Kenya has suspended flights from India for 14 days, according to the Kenya Ministry of Health. Kenya Airways and Rwandair have also suspended flights from and to India. However, East African residents will be allowed to return home. India is a top medical tourism destination for residents in East Africa. The three countries are demanding that travellers who have been to India or travelled through India in the last 14 days, be in possession of a negative PCR COVID-19 test certificate that is digitally verifiable and has been conducted within 120 hours of travel. They will also undergo a PCR test upon arrival. Uganda will allow cargo flights from India where the crew do not disembark and technical stops where travelers do not disembark. It is also allowing aircraft in a state of emergency, operations related to humanitarian aid, medical evacuation, diplomatic flights approved by the appropriate Authority. Uganda has also advised travellers from the USA, United Kingdom, United Arab Emirates, Turkey, South Africa, and Tanzania to consider postponing non-essential travel to Uganda. Travellers from these countries, including Ugandans, will be subjected to a PCR test upon arrival at the points of entry into the country said Dr Jane Ruth Aceng, Uganda’s Minister of Health, during a weekly briefing. “We should make a difference between people and the virus. The virus is the enemy, not the people. If someone has an authentic negative PCR test, they do not cause a problem,” said Dr John Nkengasong, director for Africa Centres for Disease Control and Prevention (CDC). Truck Drivers’ Testing is Tightened The East African Community (EAC) is tightening up on the COVID-19 testing requirements of interstate truck drivers, identified as vectors of the virus, amid numerous problems including forged tests At a recent EAC meeting, Uganda, Kenya, Tanzania, Burundi and South Sudan agreed to submit the names of accredited national laboratories for COVID-19 testing so that these could be linked to the upgraded Regional Electronic Cargo and Driver Tracking System (RECDTS), which recognises digital COVID-19 certificates for truck drivers. The deadline for uploading all accredited COVID-19 testing laboratories in the RECDTS is 15 May. This will ensure that interstate truck drivers and other travellers test for COVID-19 in only through accredited laboratories and that all partner states take up and implement the RECDTS system. Digital certificates are uploaded on the drivers’ smartphones through an app and are valid for 14 days. The App, which was launched in September 2020, was developed with donor funding. It provides a surveillance system to monitor long-distance truckers’ health and enables contact tracing. It also allows partner states to electronically share truck drivers’ COVID-19 test results. The new system is aimed at resolving some of the challenges that were being experienced in the execution of health protocols including multiple testing of truck drivers at the border crossing as there lacked a framework of mutual recognition, document fraud and conflicting test results. The interstate truck drivers also are the single largest group of people who have been identified to be carrying the variants of concern – the B.1.351 variant from South Africa and the B.1.1.7 from the UK. From 399 samples sequenced by the Uganda Virus Research Institute (UVRI) these two variants were detected in 30 truck drivers.The Indian variant has been identified in one patient who was admitted to Mulago Hospital. By Wednesday, the EAC Secretariat expects to have shared a detailed concept note on the development of a common regional health pass to be linked to the upgraded surveillance. Uganda and Kenya Cases Increase By Monday, the Ministry of Health in Kenya had reported that 369 people had tested positive for the disease, from a sample of 4,469 tested in the last 24 hours – a positivity rate of 8.3% compared to the world average of 2.2%. A total of 1,298 patients are in various health facilities countrywide, while 6,652 patients are in isolation at their homes and 19 had died in the 24 hours before Monday. Total confirmed positive cases are now 160,422 and cumulative tests so far conducted are 1,679,779. Some 190 patients are in the ICU, 29 of whom are on ventilatory support and 118 on supplemental oxygen – 43 patients are on observation. Aceng said that Uganda was “experiencing a gradual increase in the COVID-19 cases and it is the beginning of a resurgence”. “This surge is already showing in districts that have remained on high alert and have been carrying out active surveillance,” said Aceng, adding that “this second wave will be worse than the first one”. Uganda has already organised a resurgence plan which is projected to cost over $290 million and is organised around three thresholds: control, alert, and action. The alert threshold is reached when there is a 10% increase in cases while the action threshold begins when there is a 20% increase in the cases observed from the baseline in any geographical location. “The main objective of the resurgence plan is to mitigate transmission and minimise the public health and social economic impact,” said Aceng. The resurgence plan will include enhanced surveillance, active case search, contact tracing, procurement of test kits, Personal Protective Equipment, critical care support, strengthening community engagement and risk communications, and supporting the vaccination teams but it does not include procurement of vaccines. By 30 April, Uganda’s cumulative COVID-19 cases stood at 41,866 with 342 deaths. There are currently 444 active cases. WHO Warns of African Resurgence Dr Matshidiso Moeti, WHO Regional Director for Africa. The World Health Organisation (WHO) predicts a high risk of COVID-19 resurgence in several African countries due to poor adherence to public health measures, mass gatherings, low testing and vaccination rates. “We cannot be lulled into a false sense of security. The devastating surge of cases and deaths in India, and increases in other regions of the world, are clear signs that the pandemic is not yet over in African countries,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “ A new upsurge of COVID-19 infections is a real risk in many countries even if the region’s case count in recent weeks appears to be stable,” she added. “Combatting COVID-19 fatigue appears to be the key battle in our collective response to the pandemic.” According to the WHO analysis of 46 African countries, Kenya, Egypt, Ethiopia face a very high risk of resurgence, while a further 20 countries face a high risk and 22, moderate risk, and only one country faces low risk. The risk was calculated using seven indicators with data from the past four weeks, including COVID-19 cases per million people; the percentage of change in new cases; the percentage of change in new deaths; the reproductive number (the rate at which an infection spreads); the pandemic trend; the average weekly number of tests per 10 000 people; and the percentage of the population that has received at least one vaccine dose. With more than 4.5 million confirmed cases and over 120 000 deaths to date, the continent has not experienced a surge in cases since January and the epidemic curve has plateaued for six weeks. But the relatively low number of cases has encouraged complacency and reduced adherence to behavioural measures to prevent the spread of the virus. In addition, recent political rallies in Benin, Cote d’Ivoire, Guinea and Kenya caused a spike in new cases. Upcoming elections in Cape Verde, Ethiopia, Gambia, Sao Tome and Principe and Zambia could also trigger cases due to mass gatherings, said Moeti. Of the 46 countries analysed, 31 performed fewer than 10 tests per 10,000 people per week in the past four weeks. “Most new cases are still not being detected among known contacts. Investigation of clusters of cases and contact tracing are worryingly low in most countries in the region,” Moeti said. “We must scale up testing including through rapid diagnostic tests to enhance response to the pandemic.” Image Credits: EAC. WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines 03/05/2021 Svĕt Lustig Vijay A shipment of the Chinese Sinopharm vaccine reaches Peru The World Health Organization (WHO) appears to be inching towards the approval of the Chinese Sinopharm and Sinovac vaccines as it struggles to fill a looming vaccine vacuum left by India’s Serum Institute – which has halted exports as the country continues to reel from a tragic coronavirus outbreak. Meanwhile, the WHO declared the latest Ebola outbreak in the Democratic Republic of Congo to be over, just three months after the first case was reported in North Kivu. Chinese Sinopharm & Sinovac May be Approved By End of Week Mariângela Simão, WHO Assistant-Director General for Access to Medicines The Chinese vaccines from Sinopharm and Sinovac could be approved by the end of this week, noted the WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals Mariangela Simao, speaking at a WHO press conference on Monday. “We are finalizing the assessment of Sinopharm [but] there’s still some documentation that needs to be added,” she said. “We will start the final assessment for the listing of Sinovac on the fifth [of May], so we expect both the Chinese vaccines [to] be finalized by the end of this week.” If both vaccines receive the WHO’s green light, China could could become the world’s largest vaccine supplier, assuming that Sinovac and Sinopharm will honor their commitment to produce two billion vaccine doses this year. Despite the lack of published data for the two vaccines, as well as their hefty price, both seem to have met the WHO’s minimum efficacy requirement of 50%, the WHO’s chairperson of Strategic Advisory Group of Experts (SAGE) said late last month. With regards to the WHO’s approval of another vaccine frontrunner that seems to be significantly more potent and cheaper than its Chinese counterparts, Russia’s Sputnik V, the WHO expects a final decision by June or even July, said Simao. “WHO still does not have the entire dossier [for Sputnik], it’s not complete yet,” she said, noting that the WHO is in the process of assessing good clinical practices for Sputnik V and is set to begin evaluating manufacturing practices next Monday until early June. “We expect that as soon as we have the entire dossier, plus the compliance to both good manufacturing practices and the good clinical practice, the vaccine can be assessed then by the technical expert group [SAGE] and we expect that this is likely to happen [by the] end of June or probably in July.” Ebola Outbreak in DRC Declared Over by WHO Meanwhile, the WHO’s Director General, Dr Tedros Adhanom Ghebreyesus, hailed the DRC’s milestone in bringing an end to the twelfth Ebola outbreak in the country – a deadly disease that kills about half of the people it infects. The latest #Ebola outbreak in #DRC🇨🇩 has been declared over after just 3 months. Twelve cases, six deaths & six recoveries were recorded in four health zones in North Kivu during this outbreak.@WHO congratulates DRC’s swift response to this outbreak! 👉🏿https://t.co/2gNHJR22B6 pic.twitter.com/hNZ1moYLaT — WHO African Region (@WHOAFRO) May 3, 2021 “Earlier today, the government of the Democratic Republic of the Congo, announced the end of the most recent Ebola outbreak three months after the first case was reported in North Kivu,” said Dr. Tedros on Monday, emphasizing that a comprehensive public health approach was crucial in ending the latest outbreak of Ebola. “Huge credit must be given to the local health workers and the national authorities for their prompt response, tenacity, experience and hard work that brought this outbreak under control,” added Dr Matshidiso Moeti, WHO Regional Director for Africa. She was referring to the country’s swift move to vaccinate almost 2,000 people at high-risk of contracting the virus and providing treatment as soon as the outbreak was declared in February. However, she stressed that going forward, strong surveillance systems will be crucial to swiftly detect potential flare-ups and to fight parallel epidemics of measles, cholera and COVID-19. “Although the outbreak has ended, we must stay alert for possible resurgence and at the same time use the growing expertise on emergency response to address other health threats the country faces.” Image Credits: Sinopharm, Peruvian Ministry of External Affairs. After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO & UNICEF Call For Better Hygiene & More Affordable Water & Sanitation To Stop The Spread Of Deadly Infections 06/05/2021 Editorial team Low-and-middle-income countries have made significantly less progress than high-income countries in implementing hand hygiene and infection prevention programmes that can stop deadly diseases, from diarrhoea to COVID-19, according to a recent A World Health Organization survey of 88 countries. And one in four health care facilities in poorer countries do not have basic water services and one in three lacks hand hygiene supplies, said WHO, marking World Hygiene Day on Wednesday. Meanwhile, universal access to safe drinking waters, sanitation and hygiene, are unlikely to be met unless affordability is addressed and monitored – according to a new report by UNICEF and WHO, released on World Hygiene Day. Improved monitoring of “affordability” indicators will ultimately allow governments and the water, sanitation and hygiene (WASH) sector to more effectively target support and to make WASH services affordable to all. Good Hygiene Critical to Stopping COVID-10 – as well as Other Deadly Diseases Good hygiene practices remain a “serious challenge” at any time, but more so when the world is fighting the deadly COVID-19 pandemic, WHO said in a statement. “COVID-19 has dramatically demonstrated just how important good hand hygiene practices are in reducing the risk of transmission, when used as part of a comprehensive package of preventative measures. “For example, in some low-and-middle-income countries, only one in 10 have workers who practice proper hand hygiene while caring for patients at high-risk of health care susceptibility infection in intensive care units. While, also in high-income countries, hand hygiene compliance rarely exceeds 60% to 70%.” Moreover, few low-income countries have the capacity to monitor Infection, Prevention and Control (IPC) effectively. A new WHO online monitoring portal will help countries identify and address gaps. The first ever IPC monitoring portal is a protected online platform for countries to collect data in a standardised and user-friendly manner and download their situation analysis following data entry along with advice on areas and approaches for improvement. Infections acquired in health care settings like hospitals and clinics affect millions of patients and health workers globally. Europe alone records nearly nine million infections yearly, said the U.N. agency. But highly effective and low-cost hand hygiene strategies are available that could reduce these infections by half. “Half these infections can be avoided by implementing effective IPC practices and programmes, including hand hygiene improvement strategies. Such strategies can also prevent 3 out of 4 the AMR-related deaths that occur in health care facilities.” The organisation has also declared 2021 the “Year of the Health and Care Worker”, and in relation to that, evidence has shown that appropriate hand hygiene practices reduce infections during health care delivery: “So, engaging different health professionals, as well as patients and everyone in the society in World Hand Hygiene Day 2021 is critical also to supporting the “Year of Health and Care Workers”. Image Credits: Pixabay. New Report Calls For More Midwives To Help Prevent Millions Of Childbirth Deaths 05/05/2021 Chandre Prince A new report recommends that governments prioritise funding and support for midwifery amid a global shortfall of 900,000 midwives. Two in every three deaths in childbirth could be prevented by 2035 if the world starts recruiting and training more midwives, a new report on the “State of World’s Midwifery 2021” has found. The report, launched by the UN Population Fund (UNFPA) on Wednesday found a global shortfall of 900,000 midwives – and said that the global midwifery workforce needs to be expanded by some 30% to close that gap. Compiled by the UNFPA, the UN’s sexual and reproductive health agency (UNFPA), WHO (World Health Organization), the International Confederation of Midwives (ICM) and other partners, the report evaluates the midwifery workforce and related health resources in 194 countries. It states that for “midwives to achieve their life-saving and life-changing potential, greater investment is needed in their education and training, midwife-led service delivery, and midwifery leadership”. Governments must prioritise funding and support for midwifery and take concrete steps to include midwives in determining health policies. “Midwives play a vital role in reducing the risks of childbirth for women all over the world,” said WHO director general Dr Tedros Adhanom Ghebreyesus. Increasing their numbers will “deliver a triple dividend in contributing to better health, gender equality and inclusive economic growth,” he said. The last State of the World’s Midwifery report, published in 2014, also raised the alarm over shortages and provided a roadmap on how to remedy this deficit. But progress over the past eight years has been too slow, the report found. The analysis in this year’s report shows that, at current rates of progress, the situation will have improved only slightly by 2030. ICM president Franka Cadee said “midwives are continually overlooked and ignored” and called on “governments to acknowledge the evidence surrounding the life-promoting, life-saving impact of midwife-led care, and take action on the report’s recommendations”. Almost one in five women give birth without a skilled health provider, exposing both mothers and babies to risk, the report further found. It gives the latest stillbirths estimates at about two million a year, along with an estimated 2.4 million new-born deaths and some 295,000 maternal deaths, either during or soon after pregnancy. Describing the report’s findings as “alarming”, UNFPA executive director Dr Natalia Kanem said 1.1million more essential health workers are needed to deliver sexual, reproductive, maternal, newborn and adolescent health care, and 80 per cent of these missing essential health workers are midwives. “A capable, well-trained midwife can have an enormous impact on childbearing women and their families – an impact often passed on from one generation to the next,” Kanem said. The lack of midwives, the report states, is driven by gender inequality, with countries overlooking sexual and reproductive health and under-estimating the value of a female-dominated workforce. Fixing the gaps in provision could save an estimated 4.3 million mothers and babies a year, cutting two in three needless deaths by 2035, said analysis conducted for the report published in The Lancet medical journal last December. The report urged governments to put money into boosting midwife numbers, improving training and offering midwives a greater role in health policy and maternal healthcare. Image Credits: WHO, WHO SEARO. WHO Global Data Hub To Help Fight Future Pandemics 05/05/2021 Chandre Prince German Chancellor Angela Merkel The World Health Organization and the German government on Wednesday announced the launch of a new Global Hub for Pandemic and Epidemic Intelligence that aims to harness the world of big data, media and epidemiological reports to more rapidly identify and respond to emerging disease risks. The hub, to be launched in Berlin later this year, would bring together scientists, data experts and other know-how from governments, international organizations and the private sector, in new, and more flexible forms of collaboration, WHO’s Director of Health Emergencies, Mike Ryan, said at a press briefing on Wednesday. Launch of the hub is being supported by €30 million in seed funds from the German government, said officials at the briefing, addressed by German Chancellor Angela Merkel and Health Minister Jens Spahn. “The WHO Hub for Pandemic and Epidemic Intelligence can make a difference for a safer future…(we should focus on) the development of a global data ecosystem to produce timely insights and tools for policymakers, before and after an epidemic and pandemic events,” Spahn said. The hub would help gather data more efficiently to predict, prevent and respond to future pandemics and epidemic risks worldwide, said WHO Director General Dr Tedros Adhanom Ghebreyesus. “One of the lessons of the Covid-19 pandemic is that the world needs a significant leap forward in data analysis to help leaders make informed public health decisions,” Tedros said. “This requires harnessing the potential of advanced technologies such as artificial intelligence, combining diverse data sources, and collaborating across multiple disciplines. Better data and better analytics will lead to better decisions,” he said. Faster Identification of Threats and Responses Some of the first SARS-COV-2 cases emerged around Wuhan’s “wet markets” selling wild animals for slaughter and meat consumption; such markets can be a flashpoint for pathogen transmission to humans. The initiative responds to a key issue raised by WHO member states and independent reviewers regarding the initial stages of COVID-19 pandemic response – and the belated recognition of the SARS-CoV2 outbreak that was now obviously simmering in Wuhan throughout the fall of 2019 – and possibly even spreading then to other countries, such as Italy, where COVID-positive serum samples from the period were later identified. Even so, the first Chinese government and media reports of the mysterious pneumonia-like outbreak in Wuhan were only picked up on 31 December, 2019 – by WHO’s China country office as well as by the WHO EIOS (Epidemic Intelligence Open Sources) platform – which noted a report from ProMED, the International Society for Infectious Diseases. Following that, criticism has also been leveraged against the quality of data collection by WHO, China and other member states reflecting the early days of the pandemic spread – which may have contributed to WHO’s delays in declaring an international public health emergency over the virus – which so far has killed over 3.2 million people worldwide. Although not “new”, the idea of a hub, according to Tedros, coalesced during discussions with Merkel in October 2020 about the creation of a centre that would serve as a global nerve centre to enhance global capacity for pandemic and epidemic intelligence. Merkel, in a video message, said that the COVID-19 pandemic “has taught us that we can only fight pandemics and epidemics together”. “The new WHO Hub will be a global platform for pandemic prevention, bringing together various governmental, academic and private sector institutions,” Merkel said, further welcoming WHO’s decision to base the hub in Berlin. The hub will bring together governmental, academic and private sector institutions to harness global data, surveillance and analytics and will involve a global collaboration of countries and partners to look for pre-signals that go beyond current systems that monitor publicly available information for signs of emerging outbreaks. Build Upon EIOS – CERN-like Model For Cooperation WHO’s Director of Health Emergencies, Mike Ryan Ryan said that the hub would not be about creating another “big bureaucratic WHO institution” but rather a transformed and engaging centre. He said that WHO envisages the platform as functioning similar to CERN, the European Organization for Nuclear Research – an iconic Geneva-area institution that brings together research fellows, visiting scholars and other experts for brief stints, where they can share and apply their knowledge and skills. “It’s about creating a platform with Germany, where everyone can come and contribute. And this becomes a facilitating environment. We bring the best minds, we bring the best ideas and we facilitate that with the infrastructure and the tools and all of the things that we need…(to) allow others to take the real innovative steps to move us forward in this regard,” Ryan added. He said that the hub would build upon the networks created by EIOS – in a more sophisticated model – to become operational from September. Germany has offered a seed fund of €30 million annually as a startup for the hub, with WHO still working on further details of the budget, he added. . Appeals for further funding are being discussed with various potential donors at the G7 level, said Ryan. Berlin “Ideal Location” for Global Hub German Health Minister Jens Spahn Merkel said Berlin was an ideal location for the hub as it already had leading players in the digital and health fields, such as the Robert Koch Institute, the German federal government’s scientific research institution. “If that expertise is now supplemented by the WHO Hub, we will create a unique environment for pandemic and health research here in Berlin — an environment from which important action-oriented insights will emerge for governments and leaders around the world,” she said. Emphasising that the new hub would still fall under WHO’s governance, Spahn said Germany was offering an “enabling environment for the inter linkages between public health and digital players”. “We are very confident that this local environment will provide numerous opportunities for synergies with a new double edge for the hub,” Spahn said, echoing Tedros’ sentiments that there was a clear need for stronger early local warning alerts and emergency response system to help improve public health intelligence and risk analysis. Transparent Data is Imperative WHO affirmed that data from the new global hub will be held openly and transparently. While affirming that data, in principle, should be held openly and transparently, Ryan acknowledged that it will still be up to the member states and the rules of the International Health Regulations to decide how, and with whom, to share verified information. “The aim is to bring together partners from around the world to develop better access to data and to develop tools we need to generate the insights we need before, during and after pandemics. But, also to build trust between partners in sharing that data in sharing those insights. We aim to bring that whole process together,” Ryan said. He acknowledged, however, that access to data as well as tools for generating insight from such data is not evenly distributed across the member states. And the hub would try to address those inequalities, as well. “I can assure you that that’s the point of the centre… to democratize that process, bring more parameters and create facilities, translate trends and transformative technologies on the capabilities to our member states.” However, issues around transparency and accountability will not be solved by new technologies, but by building trust between partners in sharing data and insights, Ryan added. Three independent panels are due to report at the upcoming World Health Assembly (WHA)on how the WHO and member states reacted to the pandemic, and propose reforms in rules and procedures. Effectively the creation of the hub leapfrogs over what is likely to be highly politicized deliberations on those reforms at the WHA – to create at least one fait accompli that would support earlier warnings. Image Credits: Breaking Asia, UCT. Time to End ‘Delaying Tactics’ on TRIPS Waiver, Say India And South Africa Ahead Of Critical WTO Meeting 04/05/2021 Kerry Cullinan High-level panel on TRIPS waiver CAPE TOWN – The “circular discussion” at the World Trade Organization (WTO) on the TRIPS waiver needs to move to “text-based” negotiations, Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO said on Tuesday. Her Indian counterpart, Brajendra Navnit, added that opponents of the waiver had been using “delaying tactics” since the beginning of the year, “changing goalposts” to raise new problems once their earlier concerns had been addressed. Mlumbi-Peter and Navnit were addressing a high-level panel on Tuesday organised by a range of civil society organisations, on the eve of yet another meeting of the TRIPS Council on the waiver issue, set for Wednesday and Thursday. A waiver in the enforcement of patents, copyright, industrial designs, and trade secrets, under WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), was proposed in October 2020 by India and South Africa, for all COVID-related health products for the duration of the pandemic. This proposal has been supported by over 60 member states, but opposed by mostly high-income nations. During the ensuing six months of negotiations, a further two million people have died from the SARS-CoV2 virus, participants at Tuesday’s panel pointed out. A revised version of the TRIPS waiver proposal is to be presented at Wednesday’s TRIPS General Council “in a bid to reconcile positions”, according to the WTO. ‘Hopeful Signs” on US Position Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO Until recently, Mlumbi-Peters had chaired the WTO TRIPS Council, on behalf of South Africa, and had thus been unable to speak publicly in support of the waiver proposal. Another panelist, United States Congresswoman Jan Schakowsky, who has been championing the waiver in her country, said that it was still unclear if the US administration would support the waiver – but there were some hopeful signs of “dramatic change”. “The United States position is evolving. There are divisions even within the administration – and [within] the Members of Congress, a majority of the Democrats have weighed in, in favour of a TRIPS waiver,” said Schakowsky. “When Big Pharma talks about its priorities and that intellectual property rights rule everything, they are forgetting that the American people, the taxpayers, have spent billions and billions of dollars in research and development and distribution, have a huge stake in this,” she added. No ‘Good Examples’ of Voluntary Licensing Schakowsky supported text-based negotiations on the waiver “to make the changes that are necessary that are going to allow all countries to have access”. “We really don’t have the time to argue with the pharmaceutical industry,” said added. Kathleen Van Brempt, Belgian Member of the European Parliament and the trade coordinator for the Parliament’s Progressive Alliance of Socialists and Democrats Group, proposed “a coalition of the willing” involving European and US politicians in particular. Van Brempt said that opponents of the waiver claimed that it was an “ideological” proposal that would not facilitate the technology transfer needed to speed up vaccine production, and that this could be achieved with voluntary licensing of COVID-19 treatments and medicines. “The facts and figures prove them wrong,” said Van Brempt. “I don’t know any good examples of voluntary licensing, or even of compulsory licensing, that would ramp up production. That is not the case today, and that’s why we have to move on.” Kathleen Van Brempt, Belgian Member of the European Parliament Van Brempt added: “I’m very happy to see my colleague of the US Congress [Schakowsky]. I think we should work much more closely together because I hear that the Biden Administration might move.” She also suggested engaging with the pharmaceutical industry as a first step to inform them about “how unacceptable it is that they decide on the price, and they decide who can produce”, when these decisions “should be steered by governments”. She also suggested opening up the discussion on the TRIPS waiver with the aim of “ramping up [vaccine] production”. More Pragmatic Than Ideological Ruth Dreifuss, former President of Switzerland, said that “unilateral, bilateral tools, like voluntary licenses, compulsory licenses, parallel imports have not adapted to the current situation”. “We urgently need a more global approach as proposed by India and South Africa,” added Dreifuss, who chairs WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) and was co-chair of the UN Secretary General’s High-Level Panel on Access to Medicines. Neither voluntary licenses (issued by pharma companies) nor compulsory licenses (which may be issued by countries in health emergencies) are tools “that would allow us to go as swiftly as we should”, as they have always involved bilateral arrangements or decisions by individual states, which do not address the broader global situation. “With more than $100 billion of public money invested in R&D and supply of vaccines and therapeutics, the risk taken by the pharmaceutical industry has been largely overtaken by the taxpayers,” Dreifuss added. “It is, therefore, an obligation for the states to guarantee fair access, and therefore the means to control the pandemic worldwide.” Dreifuss added that Switzerland “doesn’t share this idea, but I think it is a victim of a vision that is more ideological – not really pragmatic and adapted to the challenge we are facing now.” “Making the rights of intellectual property something very sacred is not a political position I can share,” she added. Van Brempt, meanwhile, said she had been encouraged that the ambassadors of India and South Africa are “not locked into their own truth” but open to negotiations. “I might be wrong but I think I can establish a majority of the European Parliamentarians, but it will involve compromises, and maybe it will not say that we fully support the waiver, as requested by India and South Africa. Maybe it will need another wording, but what I want is a shift in how the Commission looks at it.” Image Credits: Tadeau Andre/MSF . As Indian Pandemic Worsens, Social Networks Save Lives – Government Promotes Alternative Therapies 04/05/2021 Disha Shetty India has received emergency COVID-19 supplies from several countries. PUNE – For two weeks now Sijo Raju, along with a group of 20 young men and women, have been fielding calls from family members looking for oxygen cylinders, ventilator beds and ambulances. Finding a match can take a few hours as India’s overwhelmed health system and front-line healthcare workers try desperately to provide a semblance of care to the massive number of COVID patients. In the absence of a centrally coordinated response, citizens like Raju have stepped up. They verify messages posted online, guide family members to facilities with resources, and do their best to step in place of a government machinery that has effectively abandoned its citizens. “There is just too much information on the internet,” Raju told Health Policy Watch. While the group members, most of them in their 20s and 30s, are based in the Mumbai metropolitan area, they are now trying to help verify requests coming from across India and are among many such citizen groups that have banded together in the past few weeks. On 1 May, India reported over 400,000 cases – a record-high figure in the history of the COVID-19 pandemic so far. It was also the day the country officially lowered the age for those eligible for vaccines from 45 and above to 18 and above. The government had placed orders for the additional vaccines that would be needed just two days before vaccination was to be expanded, and not surprisingly most young people aren’t able to find slots as they try to register for vaccines. But Adar Poonawalla, whose company Serum Institute of India (SII) is responsible for supplying the bulk of the vaccines, said given that the orders were recently received, ramping up production would take still time. Cases continue to rise in India overwhelming the country’s already fragile health infrastructure Promoting Alternative Medicines Meanwhile, India’s government is promoting a poly herbal drug named Ayush-64, calling it a “ray of hope”. The drug is being promoted by the Ministry of Ayurvedic Medicines, Yoga, Unani, Siddha and Homeopathy (AYUSH). Alternative therapies are widely popular albeit not without controversy as mainstream treatments in the pandemic. The government said the drug has been found to be useful in mild to moderate cases. It is also promoting yoga as a way to “strengthen natural immunity”. Most COVID-19 cases are mild to moderate that require little to no treatment under normal circumstances. “The claims made about certain AYUSH interventions in the absence of quality clinical studies and data being presented is unfortunate,” said Anant Bhan, a bioethicist and global health policy expert based in India. “It could lead to reliance on interventions which could not be working, and take the focus away from interventions which do. As is the requirement with allopathic medicines, any claims about AYUSH interventions and utility in COVID-19 needs to be backed by data.” Indian government’s push for alternative medicines comes at a time when Indians are in need of a planned COVID-19 response and urgent ramping up of health facilities. The country’s cases have been on an upward trajectory since March when Prime Minister Narendra Modi held massive election rallies in the state of West Bengal and allowed the Hindu religious event Kumbh Mela to go on that saw gathering of thousands of devotees to perform rituals by the holy river Ganges. Both these events ended up being super spreader ones and worsened the pandemic. Restrictions continue in many high burden states in India and the popular cricket tournament Indian Premier League has also been postponed. The tournament had come under heavy criticism for continuing despite rising COVID-19 deaths. The secretary of the Board of Cricket Administration is Jay Shah, the son of India’s home minister Amit Shah, a key figure in the Modi Administration. Aid Distribution and Vaccine Rollout After India’s pandemic made headlines around the world, the country started receiving aid. Ireland became the most recent country to send aid and US aid has also arrived. Despite this, ordinary citizens continue to struggle for basics based on messages on social media. The government issued a statement saying that the aid will be distributed based on the number of cases and the need in the states – after questions were raised in the Indian media about the plans for distribution. This while the public waits for the Serum Institute to ramp up its production further. Amongst multiple reports it is important that correct information be shared with the public. pic.twitter.com/nzyOZwVBxH — Adar Poonawalla (@adarpoonawalla) May 3, 2021 India’s Supreme Court has also pulled up the Modi administration for failing to regulate the prices of the vaccines. Currently vaccine manufacturers are offering different prices to the centre and state governments, as well as private players, as Health Policy Watch reported in an earlier story. Health experts have said this would set a dangerous precedent while policy experts have criticized the government for its handling of the vaccine distribution. Disha Shetty is an independent journalist based in Pune, India Image Credits: @MEAIndia -Ministry of External Affairs, Spokesman's office , Our World In Data . East Africa Restricts Travellers From India And Tightens Tests for Truckers 04/05/2021 Esther Nakkazi East African truck drivers will get access to one common COVID-19 testing system by mid-May. KAMPALA – Uganda, Kenya and Rwanda have suspended passenger flights from India amid that country’s surge in COVID-19 cases and fears that a number of African countries are on the brink of their own surges. “All flights from India and all passengers originating from India are suspended from 1 May,” the Uganda Ministry of Health said in a statement. “All passenger flights are suspended until further notice. No travellers from India shall be allowed into Uganda regardless of the route of travel.” Meanwhile, Kenya has suspended flights from India for 14 days, according to the Kenya Ministry of Health. Kenya Airways and Rwandair have also suspended flights from and to India. However, East African residents will be allowed to return home. India is a top medical tourism destination for residents in East Africa. The three countries are demanding that travellers who have been to India or travelled through India in the last 14 days, be in possession of a negative PCR COVID-19 test certificate that is digitally verifiable and has been conducted within 120 hours of travel. They will also undergo a PCR test upon arrival. Uganda will allow cargo flights from India where the crew do not disembark and technical stops where travelers do not disembark. It is also allowing aircraft in a state of emergency, operations related to humanitarian aid, medical evacuation, diplomatic flights approved by the appropriate Authority. Uganda has also advised travellers from the USA, United Kingdom, United Arab Emirates, Turkey, South Africa, and Tanzania to consider postponing non-essential travel to Uganda. Travellers from these countries, including Ugandans, will be subjected to a PCR test upon arrival at the points of entry into the country said Dr Jane Ruth Aceng, Uganda’s Minister of Health, during a weekly briefing. “We should make a difference between people and the virus. The virus is the enemy, not the people. If someone has an authentic negative PCR test, they do not cause a problem,” said Dr John Nkengasong, director for Africa Centres for Disease Control and Prevention (CDC). Truck Drivers’ Testing is Tightened The East African Community (EAC) is tightening up on the COVID-19 testing requirements of interstate truck drivers, identified as vectors of the virus, amid numerous problems including forged tests At a recent EAC meeting, Uganda, Kenya, Tanzania, Burundi and South Sudan agreed to submit the names of accredited national laboratories for COVID-19 testing so that these could be linked to the upgraded Regional Electronic Cargo and Driver Tracking System (RECDTS), which recognises digital COVID-19 certificates for truck drivers. The deadline for uploading all accredited COVID-19 testing laboratories in the RECDTS is 15 May. This will ensure that interstate truck drivers and other travellers test for COVID-19 in only through accredited laboratories and that all partner states take up and implement the RECDTS system. Digital certificates are uploaded on the drivers’ smartphones through an app and are valid for 14 days. The App, which was launched in September 2020, was developed with donor funding. It provides a surveillance system to monitor long-distance truckers’ health and enables contact tracing. It also allows partner states to electronically share truck drivers’ COVID-19 test results. The new system is aimed at resolving some of the challenges that were being experienced in the execution of health protocols including multiple testing of truck drivers at the border crossing as there lacked a framework of mutual recognition, document fraud and conflicting test results. The interstate truck drivers also are the single largest group of people who have been identified to be carrying the variants of concern – the B.1.351 variant from South Africa and the B.1.1.7 from the UK. From 399 samples sequenced by the Uganda Virus Research Institute (UVRI) these two variants were detected in 30 truck drivers.The Indian variant has been identified in one patient who was admitted to Mulago Hospital. By Wednesday, the EAC Secretariat expects to have shared a detailed concept note on the development of a common regional health pass to be linked to the upgraded surveillance. Uganda and Kenya Cases Increase By Monday, the Ministry of Health in Kenya had reported that 369 people had tested positive for the disease, from a sample of 4,469 tested in the last 24 hours – a positivity rate of 8.3% compared to the world average of 2.2%. A total of 1,298 patients are in various health facilities countrywide, while 6,652 patients are in isolation at their homes and 19 had died in the 24 hours before Monday. Total confirmed positive cases are now 160,422 and cumulative tests so far conducted are 1,679,779. Some 190 patients are in the ICU, 29 of whom are on ventilatory support and 118 on supplemental oxygen – 43 patients are on observation. Aceng said that Uganda was “experiencing a gradual increase in the COVID-19 cases and it is the beginning of a resurgence”. “This surge is already showing in districts that have remained on high alert and have been carrying out active surveillance,” said Aceng, adding that “this second wave will be worse than the first one”. Uganda has already organised a resurgence plan which is projected to cost over $290 million and is organised around three thresholds: control, alert, and action. The alert threshold is reached when there is a 10% increase in cases while the action threshold begins when there is a 20% increase in the cases observed from the baseline in any geographical location. “The main objective of the resurgence plan is to mitigate transmission and minimise the public health and social economic impact,” said Aceng. The resurgence plan will include enhanced surveillance, active case search, contact tracing, procurement of test kits, Personal Protective Equipment, critical care support, strengthening community engagement and risk communications, and supporting the vaccination teams but it does not include procurement of vaccines. By 30 April, Uganda’s cumulative COVID-19 cases stood at 41,866 with 342 deaths. There are currently 444 active cases. WHO Warns of African Resurgence Dr Matshidiso Moeti, WHO Regional Director for Africa. The World Health Organisation (WHO) predicts a high risk of COVID-19 resurgence in several African countries due to poor adherence to public health measures, mass gatherings, low testing and vaccination rates. “We cannot be lulled into a false sense of security. The devastating surge of cases and deaths in India, and increases in other regions of the world, are clear signs that the pandemic is not yet over in African countries,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “ A new upsurge of COVID-19 infections is a real risk in many countries even if the region’s case count in recent weeks appears to be stable,” she added. “Combatting COVID-19 fatigue appears to be the key battle in our collective response to the pandemic.” According to the WHO analysis of 46 African countries, Kenya, Egypt, Ethiopia face a very high risk of resurgence, while a further 20 countries face a high risk and 22, moderate risk, and only one country faces low risk. The risk was calculated using seven indicators with data from the past four weeks, including COVID-19 cases per million people; the percentage of change in new cases; the percentage of change in new deaths; the reproductive number (the rate at which an infection spreads); the pandemic trend; the average weekly number of tests per 10 000 people; and the percentage of the population that has received at least one vaccine dose. With more than 4.5 million confirmed cases and over 120 000 deaths to date, the continent has not experienced a surge in cases since January and the epidemic curve has plateaued for six weeks. But the relatively low number of cases has encouraged complacency and reduced adherence to behavioural measures to prevent the spread of the virus. In addition, recent political rallies in Benin, Cote d’Ivoire, Guinea and Kenya caused a spike in new cases. Upcoming elections in Cape Verde, Ethiopia, Gambia, Sao Tome and Principe and Zambia could also trigger cases due to mass gatherings, said Moeti. Of the 46 countries analysed, 31 performed fewer than 10 tests per 10,000 people per week in the past four weeks. “Most new cases are still not being detected among known contacts. Investigation of clusters of cases and contact tracing are worryingly low in most countries in the region,” Moeti said. “We must scale up testing including through rapid diagnostic tests to enhance response to the pandemic.” Image Credits: EAC. WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines 03/05/2021 Svĕt Lustig Vijay A shipment of the Chinese Sinopharm vaccine reaches Peru The World Health Organization (WHO) appears to be inching towards the approval of the Chinese Sinopharm and Sinovac vaccines as it struggles to fill a looming vaccine vacuum left by India’s Serum Institute – which has halted exports as the country continues to reel from a tragic coronavirus outbreak. Meanwhile, the WHO declared the latest Ebola outbreak in the Democratic Republic of Congo to be over, just three months after the first case was reported in North Kivu. Chinese Sinopharm & Sinovac May be Approved By End of Week Mariângela Simão, WHO Assistant-Director General for Access to Medicines The Chinese vaccines from Sinopharm and Sinovac could be approved by the end of this week, noted the WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals Mariangela Simao, speaking at a WHO press conference on Monday. “We are finalizing the assessment of Sinopharm [but] there’s still some documentation that needs to be added,” she said. “We will start the final assessment for the listing of Sinovac on the fifth [of May], so we expect both the Chinese vaccines [to] be finalized by the end of this week.” If both vaccines receive the WHO’s green light, China could could become the world’s largest vaccine supplier, assuming that Sinovac and Sinopharm will honor their commitment to produce two billion vaccine doses this year. Despite the lack of published data for the two vaccines, as well as their hefty price, both seem to have met the WHO’s minimum efficacy requirement of 50%, the WHO’s chairperson of Strategic Advisory Group of Experts (SAGE) said late last month. With regards to the WHO’s approval of another vaccine frontrunner that seems to be significantly more potent and cheaper than its Chinese counterparts, Russia’s Sputnik V, the WHO expects a final decision by June or even July, said Simao. “WHO still does not have the entire dossier [for Sputnik], it’s not complete yet,” she said, noting that the WHO is in the process of assessing good clinical practices for Sputnik V and is set to begin evaluating manufacturing practices next Monday until early June. “We expect that as soon as we have the entire dossier, plus the compliance to both good manufacturing practices and the good clinical practice, the vaccine can be assessed then by the technical expert group [SAGE] and we expect that this is likely to happen [by the] end of June or probably in July.” Ebola Outbreak in DRC Declared Over by WHO Meanwhile, the WHO’s Director General, Dr Tedros Adhanom Ghebreyesus, hailed the DRC’s milestone in bringing an end to the twelfth Ebola outbreak in the country – a deadly disease that kills about half of the people it infects. The latest #Ebola outbreak in #DRC🇨🇩 has been declared over after just 3 months. Twelve cases, six deaths & six recoveries were recorded in four health zones in North Kivu during this outbreak.@WHO congratulates DRC’s swift response to this outbreak! 👉🏿https://t.co/2gNHJR22B6 pic.twitter.com/hNZ1moYLaT — WHO African Region (@WHOAFRO) May 3, 2021 “Earlier today, the government of the Democratic Republic of the Congo, announced the end of the most recent Ebola outbreak three months after the first case was reported in North Kivu,” said Dr. Tedros on Monday, emphasizing that a comprehensive public health approach was crucial in ending the latest outbreak of Ebola. “Huge credit must be given to the local health workers and the national authorities for their prompt response, tenacity, experience and hard work that brought this outbreak under control,” added Dr Matshidiso Moeti, WHO Regional Director for Africa. She was referring to the country’s swift move to vaccinate almost 2,000 people at high-risk of contracting the virus and providing treatment as soon as the outbreak was declared in February. However, she stressed that going forward, strong surveillance systems will be crucial to swiftly detect potential flare-ups and to fight parallel epidemics of measles, cholera and COVID-19. “Although the outbreak has ended, we must stay alert for possible resurgence and at the same time use the growing expertise on emergency response to address other health threats the country faces.” Image Credits: Sinopharm, Peruvian Ministry of External Affairs. After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New Report Calls For More Midwives To Help Prevent Millions Of Childbirth Deaths 05/05/2021 Chandre Prince A new report recommends that governments prioritise funding and support for midwifery amid a global shortfall of 900,000 midwives. Two in every three deaths in childbirth could be prevented by 2035 if the world starts recruiting and training more midwives, a new report on the “State of World’s Midwifery 2021” has found. The report, launched by the UN Population Fund (UNFPA) on Wednesday found a global shortfall of 900,000 midwives – and said that the global midwifery workforce needs to be expanded by some 30% to close that gap. Compiled by the UNFPA, the UN’s sexual and reproductive health agency (UNFPA), WHO (World Health Organization), the International Confederation of Midwives (ICM) and other partners, the report evaluates the midwifery workforce and related health resources in 194 countries. It states that for “midwives to achieve their life-saving and life-changing potential, greater investment is needed in their education and training, midwife-led service delivery, and midwifery leadership”. Governments must prioritise funding and support for midwifery and take concrete steps to include midwives in determining health policies. “Midwives play a vital role in reducing the risks of childbirth for women all over the world,” said WHO director general Dr Tedros Adhanom Ghebreyesus. Increasing their numbers will “deliver a triple dividend in contributing to better health, gender equality and inclusive economic growth,” he said. The last State of the World’s Midwifery report, published in 2014, also raised the alarm over shortages and provided a roadmap on how to remedy this deficit. But progress over the past eight years has been too slow, the report found. The analysis in this year’s report shows that, at current rates of progress, the situation will have improved only slightly by 2030. ICM president Franka Cadee said “midwives are continually overlooked and ignored” and called on “governments to acknowledge the evidence surrounding the life-promoting, life-saving impact of midwife-led care, and take action on the report’s recommendations”. Almost one in five women give birth without a skilled health provider, exposing both mothers and babies to risk, the report further found. It gives the latest stillbirths estimates at about two million a year, along with an estimated 2.4 million new-born deaths and some 295,000 maternal deaths, either during or soon after pregnancy. Describing the report’s findings as “alarming”, UNFPA executive director Dr Natalia Kanem said 1.1million more essential health workers are needed to deliver sexual, reproductive, maternal, newborn and adolescent health care, and 80 per cent of these missing essential health workers are midwives. “A capable, well-trained midwife can have an enormous impact on childbearing women and their families – an impact often passed on from one generation to the next,” Kanem said. The lack of midwives, the report states, is driven by gender inequality, with countries overlooking sexual and reproductive health and under-estimating the value of a female-dominated workforce. Fixing the gaps in provision could save an estimated 4.3 million mothers and babies a year, cutting two in three needless deaths by 2035, said analysis conducted for the report published in The Lancet medical journal last December. The report urged governments to put money into boosting midwife numbers, improving training and offering midwives a greater role in health policy and maternal healthcare. Image Credits: WHO, WHO SEARO. WHO Global Data Hub To Help Fight Future Pandemics 05/05/2021 Chandre Prince German Chancellor Angela Merkel The World Health Organization and the German government on Wednesday announced the launch of a new Global Hub for Pandemic and Epidemic Intelligence that aims to harness the world of big data, media and epidemiological reports to more rapidly identify and respond to emerging disease risks. The hub, to be launched in Berlin later this year, would bring together scientists, data experts and other know-how from governments, international organizations and the private sector, in new, and more flexible forms of collaboration, WHO’s Director of Health Emergencies, Mike Ryan, said at a press briefing on Wednesday. Launch of the hub is being supported by €30 million in seed funds from the German government, said officials at the briefing, addressed by German Chancellor Angela Merkel and Health Minister Jens Spahn. “The WHO Hub for Pandemic and Epidemic Intelligence can make a difference for a safer future…(we should focus on) the development of a global data ecosystem to produce timely insights and tools for policymakers, before and after an epidemic and pandemic events,” Spahn said. The hub would help gather data more efficiently to predict, prevent and respond to future pandemics and epidemic risks worldwide, said WHO Director General Dr Tedros Adhanom Ghebreyesus. “One of the lessons of the Covid-19 pandemic is that the world needs a significant leap forward in data analysis to help leaders make informed public health decisions,” Tedros said. “This requires harnessing the potential of advanced technologies such as artificial intelligence, combining diverse data sources, and collaborating across multiple disciplines. Better data and better analytics will lead to better decisions,” he said. Faster Identification of Threats and Responses Some of the first SARS-COV-2 cases emerged around Wuhan’s “wet markets” selling wild animals for slaughter and meat consumption; such markets can be a flashpoint for pathogen transmission to humans. The initiative responds to a key issue raised by WHO member states and independent reviewers regarding the initial stages of COVID-19 pandemic response – and the belated recognition of the SARS-CoV2 outbreak that was now obviously simmering in Wuhan throughout the fall of 2019 – and possibly even spreading then to other countries, such as Italy, where COVID-positive serum samples from the period were later identified. Even so, the first Chinese government and media reports of the mysterious pneumonia-like outbreak in Wuhan were only picked up on 31 December, 2019 – by WHO’s China country office as well as by the WHO EIOS (Epidemic Intelligence Open Sources) platform – which noted a report from ProMED, the International Society for Infectious Diseases. Following that, criticism has also been leveraged against the quality of data collection by WHO, China and other member states reflecting the early days of the pandemic spread – which may have contributed to WHO’s delays in declaring an international public health emergency over the virus – which so far has killed over 3.2 million people worldwide. Although not “new”, the idea of a hub, according to Tedros, coalesced during discussions with Merkel in October 2020 about the creation of a centre that would serve as a global nerve centre to enhance global capacity for pandemic and epidemic intelligence. Merkel, in a video message, said that the COVID-19 pandemic “has taught us that we can only fight pandemics and epidemics together”. “The new WHO Hub will be a global platform for pandemic prevention, bringing together various governmental, academic and private sector institutions,” Merkel said, further welcoming WHO’s decision to base the hub in Berlin. The hub will bring together governmental, academic and private sector institutions to harness global data, surveillance and analytics and will involve a global collaboration of countries and partners to look for pre-signals that go beyond current systems that monitor publicly available information for signs of emerging outbreaks. Build Upon EIOS – CERN-like Model For Cooperation WHO’s Director of Health Emergencies, Mike Ryan Ryan said that the hub would not be about creating another “big bureaucratic WHO institution” but rather a transformed and engaging centre. He said that WHO envisages the platform as functioning similar to CERN, the European Organization for Nuclear Research – an iconic Geneva-area institution that brings together research fellows, visiting scholars and other experts for brief stints, where they can share and apply their knowledge and skills. “It’s about creating a platform with Germany, where everyone can come and contribute. And this becomes a facilitating environment. We bring the best minds, we bring the best ideas and we facilitate that with the infrastructure and the tools and all of the things that we need…(to) allow others to take the real innovative steps to move us forward in this regard,” Ryan added. He said that the hub would build upon the networks created by EIOS – in a more sophisticated model – to become operational from September. Germany has offered a seed fund of €30 million annually as a startup for the hub, with WHO still working on further details of the budget, he added. . Appeals for further funding are being discussed with various potential donors at the G7 level, said Ryan. Berlin “Ideal Location” for Global Hub German Health Minister Jens Spahn Merkel said Berlin was an ideal location for the hub as it already had leading players in the digital and health fields, such as the Robert Koch Institute, the German federal government’s scientific research institution. “If that expertise is now supplemented by the WHO Hub, we will create a unique environment for pandemic and health research here in Berlin — an environment from which important action-oriented insights will emerge for governments and leaders around the world,” she said. Emphasising that the new hub would still fall under WHO’s governance, Spahn said Germany was offering an “enabling environment for the inter linkages between public health and digital players”. “We are very confident that this local environment will provide numerous opportunities for synergies with a new double edge for the hub,” Spahn said, echoing Tedros’ sentiments that there was a clear need for stronger early local warning alerts and emergency response system to help improve public health intelligence and risk analysis. Transparent Data is Imperative WHO affirmed that data from the new global hub will be held openly and transparently. While affirming that data, in principle, should be held openly and transparently, Ryan acknowledged that it will still be up to the member states and the rules of the International Health Regulations to decide how, and with whom, to share verified information. “The aim is to bring together partners from around the world to develop better access to data and to develop tools we need to generate the insights we need before, during and after pandemics. But, also to build trust between partners in sharing that data in sharing those insights. We aim to bring that whole process together,” Ryan said. He acknowledged, however, that access to data as well as tools for generating insight from such data is not evenly distributed across the member states. And the hub would try to address those inequalities, as well. “I can assure you that that’s the point of the centre… to democratize that process, bring more parameters and create facilities, translate trends and transformative technologies on the capabilities to our member states.” However, issues around transparency and accountability will not be solved by new technologies, but by building trust between partners in sharing data and insights, Ryan added. Three independent panels are due to report at the upcoming World Health Assembly (WHA)on how the WHO and member states reacted to the pandemic, and propose reforms in rules and procedures. Effectively the creation of the hub leapfrogs over what is likely to be highly politicized deliberations on those reforms at the WHA – to create at least one fait accompli that would support earlier warnings. Image Credits: Breaking Asia, UCT. Time to End ‘Delaying Tactics’ on TRIPS Waiver, Say India And South Africa Ahead Of Critical WTO Meeting 04/05/2021 Kerry Cullinan High-level panel on TRIPS waiver CAPE TOWN – The “circular discussion” at the World Trade Organization (WTO) on the TRIPS waiver needs to move to “text-based” negotiations, Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO said on Tuesday. Her Indian counterpart, Brajendra Navnit, added that opponents of the waiver had been using “delaying tactics” since the beginning of the year, “changing goalposts” to raise new problems once their earlier concerns had been addressed. Mlumbi-Peter and Navnit were addressing a high-level panel on Tuesday organised by a range of civil society organisations, on the eve of yet another meeting of the TRIPS Council on the waiver issue, set for Wednesday and Thursday. A waiver in the enforcement of patents, copyright, industrial designs, and trade secrets, under WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), was proposed in October 2020 by India and South Africa, for all COVID-related health products for the duration of the pandemic. This proposal has been supported by over 60 member states, but opposed by mostly high-income nations. During the ensuing six months of negotiations, a further two million people have died from the SARS-CoV2 virus, participants at Tuesday’s panel pointed out. A revised version of the TRIPS waiver proposal is to be presented at Wednesday’s TRIPS General Council “in a bid to reconcile positions”, according to the WTO. ‘Hopeful Signs” on US Position Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO Until recently, Mlumbi-Peters had chaired the WTO TRIPS Council, on behalf of South Africa, and had thus been unable to speak publicly in support of the waiver proposal. Another panelist, United States Congresswoman Jan Schakowsky, who has been championing the waiver in her country, said that it was still unclear if the US administration would support the waiver – but there were some hopeful signs of “dramatic change”. “The United States position is evolving. There are divisions even within the administration – and [within] the Members of Congress, a majority of the Democrats have weighed in, in favour of a TRIPS waiver,” said Schakowsky. “When Big Pharma talks about its priorities and that intellectual property rights rule everything, they are forgetting that the American people, the taxpayers, have spent billions and billions of dollars in research and development and distribution, have a huge stake in this,” she added. No ‘Good Examples’ of Voluntary Licensing Schakowsky supported text-based negotiations on the waiver “to make the changes that are necessary that are going to allow all countries to have access”. “We really don’t have the time to argue with the pharmaceutical industry,” said added. Kathleen Van Brempt, Belgian Member of the European Parliament and the trade coordinator for the Parliament’s Progressive Alliance of Socialists and Democrats Group, proposed “a coalition of the willing” involving European and US politicians in particular. Van Brempt said that opponents of the waiver claimed that it was an “ideological” proposal that would not facilitate the technology transfer needed to speed up vaccine production, and that this could be achieved with voluntary licensing of COVID-19 treatments and medicines. “The facts and figures prove them wrong,” said Van Brempt. “I don’t know any good examples of voluntary licensing, or even of compulsory licensing, that would ramp up production. That is not the case today, and that’s why we have to move on.” Kathleen Van Brempt, Belgian Member of the European Parliament Van Brempt added: “I’m very happy to see my colleague of the US Congress [Schakowsky]. I think we should work much more closely together because I hear that the Biden Administration might move.” She also suggested engaging with the pharmaceutical industry as a first step to inform them about “how unacceptable it is that they decide on the price, and they decide who can produce”, when these decisions “should be steered by governments”. She also suggested opening up the discussion on the TRIPS waiver with the aim of “ramping up [vaccine] production”. More Pragmatic Than Ideological Ruth Dreifuss, former President of Switzerland, said that “unilateral, bilateral tools, like voluntary licenses, compulsory licenses, parallel imports have not adapted to the current situation”. “We urgently need a more global approach as proposed by India and South Africa,” added Dreifuss, who chairs WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) and was co-chair of the UN Secretary General’s High-Level Panel on Access to Medicines. Neither voluntary licenses (issued by pharma companies) nor compulsory licenses (which may be issued by countries in health emergencies) are tools “that would allow us to go as swiftly as we should”, as they have always involved bilateral arrangements or decisions by individual states, which do not address the broader global situation. “With more than $100 billion of public money invested in R&D and supply of vaccines and therapeutics, the risk taken by the pharmaceutical industry has been largely overtaken by the taxpayers,” Dreifuss added. “It is, therefore, an obligation for the states to guarantee fair access, and therefore the means to control the pandemic worldwide.” Dreifuss added that Switzerland “doesn’t share this idea, but I think it is a victim of a vision that is more ideological – not really pragmatic and adapted to the challenge we are facing now.” “Making the rights of intellectual property something very sacred is not a political position I can share,” she added. Van Brempt, meanwhile, said she had been encouraged that the ambassadors of India and South Africa are “not locked into their own truth” but open to negotiations. “I might be wrong but I think I can establish a majority of the European Parliamentarians, but it will involve compromises, and maybe it will not say that we fully support the waiver, as requested by India and South Africa. Maybe it will need another wording, but what I want is a shift in how the Commission looks at it.” Image Credits: Tadeau Andre/MSF . As Indian Pandemic Worsens, Social Networks Save Lives – Government Promotes Alternative Therapies 04/05/2021 Disha Shetty India has received emergency COVID-19 supplies from several countries. PUNE – For two weeks now Sijo Raju, along with a group of 20 young men and women, have been fielding calls from family members looking for oxygen cylinders, ventilator beds and ambulances. Finding a match can take a few hours as India’s overwhelmed health system and front-line healthcare workers try desperately to provide a semblance of care to the massive number of COVID patients. In the absence of a centrally coordinated response, citizens like Raju have stepped up. They verify messages posted online, guide family members to facilities with resources, and do their best to step in place of a government machinery that has effectively abandoned its citizens. “There is just too much information on the internet,” Raju told Health Policy Watch. While the group members, most of them in their 20s and 30s, are based in the Mumbai metropolitan area, they are now trying to help verify requests coming from across India and are among many such citizen groups that have banded together in the past few weeks. On 1 May, India reported over 400,000 cases – a record-high figure in the history of the COVID-19 pandemic so far. It was also the day the country officially lowered the age for those eligible for vaccines from 45 and above to 18 and above. The government had placed orders for the additional vaccines that would be needed just two days before vaccination was to be expanded, and not surprisingly most young people aren’t able to find slots as they try to register for vaccines. But Adar Poonawalla, whose company Serum Institute of India (SII) is responsible for supplying the bulk of the vaccines, said given that the orders were recently received, ramping up production would take still time. Cases continue to rise in India overwhelming the country’s already fragile health infrastructure Promoting Alternative Medicines Meanwhile, India’s government is promoting a poly herbal drug named Ayush-64, calling it a “ray of hope”. The drug is being promoted by the Ministry of Ayurvedic Medicines, Yoga, Unani, Siddha and Homeopathy (AYUSH). Alternative therapies are widely popular albeit not without controversy as mainstream treatments in the pandemic. The government said the drug has been found to be useful in mild to moderate cases. It is also promoting yoga as a way to “strengthen natural immunity”. Most COVID-19 cases are mild to moderate that require little to no treatment under normal circumstances. “The claims made about certain AYUSH interventions in the absence of quality clinical studies and data being presented is unfortunate,” said Anant Bhan, a bioethicist and global health policy expert based in India. “It could lead to reliance on interventions which could not be working, and take the focus away from interventions which do. As is the requirement with allopathic medicines, any claims about AYUSH interventions and utility in COVID-19 needs to be backed by data.” Indian government’s push for alternative medicines comes at a time when Indians are in need of a planned COVID-19 response and urgent ramping up of health facilities. The country’s cases have been on an upward trajectory since March when Prime Minister Narendra Modi held massive election rallies in the state of West Bengal and allowed the Hindu religious event Kumbh Mela to go on that saw gathering of thousands of devotees to perform rituals by the holy river Ganges. Both these events ended up being super spreader ones and worsened the pandemic. Restrictions continue in many high burden states in India and the popular cricket tournament Indian Premier League has also been postponed. The tournament had come under heavy criticism for continuing despite rising COVID-19 deaths. The secretary of the Board of Cricket Administration is Jay Shah, the son of India’s home minister Amit Shah, a key figure in the Modi Administration. Aid Distribution and Vaccine Rollout After India’s pandemic made headlines around the world, the country started receiving aid. Ireland became the most recent country to send aid and US aid has also arrived. Despite this, ordinary citizens continue to struggle for basics based on messages on social media. The government issued a statement saying that the aid will be distributed based on the number of cases and the need in the states – after questions were raised in the Indian media about the plans for distribution. This while the public waits for the Serum Institute to ramp up its production further. Amongst multiple reports it is important that correct information be shared with the public. pic.twitter.com/nzyOZwVBxH — Adar Poonawalla (@adarpoonawalla) May 3, 2021 India’s Supreme Court has also pulled up the Modi administration for failing to regulate the prices of the vaccines. Currently vaccine manufacturers are offering different prices to the centre and state governments, as well as private players, as Health Policy Watch reported in an earlier story. Health experts have said this would set a dangerous precedent while policy experts have criticized the government for its handling of the vaccine distribution. Disha Shetty is an independent journalist based in Pune, India Image Credits: @MEAIndia -Ministry of External Affairs, Spokesman's office , Our World In Data . East Africa Restricts Travellers From India And Tightens Tests for Truckers 04/05/2021 Esther Nakkazi East African truck drivers will get access to one common COVID-19 testing system by mid-May. KAMPALA – Uganda, Kenya and Rwanda have suspended passenger flights from India amid that country’s surge in COVID-19 cases and fears that a number of African countries are on the brink of their own surges. “All flights from India and all passengers originating from India are suspended from 1 May,” the Uganda Ministry of Health said in a statement. “All passenger flights are suspended until further notice. No travellers from India shall be allowed into Uganda regardless of the route of travel.” Meanwhile, Kenya has suspended flights from India for 14 days, according to the Kenya Ministry of Health. Kenya Airways and Rwandair have also suspended flights from and to India. However, East African residents will be allowed to return home. India is a top medical tourism destination for residents in East Africa. The three countries are demanding that travellers who have been to India or travelled through India in the last 14 days, be in possession of a negative PCR COVID-19 test certificate that is digitally verifiable and has been conducted within 120 hours of travel. They will also undergo a PCR test upon arrival. Uganda will allow cargo flights from India where the crew do not disembark and technical stops where travelers do not disembark. It is also allowing aircraft in a state of emergency, operations related to humanitarian aid, medical evacuation, diplomatic flights approved by the appropriate Authority. Uganda has also advised travellers from the USA, United Kingdom, United Arab Emirates, Turkey, South Africa, and Tanzania to consider postponing non-essential travel to Uganda. Travellers from these countries, including Ugandans, will be subjected to a PCR test upon arrival at the points of entry into the country said Dr Jane Ruth Aceng, Uganda’s Minister of Health, during a weekly briefing. “We should make a difference between people and the virus. The virus is the enemy, not the people. If someone has an authentic negative PCR test, they do not cause a problem,” said Dr John Nkengasong, director for Africa Centres for Disease Control and Prevention (CDC). Truck Drivers’ Testing is Tightened The East African Community (EAC) is tightening up on the COVID-19 testing requirements of interstate truck drivers, identified as vectors of the virus, amid numerous problems including forged tests At a recent EAC meeting, Uganda, Kenya, Tanzania, Burundi and South Sudan agreed to submit the names of accredited national laboratories for COVID-19 testing so that these could be linked to the upgraded Regional Electronic Cargo and Driver Tracking System (RECDTS), which recognises digital COVID-19 certificates for truck drivers. The deadline for uploading all accredited COVID-19 testing laboratories in the RECDTS is 15 May. This will ensure that interstate truck drivers and other travellers test for COVID-19 in only through accredited laboratories and that all partner states take up and implement the RECDTS system. Digital certificates are uploaded on the drivers’ smartphones through an app and are valid for 14 days. The App, which was launched in September 2020, was developed with donor funding. It provides a surveillance system to monitor long-distance truckers’ health and enables contact tracing. It also allows partner states to electronically share truck drivers’ COVID-19 test results. The new system is aimed at resolving some of the challenges that were being experienced in the execution of health protocols including multiple testing of truck drivers at the border crossing as there lacked a framework of mutual recognition, document fraud and conflicting test results. The interstate truck drivers also are the single largest group of people who have been identified to be carrying the variants of concern – the B.1.351 variant from South Africa and the B.1.1.7 from the UK. From 399 samples sequenced by the Uganda Virus Research Institute (UVRI) these two variants were detected in 30 truck drivers.The Indian variant has been identified in one patient who was admitted to Mulago Hospital. By Wednesday, the EAC Secretariat expects to have shared a detailed concept note on the development of a common regional health pass to be linked to the upgraded surveillance. Uganda and Kenya Cases Increase By Monday, the Ministry of Health in Kenya had reported that 369 people had tested positive for the disease, from a sample of 4,469 tested in the last 24 hours – a positivity rate of 8.3% compared to the world average of 2.2%. A total of 1,298 patients are in various health facilities countrywide, while 6,652 patients are in isolation at their homes and 19 had died in the 24 hours before Monday. Total confirmed positive cases are now 160,422 and cumulative tests so far conducted are 1,679,779. Some 190 patients are in the ICU, 29 of whom are on ventilatory support and 118 on supplemental oxygen – 43 patients are on observation. Aceng said that Uganda was “experiencing a gradual increase in the COVID-19 cases and it is the beginning of a resurgence”. “This surge is already showing in districts that have remained on high alert and have been carrying out active surveillance,” said Aceng, adding that “this second wave will be worse than the first one”. Uganda has already organised a resurgence plan which is projected to cost over $290 million and is organised around three thresholds: control, alert, and action. The alert threshold is reached when there is a 10% increase in cases while the action threshold begins when there is a 20% increase in the cases observed from the baseline in any geographical location. “The main objective of the resurgence plan is to mitigate transmission and minimise the public health and social economic impact,” said Aceng. The resurgence plan will include enhanced surveillance, active case search, contact tracing, procurement of test kits, Personal Protective Equipment, critical care support, strengthening community engagement and risk communications, and supporting the vaccination teams but it does not include procurement of vaccines. By 30 April, Uganda’s cumulative COVID-19 cases stood at 41,866 with 342 deaths. There are currently 444 active cases. WHO Warns of African Resurgence Dr Matshidiso Moeti, WHO Regional Director for Africa. The World Health Organisation (WHO) predicts a high risk of COVID-19 resurgence in several African countries due to poor adherence to public health measures, mass gatherings, low testing and vaccination rates. “We cannot be lulled into a false sense of security. The devastating surge of cases and deaths in India, and increases in other regions of the world, are clear signs that the pandemic is not yet over in African countries,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “ A new upsurge of COVID-19 infections is a real risk in many countries even if the region’s case count in recent weeks appears to be stable,” she added. “Combatting COVID-19 fatigue appears to be the key battle in our collective response to the pandemic.” According to the WHO analysis of 46 African countries, Kenya, Egypt, Ethiopia face a very high risk of resurgence, while a further 20 countries face a high risk and 22, moderate risk, and only one country faces low risk. The risk was calculated using seven indicators with data from the past four weeks, including COVID-19 cases per million people; the percentage of change in new cases; the percentage of change in new deaths; the reproductive number (the rate at which an infection spreads); the pandemic trend; the average weekly number of tests per 10 000 people; and the percentage of the population that has received at least one vaccine dose. With more than 4.5 million confirmed cases and over 120 000 deaths to date, the continent has not experienced a surge in cases since January and the epidemic curve has plateaued for six weeks. But the relatively low number of cases has encouraged complacency and reduced adherence to behavioural measures to prevent the spread of the virus. In addition, recent political rallies in Benin, Cote d’Ivoire, Guinea and Kenya caused a spike in new cases. Upcoming elections in Cape Verde, Ethiopia, Gambia, Sao Tome and Principe and Zambia could also trigger cases due to mass gatherings, said Moeti. Of the 46 countries analysed, 31 performed fewer than 10 tests per 10,000 people per week in the past four weeks. “Most new cases are still not being detected among known contacts. Investigation of clusters of cases and contact tracing are worryingly low in most countries in the region,” Moeti said. “We must scale up testing including through rapid diagnostic tests to enhance response to the pandemic.” Image Credits: EAC. WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines 03/05/2021 Svĕt Lustig Vijay A shipment of the Chinese Sinopharm vaccine reaches Peru The World Health Organization (WHO) appears to be inching towards the approval of the Chinese Sinopharm and Sinovac vaccines as it struggles to fill a looming vaccine vacuum left by India’s Serum Institute – which has halted exports as the country continues to reel from a tragic coronavirus outbreak. Meanwhile, the WHO declared the latest Ebola outbreak in the Democratic Republic of Congo to be over, just three months after the first case was reported in North Kivu. Chinese Sinopharm & Sinovac May be Approved By End of Week Mariângela Simão, WHO Assistant-Director General for Access to Medicines The Chinese vaccines from Sinopharm and Sinovac could be approved by the end of this week, noted the WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals Mariangela Simao, speaking at a WHO press conference on Monday. “We are finalizing the assessment of Sinopharm [but] there’s still some documentation that needs to be added,” she said. “We will start the final assessment for the listing of Sinovac on the fifth [of May], so we expect both the Chinese vaccines [to] be finalized by the end of this week.” If both vaccines receive the WHO’s green light, China could could become the world’s largest vaccine supplier, assuming that Sinovac and Sinopharm will honor their commitment to produce two billion vaccine doses this year. Despite the lack of published data for the two vaccines, as well as their hefty price, both seem to have met the WHO’s minimum efficacy requirement of 50%, the WHO’s chairperson of Strategic Advisory Group of Experts (SAGE) said late last month. With regards to the WHO’s approval of another vaccine frontrunner that seems to be significantly more potent and cheaper than its Chinese counterparts, Russia’s Sputnik V, the WHO expects a final decision by June or even July, said Simao. “WHO still does not have the entire dossier [for Sputnik], it’s not complete yet,” she said, noting that the WHO is in the process of assessing good clinical practices for Sputnik V and is set to begin evaluating manufacturing practices next Monday until early June. “We expect that as soon as we have the entire dossier, plus the compliance to both good manufacturing practices and the good clinical practice, the vaccine can be assessed then by the technical expert group [SAGE] and we expect that this is likely to happen [by the] end of June or probably in July.” Ebola Outbreak in DRC Declared Over by WHO Meanwhile, the WHO’s Director General, Dr Tedros Adhanom Ghebreyesus, hailed the DRC’s milestone in bringing an end to the twelfth Ebola outbreak in the country – a deadly disease that kills about half of the people it infects. The latest #Ebola outbreak in #DRC🇨🇩 has been declared over after just 3 months. Twelve cases, six deaths & six recoveries were recorded in four health zones in North Kivu during this outbreak.@WHO congratulates DRC’s swift response to this outbreak! 👉🏿https://t.co/2gNHJR22B6 pic.twitter.com/hNZ1moYLaT — WHO African Region (@WHOAFRO) May 3, 2021 “Earlier today, the government of the Democratic Republic of the Congo, announced the end of the most recent Ebola outbreak three months after the first case was reported in North Kivu,” said Dr. Tedros on Monday, emphasizing that a comprehensive public health approach was crucial in ending the latest outbreak of Ebola. “Huge credit must be given to the local health workers and the national authorities for their prompt response, tenacity, experience and hard work that brought this outbreak under control,” added Dr Matshidiso Moeti, WHO Regional Director for Africa. She was referring to the country’s swift move to vaccinate almost 2,000 people at high-risk of contracting the virus and providing treatment as soon as the outbreak was declared in February. However, she stressed that going forward, strong surveillance systems will be crucial to swiftly detect potential flare-ups and to fight parallel epidemics of measles, cholera and COVID-19. “Although the outbreak has ended, we must stay alert for possible resurgence and at the same time use the growing expertise on emergency response to address other health threats the country faces.” Image Credits: Sinopharm, Peruvian Ministry of External Affairs. After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Global Data Hub To Help Fight Future Pandemics 05/05/2021 Chandre Prince German Chancellor Angela Merkel The World Health Organization and the German government on Wednesday announced the launch of a new Global Hub for Pandemic and Epidemic Intelligence that aims to harness the world of big data, media and epidemiological reports to more rapidly identify and respond to emerging disease risks. The hub, to be launched in Berlin later this year, would bring together scientists, data experts and other know-how from governments, international organizations and the private sector, in new, and more flexible forms of collaboration, WHO’s Director of Health Emergencies, Mike Ryan, said at a press briefing on Wednesday. Launch of the hub is being supported by €30 million in seed funds from the German government, said officials at the briefing, addressed by German Chancellor Angela Merkel and Health Minister Jens Spahn. “The WHO Hub for Pandemic and Epidemic Intelligence can make a difference for a safer future…(we should focus on) the development of a global data ecosystem to produce timely insights and tools for policymakers, before and after an epidemic and pandemic events,” Spahn said. The hub would help gather data more efficiently to predict, prevent and respond to future pandemics and epidemic risks worldwide, said WHO Director General Dr Tedros Adhanom Ghebreyesus. “One of the lessons of the Covid-19 pandemic is that the world needs a significant leap forward in data analysis to help leaders make informed public health decisions,” Tedros said. “This requires harnessing the potential of advanced technologies such as artificial intelligence, combining diverse data sources, and collaborating across multiple disciplines. Better data and better analytics will lead to better decisions,” he said. Faster Identification of Threats and Responses Some of the first SARS-COV-2 cases emerged around Wuhan’s “wet markets” selling wild animals for slaughter and meat consumption; such markets can be a flashpoint for pathogen transmission to humans. The initiative responds to a key issue raised by WHO member states and independent reviewers regarding the initial stages of COVID-19 pandemic response – and the belated recognition of the SARS-CoV2 outbreak that was now obviously simmering in Wuhan throughout the fall of 2019 – and possibly even spreading then to other countries, such as Italy, where COVID-positive serum samples from the period were later identified. Even so, the first Chinese government and media reports of the mysterious pneumonia-like outbreak in Wuhan were only picked up on 31 December, 2019 – by WHO’s China country office as well as by the WHO EIOS (Epidemic Intelligence Open Sources) platform – which noted a report from ProMED, the International Society for Infectious Diseases. Following that, criticism has also been leveraged against the quality of data collection by WHO, China and other member states reflecting the early days of the pandemic spread – which may have contributed to WHO’s delays in declaring an international public health emergency over the virus – which so far has killed over 3.2 million people worldwide. Although not “new”, the idea of a hub, according to Tedros, coalesced during discussions with Merkel in October 2020 about the creation of a centre that would serve as a global nerve centre to enhance global capacity for pandemic and epidemic intelligence. Merkel, in a video message, said that the COVID-19 pandemic “has taught us that we can only fight pandemics and epidemics together”. “The new WHO Hub will be a global platform for pandemic prevention, bringing together various governmental, academic and private sector institutions,” Merkel said, further welcoming WHO’s decision to base the hub in Berlin. The hub will bring together governmental, academic and private sector institutions to harness global data, surveillance and analytics and will involve a global collaboration of countries and partners to look for pre-signals that go beyond current systems that monitor publicly available information for signs of emerging outbreaks. Build Upon EIOS – CERN-like Model For Cooperation WHO’s Director of Health Emergencies, Mike Ryan Ryan said that the hub would not be about creating another “big bureaucratic WHO institution” but rather a transformed and engaging centre. He said that WHO envisages the platform as functioning similar to CERN, the European Organization for Nuclear Research – an iconic Geneva-area institution that brings together research fellows, visiting scholars and other experts for brief stints, where they can share and apply their knowledge and skills. “It’s about creating a platform with Germany, where everyone can come and contribute. And this becomes a facilitating environment. We bring the best minds, we bring the best ideas and we facilitate that with the infrastructure and the tools and all of the things that we need…(to) allow others to take the real innovative steps to move us forward in this regard,” Ryan added. He said that the hub would build upon the networks created by EIOS – in a more sophisticated model – to become operational from September. Germany has offered a seed fund of €30 million annually as a startup for the hub, with WHO still working on further details of the budget, he added. . Appeals for further funding are being discussed with various potential donors at the G7 level, said Ryan. Berlin “Ideal Location” for Global Hub German Health Minister Jens Spahn Merkel said Berlin was an ideal location for the hub as it already had leading players in the digital and health fields, such as the Robert Koch Institute, the German federal government’s scientific research institution. “If that expertise is now supplemented by the WHO Hub, we will create a unique environment for pandemic and health research here in Berlin — an environment from which important action-oriented insights will emerge for governments and leaders around the world,” she said. Emphasising that the new hub would still fall under WHO’s governance, Spahn said Germany was offering an “enabling environment for the inter linkages between public health and digital players”. “We are very confident that this local environment will provide numerous opportunities for synergies with a new double edge for the hub,” Spahn said, echoing Tedros’ sentiments that there was a clear need for stronger early local warning alerts and emergency response system to help improve public health intelligence and risk analysis. Transparent Data is Imperative WHO affirmed that data from the new global hub will be held openly and transparently. While affirming that data, in principle, should be held openly and transparently, Ryan acknowledged that it will still be up to the member states and the rules of the International Health Regulations to decide how, and with whom, to share verified information. “The aim is to bring together partners from around the world to develop better access to data and to develop tools we need to generate the insights we need before, during and after pandemics. But, also to build trust between partners in sharing that data in sharing those insights. We aim to bring that whole process together,” Ryan said. He acknowledged, however, that access to data as well as tools for generating insight from such data is not evenly distributed across the member states. And the hub would try to address those inequalities, as well. “I can assure you that that’s the point of the centre… to democratize that process, bring more parameters and create facilities, translate trends and transformative technologies on the capabilities to our member states.” However, issues around transparency and accountability will not be solved by new technologies, but by building trust between partners in sharing data and insights, Ryan added. Three independent panels are due to report at the upcoming World Health Assembly (WHA)on how the WHO and member states reacted to the pandemic, and propose reforms in rules and procedures. Effectively the creation of the hub leapfrogs over what is likely to be highly politicized deliberations on those reforms at the WHA – to create at least one fait accompli that would support earlier warnings. Image Credits: Breaking Asia, UCT. Time to End ‘Delaying Tactics’ on TRIPS Waiver, Say India And South Africa Ahead Of Critical WTO Meeting 04/05/2021 Kerry Cullinan High-level panel on TRIPS waiver CAPE TOWN – The “circular discussion” at the World Trade Organization (WTO) on the TRIPS waiver needs to move to “text-based” negotiations, Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO said on Tuesday. Her Indian counterpart, Brajendra Navnit, added that opponents of the waiver had been using “delaying tactics” since the beginning of the year, “changing goalposts” to raise new problems once their earlier concerns had been addressed. Mlumbi-Peter and Navnit were addressing a high-level panel on Tuesday organised by a range of civil society organisations, on the eve of yet another meeting of the TRIPS Council on the waiver issue, set for Wednesday and Thursday. A waiver in the enforcement of patents, copyright, industrial designs, and trade secrets, under WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), was proposed in October 2020 by India and South Africa, for all COVID-related health products for the duration of the pandemic. This proposal has been supported by over 60 member states, but opposed by mostly high-income nations. During the ensuing six months of negotiations, a further two million people have died from the SARS-CoV2 virus, participants at Tuesday’s panel pointed out. A revised version of the TRIPS waiver proposal is to be presented at Wednesday’s TRIPS General Council “in a bid to reconcile positions”, according to the WTO. ‘Hopeful Signs” on US Position Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO Until recently, Mlumbi-Peters had chaired the WTO TRIPS Council, on behalf of South Africa, and had thus been unable to speak publicly in support of the waiver proposal. Another panelist, United States Congresswoman Jan Schakowsky, who has been championing the waiver in her country, said that it was still unclear if the US administration would support the waiver – but there were some hopeful signs of “dramatic change”. “The United States position is evolving. There are divisions even within the administration – and [within] the Members of Congress, a majority of the Democrats have weighed in, in favour of a TRIPS waiver,” said Schakowsky. “When Big Pharma talks about its priorities and that intellectual property rights rule everything, they are forgetting that the American people, the taxpayers, have spent billions and billions of dollars in research and development and distribution, have a huge stake in this,” she added. No ‘Good Examples’ of Voluntary Licensing Schakowsky supported text-based negotiations on the waiver “to make the changes that are necessary that are going to allow all countries to have access”. “We really don’t have the time to argue with the pharmaceutical industry,” said added. Kathleen Van Brempt, Belgian Member of the European Parliament and the trade coordinator for the Parliament’s Progressive Alliance of Socialists and Democrats Group, proposed “a coalition of the willing” involving European and US politicians in particular. Van Brempt said that opponents of the waiver claimed that it was an “ideological” proposal that would not facilitate the technology transfer needed to speed up vaccine production, and that this could be achieved with voluntary licensing of COVID-19 treatments and medicines. “The facts and figures prove them wrong,” said Van Brempt. “I don’t know any good examples of voluntary licensing, or even of compulsory licensing, that would ramp up production. That is not the case today, and that’s why we have to move on.” Kathleen Van Brempt, Belgian Member of the European Parliament Van Brempt added: “I’m very happy to see my colleague of the US Congress [Schakowsky]. I think we should work much more closely together because I hear that the Biden Administration might move.” She also suggested engaging with the pharmaceutical industry as a first step to inform them about “how unacceptable it is that they decide on the price, and they decide who can produce”, when these decisions “should be steered by governments”. She also suggested opening up the discussion on the TRIPS waiver with the aim of “ramping up [vaccine] production”. More Pragmatic Than Ideological Ruth Dreifuss, former President of Switzerland, said that “unilateral, bilateral tools, like voluntary licenses, compulsory licenses, parallel imports have not adapted to the current situation”. “We urgently need a more global approach as proposed by India and South Africa,” added Dreifuss, who chairs WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) and was co-chair of the UN Secretary General’s High-Level Panel on Access to Medicines. Neither voluntary licenses (issued by pharma companies) nor compulsory licenses (which may be issued by countries in health emergencies) are tools “that would allow us to go as swiftly as we should”, as they have always involved bilateral arrangements or decisions by individual states, which do not address the broader global situation. “With more than $100 billion of public money invested in R&D and supply of vaccines and therapeutics, the risk taken by the pharmaceutical industry has been largely overtaken by the taxpayers,” Dreifuss added. “It is, therefore, an obligation for the states to guarantee fair access, and therefore the means to control the pandemic worldwide.” Dreifuss added that Switzerland “doesn’t share this idea, but I think it is a victim of a vision that is more ideological – not really pragmatic and adapted to the challenge we are facing now.” “Making the rights of intellectual property something very sacred is not a political position I can share,” she added. Van Brempt, meanwhile, said she had been encouraged that the ambassadors of India and South Africa are “not locked into their own truth” but open to negotiations. “I might be wrong but I think I can establish a majority of the European Parliamentarians, but it will involve compromises, and maybe it will not say that we fully support the waiver, as requested by India and South Africa. Maybe it will need another wording, but what I want is a shift in how the Commission looks at it.” Image Credits: Tadeau Andre/MSF . As Indian Pandemic Worsens, Social Networks Save Lives – Government Promotes Alternative Therapies 04/05/2021 Disha Shetty India has received emergency COVID-19 supplies from several countries. PUNE – For two weeks now Sijo Raju, along with a group of 20 young men and women, have been fielding calls from family members looking for oxygen cylinders, ventilator beds and ambulances. Finding a match can take a few hours as India’s overwhelmed health system and front-line healthcare workers try desperately to provide a semblance of care to the massive number of COVID patients. In the absence of a centrally coordinated response, citizens like Raju have stepped up. They verify messages posted online, guide family members to facilities with resources, and do their best to step in place of a government machinery that has effectively abandoned its citizens. “There is just too much information on the internet,” Raju told Health Policy Watch. While the group members, most of them in their 20s and 30s, are based in the Mumbai metropolitan area, they are now trying to help verify requests coming from across India and are among many such citizen groups that have banded together in the past few weeks. On 1 May, India reported over 400,000 cases – a record-high figure in the history of the COVID-19 pandemic so far. It was also the day the country officially lowered the age for those eligible for vaccines from 45 and above to 18 and above. The government had placed orders for the additional vaccines that would be needed just two days before vaccination was to be expanded, and not surprisingly most young people aren’t able to find slots as they try to register for vaccines. But Adar Poonawalla, whose company Serum Institute of India (SII) is responsible for supplying the bulk of the vaccines, said given that the orders were recently received, ramping up production would take still time. Cases continue to rise in India overwhelming the country’s already fragile health infrastructure Promoting Alternative Medicines Meanwhile, India’s government is promoting a poly herbal drug named Ayush-64, calling it a “ray of hope”. The drug is being promoted by the Ministry of Ayurvedic Medicines, Yoga, Unani, Siddha and Homeopathy (AYUSH). Alternative therapies are widely popular albeit not without controversy as mainstream treatments in the pandemic. The government said the drug has been found to be useful in mild to moderate cases. It is also promoting yoga as a way to “strengthen natural immunity”. Most COVID-19 cases are mild to moderate that require little to no treatment under normal circumstances. “The claims made about certain AYUSH interventions in the absence of quality clinical studies and data being presented is unfortunate,” said Anant Bhan, a bioethicist and global health policy expert based in India. “It could lead to reliance on interventions which could not be working, and take the focus away from interventions which do. As is the requirement with allopathic medicines, any claims about AYUSH interventions and utility in COVID-19 needs to be backed by data.” Indian government’s push for alternative medicines comes at a time when Indians are in need of a planned COVID-19 response and urgent ramping up of health facilities. The country’s cases have been on an upward trajectory since March when Prime Minister Narendra Modi held massive election rallies in the state of West Bengal and allowed the Hindu religious event Kumbh Mela to go on that saw gathering of thousands of devotees to perform rituals by the holy river Ganges. Both these events ended up being super spreader ones and worsened the pandemic. Restrictions continue in many high burden states in India and the popular cricket tournament Indian Premier League has also been postponed. The tournament had come under heavy criticism for continuing despite rising COVID-19 deaths. The secretary of the Board of Cricket Administration is Jay Shah, the son of India’s home minister Amit Shah, a key figure in the Modi Administration. Aid Distribution and Vaccine Rollout After India’s pandemic made headlines around the world, the country started receiving aid. Ireland became the most recent country to send aid and US aid has also arrived. Despite this, ordinary citizens continue to struggle for basics based on messages on social media. The government issued a statement saying that the aid will be distributed based on the number of cases and the need in the states – after questions were raised in the Indian media about the plans for distribution. This while the public waits for the Serum Institute to ramp up its production further. Amongst multiple reports it is important that correct information be shared with the public. pic.twitter.com/nzyOZwVBxH — Adar Poonawalla (@adarpoonawalla) May 3, 2021 India’s Supreme Court has also pulled up the Modi administration for failing to regulate the prices of the vaccines. Currently vaccine manufacturers are offering different prices to the centre and state governments, as well as private players, as Health Policy Watch reported in an earlier story. Health experts have said this would set a dangerous precedent while policy experts have criticized the government for its handling of the vaccine distribution. Disha Shetty is an independent journalist based in Pune, India Image Credits: @MEAIndia -Ministry of External Affairs, Spokesman's office , Our World In Data . East Africa Restricts Travellers From India And Tightens Tests for Truckers 04/05/2021 Esther Nakkazi East African truck drivers will get access to one common COVID-19 testing system by mid-May. KAMPALA – Uganda, Kenya and Rwanda have suspended passenger flights from India amid that country’s surge in COVID-19 cases and fears that a number of African countries are on the brink of their own surges. “All flights from India and all passengers originating from India are suspended from 1 May,” the Uganda Ministry of Health said in a statement. “All passenger flights are suspended until further notice. No travellers from India shall be allowed into Uganda regardless of the route of travel.” Meanwhile, Kenya has suspended flights from India for 14 days, according to the Kenya Ministry of Health. Kenya Airways and Rwandair have also suspended flights from and to India. However, East African residents will be allowed to return home. India is a top medical tourism destination for residents in East Africa. The three countries are demanding that travellers who have been to India or travelled through India in the last 14 days, be in possession of a negative PCR COVID-19 test certificate that is digitally verifiable and has been conducted within 120 hours of travel. They will also undergo a PCR test upon arrival. Uganda will allow cargo flights from India where the crew do not disembark and technical stops where travelers do not disembark. It is also allowing aircraft in a state of emergency, operations related to humanitarian aid, medical evacuation, diplomatic flights approved by the appropriate Authority. Uganda has also advised travellers from the USA, United Kingdom, United Arab Emirates, Turkey, South Africa, and Tanzania to consider postponing non-essential travel to Uganda. Travellers from these countries, including Ugandans, will be subjected to a PCR test upon arrival at the points of entry into the country said Dr Jane Ruth Aceng, Uganda’s Minister of Health, during a weekly briefing. “We should make a difference between people and the virus. The virus is the enemy, not the people. If someone has an authentic negative PCR test, they do not cause a problem,” said Dr John Nkengasong, director for Africa Centres for Disease Control and Prevention (CDC). Truck Drivers’ Testing is Tightened The East African Community (EAC) is tightening up on the COVID-19 testing requirements of interstate truck drivers, identified as vectors of the virus, amid numerous problems including forged tests At a recent EAC meeting, Uganda, Kenya, Tanzania, Burundi and South Sudan agreed to submit the names of accredited national laboratories for COVID-19 testing so that these could be linked to the upgraded Regional Electronic Cargo and Driver Tracking System (RECDTS), which recognises digital COVID-19 certificates for truck drivers. The deadline for uploading all accredited COVID-19 testing laboratories in the RECDTS is 15 May. This will ensure that interstate truck drivers and other travellers test for COVID-19 in only through accredited laboratories and that all partner states take up and implement the RECDTS system. Digital certificates are uploaded on the drivers’ smartphones through an app and are valid for 14 days. The App, which was launched in September 2020, was developed with donor funding. It provides a surveillance system to monitor long-distance truckers’ health and enables contact tracing. It also allows partner states to electronically share truck drivers’ COVID-19 test results. The new system is aimed at resolving some of the challenges that were being experienced in the execution of health protocols including multiple testing of truck drivers at the border crossing as there lacked a framework of mutual recognition, document fraud and conflicting test results. The interstate truck drivers also are the single largest group of people who have been identified to be carrying the variants of concern – the B.1.351 variant from South Africa and the B.1.1.7 from the UK. From 399 samples sequenced by the Uganda Virus Research Institute (UVRI) these two variants were detected in 30 truck drivers.The Indian variant has been identified in one patient who was admitted to Mulago Hospital. By Wednesday, the EAC Secretariat expects to have shared a detailed concept note on the development of a common regional health pass to be linked to the upgraded surveillance. Uganda and Kenya Cases Increase By Monday, the Ministry of Health in Kenya had reported that 369 people had tested positive for the disease, from a sample of 4,469 tested in the last 24 hours – a positivity rate of 8.3% compared to the world average of 2.2%. A total of 1,298 patients are in various health facilities countrywide, while 6,652 patients are in isolation at their homes and 19 had died in the 24 hours before Monday. Total confirmed positive cases are now 160,422 and cumulative tests so far conducted are 1,679,779. Some 190 patients are in the ICU, 29 of whom are on ventilatory support and 118 on supplemental oxygen – 43 patients are on observation. Aceng said that Uganda was “experiencing a gradual increase in the COVID-19 cases and it is the beginning of a resurgence”. “This surge is already showing in districts that have remained on high alert and have been carrying out active surveillance,” said Aceng, adding that “this second wave will be worse than the first one”. Uganda has already organised a resurgence plan which is projected to cost over $290 million and is organised around three thresholds: control, alert, and action. The alert threshold is reached when there is a 10% increase in cases while the action threshold begins when there is a 20% increase in the cases observed from the baseline in any geographical location. “The main objective of the resurgence plan is to mitigate transmission and minimise the public health and social economic impact,” said Aceng. The resurgence plan will include enhanced surveillance, active case search, contact tracing, procurement of test kits, Personal Protective Equipment, critical care support, strengthening community engagement and risk communications, and supporting the vaccination teams but it does not include procurement of vaccines. By 30 April, Uganda’s cumulative COVID-19 cases stood at 41,866 with 342 deaths. There are currently 444 active cases. WHO Warns of African Resurgence Dr Matshidiso Moeti, WHO Regional Director for Africa. The World Health Organisation (WHO) predicts a high risk of COVID-19 resurgence in several African countries due to poor adherence to public health measures, mass gatherings, low testing and vaccination rates. “We cannot be lulled into a false sense of security. The devastating surge of cases and deaths in India, and increases in other regions of the world, are clear signs that the pandemic is not yet over in African countries,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “ A new upsurge of COVID-19 infections is a real risk in many countries even if the region’s case count in recent weeks appears to be stable,” she added. “Combatting COVID-19 fatigue appears to be the key battle in our collective response to the pandemic.” According to the WHO analysis of 46 African countries, Kenya, Egypt, Ethiopia face a very high risk of resurgence, while a further 20 countries face a high risk and 22, moderate risk, and only one country faces low risk. The risk was calculated using seven indicators with data from the past four weeks, including COVID-19 cases per million people; the percentage of change in new cases; the percentage of change in new deaths; the reproductive number (the rate at which an infection spreads); the pandemic trend; the average weekly number of tests per 10 000 people; and the percentage of the population that has received at least one vaccine dose. With more than 4.5 million confirmed cases and over 120 000 deaths to date, the continent has not experienced a surge in cases since January and the epidemic curve has plateaued for six weeks. But the relatively low number of cases has encouraged complacency and reduced adherence to behavioural measures to prevent the spread of the virus. In addition, recent political rallies in Benin, Cote d’Ivoire, Guinea and Kenya caused a spike in new cases. Upcoming elections in Cape Verde, Ethiopia, Gambia, Sao Tome and Principe and Zambia could also trigger cases due to mass gatherings, said Moeti. Of the 46 countries analysed, 31 performed fewer than 10 tests per 10,000 people per week in the past four weeks. “Most new cases are still not being detected among known contacts. Investigation of clusters of cases and contact tracing are worryingly low in most countries in the region,” Moeti said. “We must scale up testing including through rapid diagnostic tests to enhance response to the pandemic.” Image Credits: EAC. WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines 03/05/2021 Svĕt Lustig Vijay A shipment of the Chinese Sinopharm vaccine reaches Peru The World Health Organization (WHO) appears to be inching towards the approval of the Chinese Sinopharm and Sinovac vaccines as it struggles to fill a looming vaccine vacuum left by India’s Serum Institute – which has halted exports as the country continues to reel from a tragic coronavirus outbreak. Meanwhile, the WHO declared the latest Ebola outbreak in the Democratic Republic of Congo to be over, just three months after the first case was reported in North Kivu. Chinese Sinopharm & Sinovac May be Approved By End of Week Mariângela Simão, WHO Assistant-Director General for Access to Medicines The Chinese vaccines from Sinopharm and Sinovac could be approved by the end of this week, noted the WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals Mariangela Simao, speaking at a WHO press conference on Monday. “We are finalizing the assessment of Sinopharm [but] there’s still some documentation that needs to be added,” she said. “We will start the final assessment for the listing of Sinovac on the fifth [of May], so we expect both the Chinese vaccines [to] be finalized by the end of this week.” If both vaccines receive the WHO’s green light, China could could become the world’s largest vaccine supplier, assuming that Sinovac and Sinopharm will honor their commitment to produce two billion vaccine doses this year. Despite the lack of published data for the two vaccines, as well as their hefty price, both seem to have met the WHO’s minimum efficacy requirement of 50%, the WHO’s chairperson of Strategic Advisory Group of Experts (SAGE) said late last month. With regards to the WHO’s approval of another vaccine frontrunner that seems to be significantly more potent and cheaper than its Chinese counterparts, Russia’s Sputnik V, the WHO expects a final decision by June or even July, said Simao. “WHO still does not have the entire dossier [for Sputnik], it’s not complete yet,” she said, noting that the WHO is in the process of assessing good clinical practices for Sputnik V and is set to begin evaluating manufacturing practices next Monday until early June. “We expect that as soon as we have the entire dossier, plus the compliance to both good manufacturing practices and the good clinical practice, the vaccine can be assessed then by the technical expert group [SAGE] and we expect that this is likely to happen [by the] end of June or probably in July.” Ebola Outbreak in DRC Declared Over by WHO Meanwhile, the WHO’s Director General, Dr Tedros Adhanom Ghebreyesus, hailed the DRC’s milestone in bringing an end to the twelfth Ebola outbreak in the country – a deadly disease that kills about half of the people it infects. The latest #Ebola outbreak in #DRC🇨🇩 has been declared over after just 3 months. Twelve cases, six deaths & six recoveries were recorded in four health zones in North Kivu during this outbreak.@WHO congratulates DRC’s swift response to this outbreak! 👉🏿https://t.co/2gNHJR22B6 pic.twitter.com/hNZ1moYLaT — WHO African Region (@WHOAFRO) May 3, 2021 “Earlier today, the government of the Democratic Republic of the Congo, announced the end of the most recent Ebola outbreak three months after the first case was reported in North Kivu,” said Dr. Tedros on Monday, emphasizing that a comprehensive public health approach was crucial in ending the latest outbreak of Ebola. “Huge credit must be given to the local health workers and the national authorities for their prompt response, tenacity, experience and hard work that brought this outbreak under control,” added Dr Matshidiso Moeti, WHO Regional Director for Africa. She was referring to the country’s swift move to vaccinate almost 2,000 people at high-risk of contracting the virus and providing treatment as soon as the outbreak was declared in February. However, she stressed that going forward, strong surveillance systems will be crucial to swiftly detect potential flare-ups and to fight parallel epidemics of measles, cholera and COVID-19. “Although the outbreak has ended, we must stay alert for possible resurgence and at the same time use the growing expertise on emergency response to address other health threats the country faces.” Image Credits: Sinopharm, Peruvian Ministry of External Affairs. After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Time to End ‘Delaying Tactics’ on TRIPS Waiver, Say India And South Africa Ahead Of Critical WTO Meeting 04/05/2021 Kerry Cullinan High-level panel on TRIPS waiver CAPE TOWN – The “circular discussion” at the World Trade Organization (WTO) on the TRIPS waiver needs to move to “text-based” negotiations, Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO said on Tuesday. Her Indian counterpart, Brajendra Navnit, added that opponents of the waiver had been using “delaying tactics” since the beginning of the year, “changing goalposts” to raise new problems once their earlier concerns had been addressed. Mlumbi-Peter and Navnit were addressing a high-level panel on Tuesday organised by a range of civil society organisations, on the eve of yet another meeting of the TRIPS Council on the waiver issue, set for Wednesday and Thursday. A waiver in the enforcement of patents, copyright, industrial designs, and trade secrets, under WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), was proposed in October 2020 by India and South Africa, for all COVID-related health products for the duration of the pandemic. This proposal has been supported by over 60 member states, but opposed by mostly high-income nations. During the ensuing six months of negotiations, a further two million people have died from the SARS-CoV2 virus, participants at Tuesday’s panel pointed out. A revised version of the TRIPS waiver proposal is to be presented at Wednesday’s TRIPS General Council “in a bid to reconcile positions”, according to the WTO. ‘Hopeful Signs” on US Position Ambassador Xolelwa Mlumbi-Peter, South Africa’s Permanent Representative to the WTO Until recently, Mlumbi-Peters had chaired the WTO TRIPS Council, on behalf of South Africa, and had thus been unable to speak publicly in support of the waiver proposal. Another panelist, United States Congresswoman Jan Schakowsky, who has been championing the waiver in her country, said that it was still unclear if the US administration would support the waiver – but there were some hopeful signs of “dramatic change”. “The United States position is evolving. There are divisions even within the administration – and [within] the Members of Congress, a majority of the Democrats have weighed in, in favour of a TRIPS waiver,” said Schakowsky. “When Big Pharma talks about its priorities and that intellectual property rights rule everything, they are forgetting that the American people, the taxpayers, have spent billions and billions of dollars in research and development and distribution, have a huge stake in this,” she added. No ‘Good Examples’ of Voluntary Licensing Schakowsky supported text-based negotiations on the waiver “to make the changes that are necessary that are going to allow all countries to have access”. “We really don’t have the time to argue with the pharmaceutical industry,” said added. Kathleen Van Brempt, Belgian Member of the European Parliament and the trade coordinator for the Parliament’s Progressive Alliance of Socialists and Democrats Group, proposed “a coalition of the willing” involving European and US politicians in particular. Van Brempt said that opponents of the waiver claimed that it was an “ideological” proposal that would not facilitate the technology transfer needed to speed up vaccine production, and that this could be achieved with voluntary licensing of COVID-19 treatments and medicines. “The facts and figures prove them wrong,” said Van Brempt. “I don’t know any good examples of voluntary licensing, or even of compulsory licensing, that would ramp up production. That is not the case today, and that’s why we have to move on.” Kathleen Van Brempt, Belgian Member of the European Parliament Van Brempt added: “I’m very happy to see my colleague of the US Congress [Schakowsky]. I think we should work much more closely together because I hear that the Biden Administration might move.” She also suggested engaging with the pharmaceutical industry as a first step to inform them about “how unacceptable it is that they decide on the price, and they decide who can produce”, when these decisions “should be steered by governments”. She also suggested opening up the discussion on the TRIPS waiver with the aim of “ramping up [vaccine] production”. More Pragmatic Than Ideological Ruth Dreifuss, former President of Switzerland, said that “unilateral, bilateral tools, like voluntary licenses, compulsory licenses, parallel imports have not adapted to the current situation”. “We urgently need a more global approach as proposed by India and South Africa,” added Dreifuss, who chairs WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) and was co-chair of the UN Secretary General’s High-Level Panel on Access to Medicines. Neither voluntary licenses (issued by pharma companies) nor compulsory licenses (which may be issued by countries in health emergencies) are tools “that would allow us to go as swiftly as we should”, as they have always involved bilateral arrangements or decisions by individual states, which do not address the broader global situation. “With more than $100 billion of public money invested in R&D and supply of vaccines and therapeutics, the risk taken by the pharmaceutical industry has been largely overtaken by the taxpayers,” Dreifuss added. “It is, therefore, an obligation for the states to guarantee fair access, and therefore the means to control the pandemic worldwide.” Dreifuss added that Switzerland “doesn’t share this idea, but I think it is a victim of a vision that is more ideological – not really pragmatic and adapted to the challenge we are facing now.” “Making the rights of intellectual property something very sacred is not a political position I can share,” she added. Van Brempt, meanwhile, said she had been encouraged that the ambassadors of India and South Africa are “not locked into their own truth” but open to negotiations. “I might be wrong but I think I can establish a majority of the European Parliamentarians, but it will involve compromises, and maybe it will not say that we fully support the waiver, as requested by India and South Africa. Maybe it will need another wording, but what I want is a shift in how the Commission looks at it.” Image Credits: Tadeau Andre/MSF . As Indian Pandemic Worsens, Social Networks Save Lives – Government Promotes Alternative Therapies 04/05/2021 Disha Shetty India has received emergency COVID-19 supplies from several countries. PUNE – For two weeks now Sijo Raju, along with a group of 20 young men and women, have been fielding calls from family members looking for oxygen cylinders, ventilator beds and ambulances. Finding a match can take a few hours as India’s overwhelmed health system and front-line healthcare workers try desperately to provide a semblance of care to the massive number of COVID patients. In the absence of a centrally coordinated response, citizens like Raju have stepped up. They verify messages posted online, guide family members to facilities with resources, and do their best to step in place of a government machinery that has effectively abandoned its citizens. “There is just too much information on the internet,” Raju told Health Policy Watch. While the group members, most of them in their 20s and 30s, are based in the Mumbai metropolitan area, they are now trying to help verify requests coming from across India and are among many such citizen groups that have banded together in the past few weeks. On 1 May, India reported over 400,000 cases – a record-high figure in the history of the COVID-19 pandemic so far. It was also the day the country officially lowered the age for those eligible for vaccines from 45 and above to 18 and above. The government had placed orders for the additional vaccines that would be needed just two days before vaccination was to be expanded, and not surprisingly most young people aren’t able to find slots as they try to register for vaccines. But Adar Poonawalla, whose company Serum Institute of India (SII) is responsible for supplying the bulk of the vaccines, said given that the orders were recently received, ramping up production would take still time. Cases continue to rise in India overwhelming the country’s already fragile health infrastructure Promoting Alternative Medicines Meanwhile, India’s government is promoting a poly herbal drug named Ayush-64, calling it a “ray of hope”. The drug is being promoted by the Ministry of Ayurvedic Medicines, Yoga, Unani, Siddha and Homeopathy (AYUSH). Alternative therapies are widely popular albeit not without controversy as mainstream treatments in the pandemic. The government said the drug has been found to be useful in mild to moderate cases. It is also promoting yoga as a way to “strengthen natural immunity”. Most COVID-19 cases are mild to moderate that require little to no treatment under normal circumstances. “The claims made about certain AYUSH interventions in the absence of quality clinical studies and data being presented is unfortunate,” said Anant Bhan, a bioethicist and global health policy expert based in India. “It could lead to reliance on interventions which could not be working, and take the focus away from interventions which do. As is the requirement with allopathic medicines, any claims about AYUSH interventions and utility in COVID-19 needs to be backed by data.” Indian government’s push for alternative medicines comes at a time when Indians are in need of a planned COVID-19 response and urgent ramping up of health facilities. The country’s cases have been on an upward trajectory since March when Prime Minister Narendra Modi held massive election rallies in the state of West Bengal and allowed the Hindu religious event Kumbh Mela to go on that saw gathering of thousands of devotees to perform rituals by the holy river Ganges. Both these events ended up being super spreader ones and worsened the pandemic. Restrictions continue in many high burden states in India and the popular cricket tournament Indian Premier League has also been postponed. The tournament had come under heavy criticism for continuing despite rising COVID-19 deaths. The secretary of the Board of Cricket Administration is Jay Shah, the son of India’s home minister Amit Shah, a key figure in the Modi Administration. Aid Distribution and Vaccine Rollout After India’s pandemic made headlines around the world, the country started receiving aid. Ireland became the most recent country to send aid and US aid has also arrived. Despite this, ordinary citizens continue to struggle for basics based on messages on social media. The government issued a statement saying that the aid will be distributed based on the number of cases and the need in the states – after questions were raised in the Indian media about the plans for distribution. This while the public waits for the Serum Institute to ramp up its production further. Amongst multiple reports it is important that correct information be shared with the public. pic.twitter.com/nzyOZwVBxH — Adar Poonawalla (@adarpoonawalla) May 3, 2021 India’s Supreme Court has also pulled up the Modi administration for failing to regulate the prices of the vaccines. Currently vaccine manufacturers are offering different prices to the centre and state governments, as well as private players, as Health Policy Watch reported in an earlier story. Health experts have said this would set a dangerous precedent while policy experts have criticized the government for its handling of the vaccine distribution. Disha Shetty is an independent journalist based in Pune, India Image Credits: @MEAIndia -Ministry of External Affairs, Spokesman's office , Our World In Data . East Africa Restricts Travellers From India And Tightens Tests for Truckers 04/05/2021 Esther Nakkazi East African truck drivers will get access to one common COVID-19 testing system by mid-May. KAMPALA – Uganda, Kenya and Rwanda have suspended passenger flights from India amid that country’s surge in COVID-19 cases and fears that a number of African countries are on the brink of their own surges. “All flights from India and all passengers originating from India are suspended from 1 May,” the Uganda Ministry of Health said in a statement. “All passenger flights are suspended until further notice. No travellers from India shall be allowed into Uganda regardless of the route of travel.” Meanwhile, Kenya has suspended flights from India for 14 days, according to the Kenya Ministry of Health. Kenya Airways and Rwandair have also suspended flights from and to India. However, East African residents will be allowed to return home. India is a top medical tourism destination for residents in East Africa. The three countries are demanding that travellers who have been to India or travelled through India in the last 14 days, be in possession of a negative PCR COVID-19 test certificate that is digitally verifiable and has been conducted within 120 hours of travel. They will also undergo a PCR test upon arrival. Uganda will allow cargo flights from India where the crew do not disembark and technical stops where travelers do not disembark. It is also allowing aircraft in a state of emergency, operations related to humanitarian aid, medical evacuation, diplomatic flights approved by the appropriate Authority. Uganda has also advised travellers from the USA, United Kingdom, United Arab Emirates, Turkey, South Africa, and Tanzania to consider postponing non-essential travel to Uganda. Travellers from these countries, including Ugandans, will be subjected to a PCR test upon arrival at the points of entry into the country said Dr Jane Ruth Aceng, Uganda’s Minister of Health, during a weekly briefing. “We should make a difference between people and the virus. The virus is the enemy, not the people. If someone has an authentic negative PCR test, they do not cause a problem,” said Dr John Nkengasong, director for Africa Centres for Disease Control and Prevention (CDC). Truck Drivers’ Testing is Tightened The East African Community (EAC) is tightening up on the COVID-19 testing requirements of interstate truck drivers, identified as vectors of the virus, amid numerous problems including forged tests At a recent EAC meeting, Uganda, Kenya, Tanzania, Burundi and South Sudan agreed to submit the names of accredited national laboratories for COVID-19 testing so that these could be linked to the upgraded Regional Electronic Cargo and Driver Tracking System (RECDTS), which recognises digital COVID-19 certificates for truck drivers. The deadline for uploading all accredited COVID-19 testing laboratories in the RECDTS is 15 May. This will ensure that interstate truck drivers and other travellers test for COVID-19 in only through accredited laboratories and that all partner states take up and implement the RECDTS system. Digital certificates are uploaded on the drivers’ smartphones through an app and are valid for 14 days. The App, which was launched in September 2020, was developed with donor funding. It provides a surveillance system to monitor long-distance truckers’ health and enables contact tracing. It also allows partner states to electronically share truck drivers’ COVID-19 test results. The new system is aimed at resolving some of the challenges that were being experienced in the execution of health protocols including multiple testing of truck drivers at the border crossing as there lacked a framework of mutual recognition, document fraud and conflicting test results. The interstate truck drivers also are the single largest group of people who have been identified to be carrying the variants of concern – the B.1.351 variant from South Africa and the B.1.1.7 from the UK. From 399 samples sequenced by the Uganda Virus Research Institute (UVRI) these two variants were detected in 30 truck drivers.The Indian variant has been identified in one patient who was admitted to Mulago Hospital. By Wednesday, the EAC Secretariat expects to have shared a detailed concept note on the development of a common regional health pass to be linked to the upgraded surveillance. Uganda and Kenya Cases Increase By Monday, the Ministry of Health in Kenya had reported that 369 people had tested positive for the disease, from a sample of 4,469 tested in the last 24 hours – a positivity rate of 8.3% compared to the world average of 2.2%. A total of 1,298 patients are in various health facilities countrywide, while 6,652 patients are in isolation at their homes and 19 had died in the 24 hours before Monday. Total confirmed positive cases are now 160,422 and cumulative tests so far conducted are 1,679,779. Some 190 patients are in the ICU, 29 of whom are on ventilatory support and 118 on supplemental oxygen – 43 patients are on observation. Aceng said that Uganda was “experiencing a gradual increase in the COVID-19 cases and it is the beginning of a resurgence”. “This surge is already showing in districts that have remained on high alert and have been carrying out active surveillance,” said Aceng, adding that “this second wave will be worse than the first one”. Uganda has already organised a resurgence plan which is projected to cost over $290 million and is organised around three thresholds: control, alert, and action. The alert threshold is reached when there is a 10% increase in cases while the action threshold begins when there is a 20% increase in the cases observed from the baseline in any geographical location. “The main objective of the resurgence plan is to mitigate transmission and minimise the public health and social economic impact,” said Aceng. The resurgence plan will include enhanced surveillance, active case search, contact tracing, procurement of test kits, Personal Protective Equipment, critical care support, strengthening community engagement and risk communications, and supporting the vaccination teams but it does not include procurement of vaccines. By 30 April, Uganda’s cumulative COVID-19 cases stood at 41,866 with 342 deaths. There are currently 444 active cases. WHO Warns of African Resurgence Dr Matshidiso Moeti, WHO Regional Director for Africa. The World Health Organisation (WHO) predicts a high risk of COVID-19 resurgence in several African countries due to poor adherence to public health measures, mass gatherings, low testing and vaccination rates. “We cannot be lulled into a false sense of security. The devastating surge of cases and deaths in India, and increases in other regions of the world, are clear signs that the pandemic is not yet over in African countries,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “ A new upsurge of COVID-19 infections is a real risk in many countries even if the region’s case count in recent weeks appears to be stable,” she added. “Combatting COVID-19 fatigue appears to be the key battle in our collective response to the pandemic.” According to the WHO analysis of 46 African countries, Kenya, Egypt, Ethiopia face a very high risk of resurgence, while a further 20 countries face a high risk and 22, moderate risk, and only one country faces low risk. The risk was calculated using seven indicators with data from the past four weeks, including COVID-19 cases per million people; the percentage of change in new cases; the percentage of change in new deaths; the reproductive number (the rate at which an infection spreads); the pandemic trend; the average weekly number of tests per 10 000 people; and the percentage of the population that has received at least one vaccine dose. With more than 4.5 million confirmed cases and over 120 000 deaths to date, the continent has not experienced a surge in cases since January and the epidemic curve has plateaued for six weeks. But the relatively low number of cases has encouraged complacency and reduced adherence to behavioural measures to prevent the spread of the virus. In addition, recent political rallies in Benin, Cote d’Ivoire, Guinea and Kenya caused a spike in new cases. Upcoming elections in Cape Verde, Ethiopia, Gambia, Sao Tome and Principe and Zambia could also trigger cases due to mass gatherings, said Moeti. Of the 46 countries analysed, 31 performed fewer than 10 tests per 10,000 people per week in the past four weeks. “Most new cases are still not being detected among known contacts. Investigation of clusters of cases and contact tracing are worryingly low in most countries in the region,” Moeti said. “We must scale up testing including through rapid diagnostic tests to enhance response to the pandemic.” Image Credits: EAC. WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines 03/05/2021 Svĕt Lustig Vijay A shipment of the Chinese Sinopharm vaccine reaches Peru The World Health Organization (WHO) appears to be inching towards the approval of the Chinese Sinopharm and Sinovac vaccines as it struggles to fill a looming vaccine vacuum left by India’s Serum Institute – which has halted exports as the country continues to reel from a tragic coronavirus outbreak. Meanwhile, the WHO declared the latest Ebola outbreak in the Democratic Republic of Congo to be over, just three months after the first case was reported in North Kivu. Chinese Sinopharm & Sinovac May be Approved By End of Week Mariângela Simão, WHO Assistant-Director General for Access to Medicines The Chinese vaccines from Sinopharm and Sinovac could be approved by the end of this week, noted the WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals Mariangela Simao, speaking at a WHO press conference on Monday. “We are finalizing the assessment of Sinopharm [but] there’s still some documentation that needs to be added,” she said. “We will start the final assessment for the listing of Sinovac on the fifth [of May], so we expect both the Chinese vaccines [to] be finalized by the end of this week.” If both vaccines receive the WHO’s green light, China could could become the world’s largest vaccine supplier, assuming that Sinovac and Sinopharm will honor their commitment to produce two billion vaccine doses this year. Despite the lack of published data for the two vaccines, as well as their hefty price, both seem to have met the WHO’s minimum efficacy requirement of 50%, the WHO’s chairperson of Strategic Advisory Group of Experts (SAGE) said late last month. With regards to the WHO’s approval of another vaccine frontrunner that seems to be significantly more potent and cheaper than its Chinese counterparts, Russia’s Sputnik V, the WHO expects a final decision by June or even July, said Simao. “WHO still does not have the entire dossier [for Sputnik], it’s not complete yet,” she said, noting that the WHO is in the process of assessing good clinical practices for Sputnik V and is set to begin evaluating manufacturing practices next Monday until early June. “We expect that as soon as we have the entire dossier, plus the compliance to both good manufacturing practices and the good clinical practice, the vaccine can be assessed then by the technical expert group [SAGE] and we expect that this is likely to happen [by the] end of June or probably in July.” Ebola Outbreak in DRC Declared Over by WHO Meanwhile, the WHO’s Director General, Dr Tedros Adhanom Ghebreyesus, hailed the DRC’s milestone in bringing an end to the twelfth Ebola outbreak in the country – a deadly disease that kills about half of the people it infects. The latest #Ebola outbreak in #DRC🇨🇩 has been declared over after just 3 months. Twelve cases, six deaths & six recoveries were recorded in four health zones in North Kivu during this outbreak.@WHO congratulates DRC’s swift response to this outbreak! 👉🏿https://t.co/2gNHJR22B6 pic.twitter.com/hNZ1moYLaT — WHO African Region (@WHOAFRO) May 3, 2021 “Earlier today, the government of the Democratic Republic of the Congo, announced the end of the most recent Ebola outbreak three months after the first case was reported in North Kivu,” said Dr. Tedros on Monday, emphasizing that a comprehensive public health approach was crucial in ending the latest outbreak of Ebola. “Huge credit must be given to the local health workers and the national authorities for their prompt response, tenacity, experience and hard work that brought this outbreak under control,” added Dr Matshidiso Moeti, WHO Regional Director for Africa. She was referring to the country’s swift move to vaccinate almost 2,000 people at high-risk of contracting the virus and providing treatment as soon as the outbreak was declared in February. However, she stressed that going forward, strong surveillance systems will be crucial to swiftly detect potential flare-ups and to fight parallel epidemics of measles, cholera and COVID-19. “Although the outbreak has ended, we must stay alert for possible resurgence and at the same time use the growing expertise on emergency response to address other health threats the country faces.” Image Credits: Sinopharm, Peruvian Ministry of External Affairs. After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
As Indian Pandemic Worsens, Social Networks Save Lives – Government Promotes Alternative Therapies 04/05/2021 Disha Shetty India has received emergency COVID-19 supplies from several countries. PUNE – For two weeks now Sijo Raju, along with a group of 20 young men and women, have been fielding calls from family members looking for oxygen cylinders, ventilator beds and ambulances. Finding a match can take a few hours as India’s overwhelmed health system and front-line healthcare workers try desperately to provide a semblance of care to the massive number of COVID patients. In the absence of a centrally coordinated response, citizens like Raju have stepped up. They verify messages posted online, guide family members to facilities with resources, and do their best to step in place of a government machinery that has effectively abandoned its citizens. “There is just too much information on the internet,” Raju told Health Policy Watch. While the group members, most of them in their 20s and 30s, are based in the Mumbai metropolitan area, they are now trying to help verify requests coming from across India and are among many such citizen groups that have banded together in the past few weeks. On 1 May, India reported over 400,000 cases – a record-high figure in the history of the COVID-19 pandemic so far. It was also the day the country officially lowered the age for those eligible for vaccines from 45 and above to 18 and above. The government had placed orders for the additional vaccines that would be needed just two days before vaccination was to be expanded, and not surprisingly most young people aren’t able to find slots as they try to register for vaccines. But Adar Poonawalla, whose company Serum Institute of India (SII) is responsible for supplying the bulk of the vaccines, said given that the orders were recently received, ramping up production would take still time. Cases continue to rise in India overwhelming the country’s already fragile health infrastructure Promoting Alternative Medicines Meanwhile, India’s government is promoting a poly herbal drug named Ayush-64, calling it a “ray of hope”. The drug is being promoted by the Ministry of Ayurvedic Medicines, Yoga, Unani, Siddha and Homeopathy (AYUSH). Alternative therapies are widely popular albeit not without controversy as mainstream treatments in the pandemic. The government said the drug has been found to be useful in mild to moderate cases. It is also promoting yoga as a way to “strengthen natural immunity”. Most COVID-19 cases are mild to moderate that require little to no treatment under normal circumstances. “The claims made about certain AYUSH interventions in the absence of quality clinical studies and data being presented is unfortunate,” said Anant Bhan, a bioethicist and global health policy expert based in India. “It could lead to reliance on interventions which could not be working, and take the focus away from interventions which do. As is the requirement with allopathic medicines, any claims about AYUSH interventions and utility in COVID-19 needs to be backed by data.” Indian government’s push for alternative medicines comes at a time when Indians are in need of a planned COVID-19 response and urgent ramping up of health facilities. The country’s cases have been on an upward trajectory since March when Prime Minister Narendra Modi held massive election rallies in the state of West Bengal and allowed the Hindu religious event Kumbh Mela to go on that saw gathering of thousands of devotees to perform rituals by the holy river Ganges. Both these events ended up being super spreader ones and worsened the pandemic. Restrictions continue in many high burden states in India and the popular cricket tournament Indian Premier League has also been postponed. The tournament had come under heavy criticism for continuing despite rising COVID-19 deaths. The secretary of the Board of Cricket Administration is Jay Shah, the son of India’s home minister Amit Shah, a key figure in the Modi Administration. Aid Distribution and Vaccine Rollout After India’s pandemic made headlines around the world, the country started receiving aid. Ireland became the most recent country to send aid and US aid has also arrived. Despite this, ordinary citizens continue to struggle for basics based on messages on social media. The government issued a statement saying that the aid will be distributed based on the number of cases and the need in the states – after questions were raised in the Indian media about the plans for distribution. This while the public waits for the Serum Institute to ramp up its production further. Amongst multiple reports it is important that correct information be shared with the public. pic.twitter.com/nzyOZwVBxH — Adar Poonawalla (@adarpoonawalla) May 3, 2021 India’s Supreme Court has also pulled up the Modi administration for failing to regulate the prices of the vaccines. Currently vaccine manufacturers are offering different prices to the centre and state governments, as well as private players, as Health Policy Watch reported in an earlier story. Health experts have said this would set a dangerous precedent while policy experts have criticized the government for its handling of the vaccine distribution. Disha Shetty is an independent journalist based in Pune, India Image Credits: @MEAIndia -Ministry of External Affairs, Spokesman's office , Our World In Data . East Africa Restricts Travellers From India And Tightens Tests for Truckers 04/05/2021 Esther Nakkazi East African truck drivers will get access to one common COVID-19 testing system by mid-May. KAMPALA – Uganda, Kenya and Rwanda have suspended passenger flights from India amid that country’s surge in COVID-19 cases and fears that a number of African countries are on the brink of their own surges. “All flights from India and all passengers originating from India are suspended from 1 May,” the Uganda Ministry of Health said in a statement. “All passenger flights are suspended until further notice. No travellers from India shall be allowed into Uganda regardless of the route of travel.” Meanwhile, Kenya has suspended flights from India for 14 days, according to the Kenya Ministry of Health. Kenya Airways and Rwandair have also suspended flights from and to India. However, East African residents will be allowed to return home. India is a top medical tourism destination for residents in East Africa. The three countries are demanding that travellers who have been to India or travelled through India in the last 14 days, be in possession of a negative PCR COVID-19 test certificate that is digitally verifiable and has been conducted within 120 hours of travel. They will also undergo a PCR test upon arrival. Uganda will allow cargo flights from India where the crew do not disembark and technical stops where travelers do not disembark. It is also allowing aircraft in a state of emergency, operations related to humanitarian aid, medical evacuation, diplomatic flights approved by the appropriate Authority. Uganda has also advised travellers from the USA, United Kingdom, United Arab Emirates, Turkey, South Africa, and Tanzania to consider postponing non-essential travel to Uganda. Travellers from these countries, including Ugandans, will be subjected to a PCR test upon arrival at the points of entry into the country said Dr Jane Ruth Aceng, Uganda’s Minister of Health, during a weekly briefing. “We should make a difference between people and the virus. The virus is the enemy, not the people. If someone has an authentic negative PCR test, they do not cause a problem,” said Dr John Nkengasong, director for Africa Centres for Disease Control and Prevention (CDC). Truck Drivers’ Testing is Tightened The East African Community (EAC) is tightening up on the COVID-19 testing requirements of interstate truck drivers, identified as vectors of the virus, amid numerous problems including forged tests At a recent EAC meeting, Uganda, Kenya, Tanzania, Burundi and South Sudan agreed to submit the names of accredited national laboratories for COVID-19 testing so that these could be linked to the upgraded Regional Electronic Cargo and Driver Tracking System (RECDTS), which recognises digital COVID-19 certificates for truck drivers. The deadline for uploading all accredited COVID-19 testing laboratories in the RECDTS is 15 May. This will ensure that interstate truck drivers and other travellers test for COVID-19 in only through accredited laboratories and that all partner states take up and implement the RECDTS system. Digital certificates are uploaded on the drivers’ smartphones through an app and are valid for 14 days. The App, which was launched in September 2020, was developed with donor funding. It provides a surveillance system to monitor long-distance truckers’ health and enables contact tracing. It also allows partner states to electronically share truck drivers’ COVID-19 test results. The new system is aimed at resolving some of the challenges that were being experienced in the execution of health protocols including multiple testing of truck drivers at the border crossing as there lacked a framework of mutual recognition, document fraud and conflicting test results. The interstate truck drivers also are the single largest group of people who have been identified to be carrying the variants of concern – the B.1.351 variant from South Africa and the B.1.1.7 from the UK. From 399 samples sequenced by the Uganda Virus Research Institute (UVRI) these two variants were detected in 30 truck drivers.The Indian variant has been identified in one patient who was admitted to Mulago Hospital. By Wednesday, the EAC Secretariat expects to have shared a detailed concept note on the development of a common regional health pass to be linked to the upgraded surveillance. Uganda and Kenya Cases Increase By Monday, the Ministry of Health in Kenya had reported that 369 people had tested positive for the disease, from a sample of 4,469 tested in the last 24 hours – a positivity rate of 8.3% compared to the world average of 2.2%. A total of 1,298 patients are in various health facilities countrywide, while 6,652 patients are in isolation at their homes and 19 had died in the 24 hours before Monday. Total confirmed positive cases are now 160,422 and cumulative tests so far conducted are 1,679,779. Some 190 patients are in the ICU, 29 of whom are on ventilatory support and 118 on supplemental oxygen – 43 patients are on observation. Aceng said that Uganda was “experiencing a gradual increase in the COVID-19 cases and it is the beginning of a resurgence”. “This surge is already showing in districts that have remained on high alert and have been carrying out active surveillance,” said Aceng, adding that “this second wave will be worse than the first one”. Uganda has already organised a resurgence plan which is projected to cost over $290 million and is organised around three thresholds: control, alert, and action. The alert threshold is reached when there is a 10% increase in cases while the action threshold begins when there is a 20% increase in the cases observed from the baseline in any geographical location. “The main objective of the resurgence plan is to mitigate transmission and minimise the public health and social economic impact,” said Aceng. The resurgence plan will include enhanced surveillance, active case search, contact tracing, procurement of test kits, Personal Protective Equipment, critical care support, strengthening community engagement and risk communications, and supporting the vaccination teams but it does not include procurement of vaccines. By 30 April, Uganda’s cumulative COVID-19 cases stood at 41,866 with 342 deaths. There are currently 444 active cases. WHO Warns of African Resurgence Dr Matshidiso Moeti, WHO Regional Director for Africa. The World Health Organisation (WHO) predicts a high risk of COVID-19 resurgence in several African countries due to poor adherence to public health measures, mass gatherings, low testing and vaccination rates. “We cannot be lulled into a false sense of security. The devastating surge of cases and deaths in India, and increases in other regions of the world, are clear signs that the pandemic is not yet over in African countries,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “ A new upsurge of COVID-19 infections is a real risk in many countries even if the region’s case count in recent weeks appears to be stable,” she added. “Combatting COVID-19 fatigue appears to be the key battle in our collective response to the pandemic.” According to the WHO analysis of 46 African countries, Kenya, Egypt, Ethiopia face a very high risk of resurgence, while a further 20 countries face a high risk and 22, moderate risk, and only one country faces low risk. The risk was calculated using seven indicators with data from the past four weeks, including COVID-19 cases per million people; the percentage of change in new cases; the percentage of change in new deaths; the reproductive number (the rate at which an infection spreads); the pandemic trend; the average weekly number of tests per 10 000 people; and the percentage of the population that has received at least one vaccine dose. With more than 4.5 million confirmed cases and over 120 000 deaths to date, the continent has not experienced a surge in cases since January and the epidemic curve has plateaued for six weeks. But the relatively low number of cases has encouraged complacency and reduced adherence to behavioural measures to prevent the spread of the virus. In addition, recent political rallies in Benin, Cote d’Ivoire, Guinea and Kenya caused a spike in new cases. Upcoming elections in Cape Verde, Ethiopia, Gambia, Sao Tome and Principe and Zambia could also trigger cases due to mass gatherings, said Moeti. Of the 46 countries analysed, 31 performed fewer than 10 tests per 10,000 people per week in the past four weeks. “Most new cases are still not being detected among known contacts. Investigation of clusters of cases and contact tracing are worryingly low in most countries in the region,” Moeti said. “We must scale up testing including through rapid diagnostic tests to enhance response to the pandemic.” Image Credits: EAC. WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines 03/05/2021 Svĕt Lustig Vijay A shipment of the Chinese Sinopharm vaccine reaches Peru The World Health Organization (WHO) appears to be inching towards the approval of the Chinese Sinopharm and Sinovac vaccines as it struggles to fill a looming vaccine vacuum left by India’s Serum Institute – which has halted exports as the country continues to reel from a tragic coronavirus outbreak. Meanwhile, the WHO declared the latest Ebola outbreak in the Democratic Republic of Congo to be over, just three months after the first case was reported in North Kivu. Chinese Sinopharm & Sinovac May be Approved By End of Week Mariângela Simão, WHO Assistant-Director General for Access to Medicines The Chinese vaccines from Sinopharm and Sinovac could be approved by the end of this week, noted the WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals Mariangela Simao, speaking at a WHO press conference on Monday. “We are finalizing the assessment of Sinopharm [but] there’s still some documentation that needs to be added,” she said. “We will start the final assessment for the listing of Sinovac on the fifth [of May], so we expect both the Chinese vaccines [to] be finalized by the end of this week.” If both vaccines receive the WHO’s green light, China could could become the world’s largest vaccine supplier, assuming that Sinovac and Sinopharm will honor their commitment to produce two billion vaccine doses this year. Despite the lack of published data for the two vaccines, as well as their hefty price, both seem to have met the WHO’s minimum efficacy requirement of 50%, the WHO’s chairperson of Strategic Advisory Group of Experts (SAGE) said late last month. With regards to the WHO’s approval of another vaccine frontrunner that seems to be significantly more potent and cheaper than its Chinese counterparts, Russia’s Sputnik V, the WHO expects a final decision by June or even July, said Simao. “WHO still does not have the entire dossier [for Sputnik], it’s not complete yet,” she said, noting that the WHO is in the process of assessing good clinical practices for Sputnik V and is set to begin evaluating manufacturing practices next Monday until early June. “We expect that as soon as we have the entire dossier, plus the compliance to both good manufacturing practices and the good clinical practice, the vaccine can be assessed then by the technical expert group [SAGE] and we expect that this is likely to happen [by the] end of June or probably in July.” Ebola Outbreak in DRC Declared Over by WHO Meanwhile, the WHO’s Director General, Dr Tedros Adhanom Ghebreyesus, hailed the DRC’s milestone in bringing an end to the twelfth Ebola outbreak in the country – a deadly disease that kills about half of the people it infects. The latest #Ebola outbreak in #DRC🇨🇩 has been declared over after just 3 months. Twelve cases, six deaths & six recoveries were recorded in four health zones in North Kivu during this outbreak.@WHO congratulates DRC’s swift response to this outbreak! 👉🏿https://t.co/2gNHJR22B6 pic.twitter.com/hNZ1moYLaT — WHO African Region (@WHOAFRO) May 3, 2021 “Earlier today, the government of the Democratic Republic of the Congo, announced the end of the most recent Ebola outbreak three months after the first case was reported in North Kivu,” said Dr. Tedros on Monday, emphasizing that a comprehensive public health approach was crucial in ending the latest outbreak of Ebola. “Huge credit must be given to the local health workers and the national authorities for their prompt response, tenacity, experience and hard work that brought this outbreak under control,” added Dr Matshidiso Moeti, WHO Regional Director for Africa. She was referring to the country’s swift move to vaccinate almost 2,000 people at high-risk of contracting the virus and providing treatment as soon as the outbreak was declared in February. However, she stressed that going forward, strong surveillance systems will be crucial to swiftly detect potential flare-ups and to fight parallel epidemics of measles, cholera and COVID-19. “Although the outbreak has ended, we must stay alert for possible resurgence and at the same time use the growing expertise on emergency response to address other health threats the country faces.” Image Credits: Sinopharm, Peruvian Ministry of External Affairs. After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
East Africa Restricts Travellers From India And Tightens Tests for Truckers 04/05/2021 Esther Nakkazi East African truck drivers will get access to one common COVID-19 testing system by mid-May. KAMPALA – Uganda, Kenya and Rwanda have suspended passenger flights from India amid that country’s surge in COVID-19 cases and fears that a number of African countries are on the brink of their own surges. “All flights from India and all passengers originating from India are suspended from 1 May,” the Uganda Ministry of Health said in a statement. “All passenger flights are suspended until further notice. No travellers from India shall be allowed into Uganda regardless of the route of travel.” Meanwhile, Kenya has suspended flights from India for 14 days, according to the Kenya Ministry of Health. Kenya Airways and Rwandair have also suspended flights from and to India. However, East African residents will be allowed to return home. India is a top medical tourism destination for residents in East Africa. The three countries are demanding that travellers who have been to India or travelled through India in the last 14 days, be in possession of a negative PCR COVID-19 test certificate that is digitally verifiable and has been conducted within 120 hours of travel. They will also undergo a PCR test upon arrival. Uganda will allow cargo flights from India where the crew do not disembark and technical stops where travelers do not disembark. It is also allowing aircraft in a state of emergency, operations related to humanitarian aid, medical evacuation, diplomatic flights approved by the appropriate Authority. Uganda has also advised travellers from the USA, United Kingdom, United Arab Emirates, Turkey, South Africa, and Tanzania to consider postponing non-essential travel to Uganda. Travellers from these countries, including Ugandans, will be subjected to a PCR test upon arrival at the points of entry into the country said Dr Jane Ruth Aceng, Uganda’s Minister of Health, during a weekly briefing. “We should make a difference between people and the virus. The virus is the enemy, not the people. If someone has an authentic negative PCR test, they do not cause a problem,” said Dr John Nkengasong, director for Africa Centres for Disease Control and Prevention (CDC). Truck Drivers’ Testing is Tightened The East African Community (EAC) is tightening up on the COVID-19 testing requirements of interstate truck drivers, identified as vectors of the virus, amid numerous problems including forged tests At a recent EAC meeting, Uganda, Kenya, Tanzania, Burundi and South Sudan agreed to submit the names of accredited national laboratories for COVID-19 testing so that these could be linked to the upgraded Regional Electronic Cargo and Driver Tracking System (RECDTS), which recognises digital COVID-19 certificates for truck drivers. The deadline for uploading all accredited COVID-19 testing laboratories in the RECDTS is 15 May. This will ensure that interstate truck drivers and other travellers test for COVID-19 in only through accredited laboratories and that all partner states take up and implement the RECDTS system. Digital certificates are uploaded on the drivers’ smartphones through an app and are valid for 14 days. The App, which was launched in September 2020, was developed with donor funding. It provides a surveillance system to monitor long-distance truckers’ health and enables contact tracing. It also allows partner states to electronically share truck drivers’ COVID-19 test results. The new system is aimed at resolving some of the challenges that were being experienced in the execution of health protocols including multiple testing of truck drivers at the border crossing as there lacked a framework of mutual recognition, document fraud and conflicting test results. The interstate truck drivers also are the single largest group of people who have been identified to be carrying the variants of concern – the B.1.351 variant from South Africa and the B.1.1.7 from the UK. From 399 samples sequenced by the Uganda Virus Research Institute (UVRI) these two variants were detected in 30 truck drivers.The Indian variant has been identified in one patient who was admitted to Mulago Hospital. By Wednesday, the EAC Secretariat expects to have shared a detailed concept note on the development of a common regional health pass to be linked to the upgraded surveillance. Uganda and Kenya Cases Increase By Monday, the Ministry of Health in Kenya had reported that 369 people had tested positive for the disease, from a sample of 4,469 tested in the last 24 hours – a positivity rate of 8.3% compared to the world average of 2.2%. A total of 1,298 patients are in various health facilities countrywide, while 6,652 patients are in isolation at their homes and 19 had died in the 24 hours before Monday. Total confirmed positive cases are now 160,422 and cumulative tests so far conducted are 1,679,779. Some 190 patients are in the ICU, 29 of whom are on ventilatory support and 118 on supplemental oxygen – 43 patients are on observation. Aceng said that Uganda was “experiencing a gradual increase in the COVID-19 cases and it is the beginning of a resurgence”. “This surge is already showing in districts that have remained on high alert and have been carrying out active surveillance,” said Aceng, adding that “this second wave will be worse than the first one”. Uganda has already organised a resurgence plan which is projected to cost over $290 million and is organised around three thresholds: control, alert, and action. The alert threshold is reached when there is a 10% increase in cases while the action threshold begins when there is a 20% increase in the cases observed from the baseline in any geographical location. “The main objective of the resurgence plan is to mitigate transmission and minimise the public health and social economic impact,” said Aceng. The resurgence plan will include enhanced surveillance, active case search, contact tracing, procurement of test kits, Personal Protective Equipment, critical care support, strengthening community engagement and risk communications, and supporting the vaccination teams but it does not include procurement of vaccines. By 30 April, Uganda’s cumulative COVID-19 cases stood at 41,866 with 342 deaths. There are currently 444 active cases. WHO Warns of African Resurgence Dr Matshidiso Moeti, WHO Regional Director for Africa. The World Health Organisation (WHO) predicts a high risk of COVID-19 resurgence in several African countries due to poor adherence to public health measures, mass gatherings, low testing and vaccination rates. “We cannot be lulled into a false sense of security. The devastating surge of cases and deaths in India, and increases in other regions of the world, are clear signs that the pandemic is not yet over in African countries,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “ A new upsurge of COVID-19 infections is a real risk in many countries even if the region’s case count in recent weeks appears to be stable,” she added. “Combatting COVID-19 fatigue appears to be the key battle in our collective response to the pandemic.” According to the WHO analysis of 46 African countries, Kenya, Egypt, Ethiopia face a very high risk of resurgence, while a further 20 countries face a high risk and 22, moderate risk, and only one country faces low risk. The risk was calculated using seven indicators with data from the past four weeks, including COVID-19 cases per million people; the percentage of change in new cases; the percentage of change in new deaths; the reproductive number (the rate at which an infection spreads); the pandemic trend; the average weekly number of tests per 10 000 people; and the percentage of the population that has received at least one vaccine dose. With more than 4.5 million confirmed cases and over 120 000 deaths to date, the continent has not experienced a surge in cases since January and the epidemic curve has plateaued for six weeks. But the relatively low number of cases has encouraged complacency and reduced adherence to behavioural measures to prevent the spread of the virus. In addition, recent political rallies in Benin, Cote d’Ivoire, Guinea and Kenya caused a spike in new cases. Upcoming elections in Cape Verde, Ethiopia, Gambia, Sao Tome and Principe and Zambia could also trigger cases due to mass gatherings, said Moeti. Of the 46 countries analysed, 31 performed fewer than 10 tests per 10,000 people per week in the past four weeks. “Most new cases are still not being detected among known contacts. Investigation of clusters of cases and contact tracing are worryingly low in most countries in the region,” Moeti said. “We must scale up testing including through rapid diagnostic tests to enhance response to the pandemic.” Image Credits: EAC. WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines 03/05/2021 Svĕt Lustig Vijay A shipment of the Chinese Sinopharm vaccine reaches Peru The World Health Organization (WHO) appears to be inching towards the approval of the Chinese Sinopharm and Sinovac vaccines as it struggles to fill a looming vaccine vacuum left by India’s Serum Institute – which has halted exports as the country continues to reel from a tragic coronavirus outbreak. Meanwhile, the WHO declared the latest Ebola outbreak in the Democratic Republic of Congo to be over, just three months after the first case was reported in North Kivu. Chinese Sinopharm & Sinovac May be Approved By End of Week Mariângela Simão, WHO Assistant-Director General for Access to Medicines The Chinese vaccines from Sinopharm and Sinovac could be approved by the end of this week, noted the WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals Mariangela Simao, speaking at a WHO press conference on Monday. “We are finalizing the assessment of Sinopharm [but] there’s still some documentation that needs to be added,” she said. “We will start the final assessment for the listing of Sinovac on the fifth [of May], so we expect both the Chinese vaccines [to] be finalized by the end of this week.” If both vaccines receive the WHO’s green light, China could could become the world’s largest vaccine supplier, assuming that Sinovac and Sinopharm will honor their commitment to produce two billion vaccine doses this year. Despite the lack of published data for the two vaccines, as well as their hefty price, both seem to have met the WHO’s minimum efficacy requirement of 50%, the WHO’s chairperson of Strategic Advisory Group of Experts (SAGE) said late last month. With regards to the WHO’s approval of another vaccine frontrunner that seems to be significantly more potent and cheaper than its Chinese counterparts, Russia’s Sputnik V, the WHO expects a final decision by June or even July, said Simao. “WHO still does not have the entire dossier [for Sputnik], it’s not complete yet,” she said, noting that the WHO is in the process of assessing good clinical practices for Sputnik V and is set to begin evaluating manufacturing practices next Monday until early June. “We expect that as soon as we have the entire dossier, plus the compliance to both good manufacturing practices and the good clinical practice, the vaccine can be assessed then by the technical expert group [SAGE] and we expect that this is likely to happen [by the] end of June or probably in July.” Ebola Outbreak in DRC Declared Over by WHO Meanwhile, the WHO’s Director General, Dr Tedros Adhanom Ghebreyesus, hailed the DRC’s milestone in bringing an end to the twelfth Ebola outbreak in the country – a deadly disease that kills about half of the people it infects. The latest #Ebola outbreak in #DRC🇨🇩 has been declared over after just 3 months. Twelve cases, six deaths & six recoveries were recorded in four health zones in North Kivu during this outbreak.@WHO congratulates DRC’s swift response to this outbreak! 👉🏿https://t.co/2gNHJR22B6 pic.twitter.com/hNZ1moYLaT — WHO African Region (@WHOAFRO) May 3, 2021 “Earlier today, the government of the Democratic Republic of the Congo, announced the end of the most recent Ebola outbreak three months after the first case was reported in North Kivu,” said Dr. Tedros on Monday, emphasizing that a comprehensive public health approach was crucial in ending the latest outbreak of Ebola. “Huge credit must be given to the local health workers and the national authorities for their prompt response, tenacity, experience and hard work that brought this outbreak under control,” added Dr Matshidiso Moeti, WHO Regional Director for Africa. She was referring to the country’s swift move to vaccinate almost 2,000 people at high-risk of contracting the virus and providing treatment as soon as the outbreak was declared in February. However, she stressed that going forward, strong surveillance systems will be crucial to swiftly detect potential flare-ups and to fight parallel epidemics of measles, cholera and COVID-19. “Although the outbreak has ended, we must stay alert for possible resurgence and at the same time use the growing expertise on emergency response to address other health threats the country faces.” Image Credits: Sinopharm, Peruvian Ministry of External Affairs. After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines 03/05/2021 Svĕt Lustig Vijay A shipment of the Chinese Sinopharm vaccine reaches Peru The World Health Organization (WHO) appears to be inching towards the approval of the Chinese Sinopharm and Sinovac vaccines as it struggles to fill a looming vaccine vacuum left by India’s Serum Institute – which has halted exports as the country continues to reel from a tragic coronavirus outbreak. Meanwhile, the WHO declared the latest Ebola outbreak in the Democratic Republic of Congo to be over, just three months after the first case was reported in North Kivu. Chinese Sinopharm & Sinovac May be Approved By End of Week Mariângela Simão, WHO Assistant-Director General for Access to Medicines The Chinese vaccines from Sinopharm and Sinovac could be approved by the end of this week, noted the WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals Mariangela Simao, speaking at a WHO press conference on Monday. “We are finalizing the assessment of Sinopharm [but] there’s still some documentation that needs to be added,” she said. “We will start the final assessment for the listing of Sinovac on the fifth [of May], so we expect both the Chinese vaccines [to] be finalized by the end of this week.” If both vaccines receive the WHO’s green light, China could could become the world’s largest vaccine supplier, assuming that Sinovac and Sinopharm will honor their commitment to produce two billion vaccine doses this year. Despite the lack of published data for the two vaccines, as well as their hefty price, both seem to have met the WHO’s minimum efficacy requirement of 50%, the WHO’s chairperson of Strategic Advisory Group of Experts (SAGE) said late last month. With regards to the WHO’s approval of another vaccine frontrunner that seems to be significantly more potent and cheaper than its Chinese counterparts, Russia’s Sputnik V, the WHO expects a final decision by June or even July, said Simao. “WHO still does not have the entire dossier [for Sputnik], it’s not complete yet,” she said, noting that the WHO is in the process of assessing good clinical practices for Sputnik V and is set to begin evaluating manufacturing practices next Monday until early June. “We expect that as soon as we have the entire dossier, plus the compliance to both good manufacturing practices and the good clinical practice, the vaccine can be assessed then by the technical expert group [SAGE] and we expect that this is likely to happen [by the] end of June or probably in July.” Ebola Outbreak in DRC Declared Over by WHO Meanwhile, the WHO’s Director General, Dr Tedros Adhanom Ghebreyesus, hailed the DRC’s milestone in bringing an end to the twelfth Ebola outbreak in the country – a deadly disease that kills about half of the people it infects. The latest #Ebola outbreak in #DRC🇨🇩 has been declared over after just 3 months. Twelve cases, six deaths & six recoveries were recorded in four health zones in North Kivu during this outbreak.@WHO congratulates DRC’s swift response to this outbreak! 👉🏿https://t.co/2gNHJR22B6 pic.twitter.com/hNZ1moYLaT — WHO African Region (@WHOAFRO) May 3, 2021 “Earlier today, the government of the Democratic Republic of the Congo, announced the end of the most recent Ebola outbreak three months after the first case was reported in North Kivu,” said Dr. Tedros on Monday, emphasizing that a comprehensive public health approach was crucial in ending the latest outbreak of Ebola. “Huge credit must be given to the local health workers and the national authorities for their prompt response, tenacity, experience and hard work that brought this outbreak under control,” added Dr Matshidiso Moeti, WHO Regional Director for Africa. She was referring to the country’s swift move to vaccinate almost 2,000 people at high-risk of contracting the virus and providing treatment as soon as the outbreak was declared in February. However, she stressed that going forward, strong surveillance systems will be crucial to swiftly detect potential flare-ups and to fight parallel epidemics of measles, cholera and COVID-19. “Although the outbreak has ended, we must stay alert for possible resurgence and at the same time use the growing expertise on emergency response to address other health threats the country faces.” Image Credits: Sinopharm, Peruvian Ministry of External Affairs. After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
After Tough Negotiations, Pfizer Delivers First COVID Vaccines to South Africa 03/05/2021 Kerry Cullinan JOHANNESBURG – South Africa received its first batch of 325,260 Pfizer vaccine doses late on Sunday night, Health Minister Zweli Mkhize announced. This follows lengthy negotiations between the South African government and Pfizer, during which the company made “difficult and sometimes unreasonable” terms including at one stage that the country put up sovereign assets as potential collateral, according to a report by the Bureau of Investigative Journalism. South Africa’s Health Minister Zweli Mkhize Mkhize sent a briefing letter to parliamentarians last month, saying that the government had been “relieved” when Pfizer eventually removed the “problematic term” which had put the government in the “precarious position of having to choose between saving our citizens’ lives and risking putting the country’s assets into private companies’ hands”, according to the bureau. Samples of the Pfizer vaccines are currently undergoing quality checks by the National Control Laboratory, and will then be sent to urban vaccination centres where they will be administered to healthcare workers. The country expects approximately the same number of doses – 325 260 – to arrive each week during May and 636 480 doses per week in June, with close to 4,5 million doses having been delivered by the end of next month. Each person needs two doses of the vaccine, which also needs ultra-cold storage which makes it unsuitable for rural distribution. Johnson & Johnson Vaccines Also Being Checked South Africa has only vaccinated slightly more than 320,000 of its estimated 1.2 million health workers so far. The country opted not to use the AstraZeneca vaccine following research that showed that it had limited efficacy against the B.1.351 variant dominant in the country. Until now, it has been vaccinating health workers with a very limited supply of the Johnson & Johnson (J&J) vaccines. However, 1.1 million more J&J vaccines are in the country undergoing safety checks that are likely to be completed in mid-May. “This is due to a protracted safety verification process with international regulatory agencies,” said Mkhize in a statement on Sunday. “This is a precautionary measure following the adverse findings during inspection of Emergent BioSolutions Bayview facility in the United States, one of the manufacturing partners of Johnson and Johnson, which prompted the authorities to extend their assessments of all Johnson and Johnson stock worldwide.” Once through the safety checks, the J&J vaccines will be used in rural settings as they don’t require ultra-cold storage and people only need one dose. The country plans to start vaccinating all citizens over the age of 60 from 17 May. Meanwhile, South Africa’s National Institute for Communicable Diseases (NICD) has released modeling data last week which predicts that the country can expect a “third wave” of the pandemic in two to three months – but that this is not likely to be as severe as the second wave as long as there are no new variants. “The most likely drivers of a third wave are behaviour change after the end of the last wave; ongoing viral mutation; seasonal factors; and reinfection due to the waning of immunity conveyed by previous infection,” according to the NICD. Image Credits: US Centers for Disease Control, GCIS. Posts navigation Older postsNewer posts